# Nephrology Dialysis Transplantation

Official Publication of the European Dialysis and Transplant Association–European Renal Association

Incorporating Proceedings of the European Dialysis and Transplant Association—European Renal Association

VOLUME 6: 1991

**Editor-in-Chief:**

**Alex M. Davison**
Leeds, UK

**Editors:**

**H. Brynger**
Göteborg, Sweden

**V. Cambi**
Parma, Italy

**J. S. Cameron**
London, UK

**T. Drüeke**
Paris, France

**J. P. Grünfeld**
Paris, France

**L. Hernando**
Madrid, Spain

**K. Hierholzer**
Berlin, FRG

**H. Klinkmann**
Rostock, GDR

**H. Kreis**
Paris, France

**E. Ritz**
Heidelberg, FRG

**C. Van Ypersele**
Bruxelles, Belgium

**Advisory Editors:**

**J. F. Bach**
Paris, France

**R. S. Barsoum**
Cairo, Egypt

**J. Bergstrom**
Stockholm Sweden

**J. Botella**
Madrid, Spain

**J. D. Briggs**
Glasgow, UK

**M. Broyer**
Paris, France

**A. Dal Canton**
Catanzaro, Italy

**G. D'Amico**
Milano, Italy

**R. A. Donckerwolcke**
Utrecht, The Netherlands

**J. F. Donohoe**
Dublin, Ireland

**P. Druet**
Paris, France

**J. Egido**
Madrid, Spain

**H. Eliahou**
Tel Hashomer, Israel

**D. Falkenhagen**
Rostock, GDR

**M. Goldman**
Bruxelles, Belgium

**R. Greger**
Frankfurt, FRG

**P. Hayry**
Helsinki, Finland

**P. J. Hoedemaeker**
Leiden, The Netherlands

**C. Jacobs**
Paris, France

**R. A. P. Koene**
Nijmegen, The Netherlands

**F. Kokot**
Katowice, Poland

**N. H. Lámeire**
Gent, Belgium

**R. Maiorca**
Brescia, Italy

**N. P. Mallick**
Manchester, UK

**June Mason**
Basel, Switzerland

**J. Ph. Méry**
Paris, France

**C. Mion**
Montpellier, France

**K. Olgaard**
Copenhagen, Denmark

**G. Opelz**
Heidelberg, FRG

**A. Pasternack**
Tampere, Finland

**R. Pichlmayr**
Hannover, FRG

**M. Polenaković**
Skopje, Yugoslavia

**C. Ponticelli**
Milano, Italy

**A. T. Raftery**
Sheffield, UK

**G. Remuzzi**
Bergamo, Italy

**L. Revert**
Barcelona, Spain

**G. F. Rizzoni**
Padova, Italy

**G. Sieberth**
Aachen, FRG

**I. Taraba**
Budapest, Hungary

**G. Thiel**
Basel, Switzerland

**D. W. Thoenes**
Mainz, FRG

**D. Thomson**
Edinburgh, UK

**A. Valek**
Praha, Czechoslovakia

**L. A. Van Es**
Leiden, The Netherlands

**A. J. Wing**
London, UK

**P. Zucchelli**
Bologna, Italy

Springer International

# *Author Index to Volume 6*


Abbott F (abst) . . . 303
Abboud O I (letter) . . . 747
Abbs I (abst) . . . 300
Abel H-H (abst) . . . 826
Aber G M (abst) . . . 756, 905, 908
Abud O (abst) . . . 373
Achard J M (abst) . . . 818
Acitelli S (abst) . . . 778
Ackrill P (abst) . . . 224
Adu D (abst) . . . 296, 899, 906
Adul D (abst) . . . 909
Agar J W M: *See* Dowlin J P, Agar J W M
Aguado S (abst) . . . 769
Aguilera B: *See* Ortiz A et al.
Agulló J (abst) . . . 783
Ahmad R: *See* Yaqoob M et al.
Airaghi C (abst) . . . 770
Ajzen H (abst) . . . 784
Akagaki Y (abst) . . . 802
Akhan G (abst) . . . 830
Akizawa T (abst) . . . 814
Akkuş I (abst) . . . 830
Al-Khursany I (abst) . . . 67, 221
Al-Nawab M D, Jones N F, Davies D R
Glomerular Epithelial Cell Endocytosis of Immune Deposits in Human Lupus Nephritis . . . 316
Aladrén M J (abst) . . . 372
Alarcón A (abst) . . . 820
Albert W: *See* Seyfert U T et al.
Albertazzi A (abst) . . . 785
Alcazar J M (abst) . . . 832
Alessi D (abst) . . . 761, 770, 818
Alexopoulos E (abst) . . . 758
Alfonso L: *See* Mastrangelo F et al.
Algarra G R: *See* Gentil M A et al.
Alivanis P (abst) . . . 822
Aljama P: *See* Martin-Malo A et al.
Aljama P (abst) . . . 809
Allan P L (abst) . . . 741
Allaria P (abst) . . . 816
Allegri L (abst) . . . 758
Allen A C (abst) . . . 901
Allinne E (abst) . . . 763
Allison M E M (abst) . . . 220
Almartine E (abst) . . . 835
Almirall J: *See* Poch E et al.
Almirall J (abst) . . . 837
Almond M K (abst) . . . 831
Alonso M (abst) . . . 815, 817
Alonso S (abst) . . . 753
Alsina J (abst) . . . 372
Altman J J (abst) . . . 769
Alvarez J: *See* Peces R et al.
Alvarez-Grande J (abst) . . . 769
Alvarez-Lara M A (abst) . . . 809
Alverstrand A (abst) . . . 809
Amamiya K (abst) . . . 808
Ambrosecchia R (abst) . . . 801
Amemiya K (abst) . . . 765
Amoedo M L (abst) . . . 822
Amore A (abst) . . . 754, 758, 759, 761, 762, 770, 771, 777
Amprimo M C (abst) . . . 767
Andersen M J F: *See* Jespersen B et al.
Anderton J L (abst) . . . 72
Andrassy K (abst) . . . 901
Andres A: *See* Praga M et al.
Andres A (abst) . . . 832, 839
Andreu J (abst) . . . 837
Andreucci V E: *See* Memoli B et al.
Androjna C: *See* Davenport A et al.
Anelli A: *See* Borgatti P P et al.
Anelli A: *See* Brancaccio D et al.
Ang K S (abst) . . . 792, 799
Angelini D (abst) . . . 759, 794
Antonelli A (abst) . . . 759, 794
Antoniadis A (abst) . . . 781, 908
Antonsen S: *See* Otte K E et al.
Anwar N (abst) . . . 838
Aoike I: *See* Arakawa M et al.
Aparicio M (abst) . . . 789, 801
Aparicio S (abst) . . . 297, 763
Aparicio S R: *See* Goode N P et al.
Aparicio S R (abst) . . . 905
Aprile M: *See* Mastrangelo F et al.
Aquilar J (abst) . . . 838
Arakawa M
Long-Term Multicentre Study on Beta$_2$-Microglobulin Removal by PMMA BK Membrane . S269
Arakawa M, Suzuki Y, Nagao M, Aoike I, Koda Y, Terada R, Kunitomo T
Development of a New Antithrombogenic Continuous Ultrafiltration System (ACUS) and its Clinical Evaluation . . . S249
Argilés A (abst) . . . 800, 813, 815
Ariano R: *See* Bufano G et al.
Arisz L: *See* Struijk D G et al.
Arisz L (abst) . . . 784, 811, 812
Armada E (abst) . . . 819, 820
Arora P: *See* Kher V et al.
Arrieta J (abst) . . . 755
Arrobas M (abst) . . . 821
Arroyo M (abst) . . . 788
Arvanitis D (abst) . . . 803
Asmus G: *See* Schaefer K et al.

Atanasov N: *See* Masin G et al.
Atanassov C (abst) . . . 901
Atkins R C (abst) . . . 801
Attoyan C (abst) . . . 801
Aucella F (abst) . . . 824
Auer J: *See* Stevens J M et al.
Avanzini G: *See* Brancaccio D et al.
Averbukh Z (abst) . . . 759, 760, 798
Avila J M: *See* Kessler M et al.
Baamonde E (abst) . . . 819, 820
Baccega M (abst) . . . 767
Baccino F M (abst) . . . 818
Badr K F
Arachidonate Cyclo-oxygenase and Lipoxygenase Products in the Mediation of Glomerular Immune Injury . . . 662
Bagger J P (abst) . . . 825
Bagnato C (abst) . . . 801
Bagros Ph (letter) . . . 151
Baguet J C (abst) . . . 828
Baicchi U (abst) . . . 827
Bailly S (abst) . . . 806
Bain B (abst) . . . 222
Bakan E: *See* Selçuk Y et al.
Baker F (abst) . . . 905
Baker L R I: *See* Brown A L et al.
Baker T (abst) . . . 299
Bakker J C: *See* Struijk D G et al.
Bala Subramanian V (abst) . . . 224, 744
Balcke P (abst) . . . 781, 807, 834, 839, 840
Baldamus C A (abst) . . . 824
Baldamus C (abst) . . . 834, 835
Baldari G (abst) . . . 793
Baldi M (abst) . . . 800
Balducci F (abst) . . . 785
Balestrieri C (abst) . . . 835
Ballanti P (abst) . . . 786
Ballarati E (abst) . . . 816
Ballardie F W (abst) . . . 302
Balletta M (abst) . . . 763
Balletta M, Libetta C, Fuiano G, Delfino M, Brunetti B, Ungaro B, Conte G
Effects of a Two-Month Treatment with Low Oral Doses of Cyclosporin on Renal Function . . . 324
Ballmer P C (abst) . . . 300
Bambauer R (abst) . . . 799
Bañasco V P: *See* Gentil M A et al.
Bancale E (abst) . . . 769, 774
Bandiani G, Camaiora E, Farina D, Nicolini M A, Perotta U, Tagliazucchi A
Long-Term Influence of Dialysis Treatment on Beta$_2$-Microglobulin, Interleukin-2 R and Tumour Necrosis Factor . . . S261
Banks R A (abst) . . . 776
Baran D (abst) . . . 768
Barazzoni G C (abst) . . . 786
Barbiano di Belgiojoso G (abst) . . . 772
Barbieri C: *See* Mondelli M U et al.
Barceló P (abst) . . . 371
Bardos P: *See* Pengloan J et al.
Barlee V (abst) . . . 808
Barone M T (abst) . . . 772
Barrau Coscuyuela J (abst) . . . 371
Barrientos A (abst) . . . 754, 788, 823
Barron J L: *See* Kwan J T C et al.
Bartlett W (abst) . . . 740
Bartoli E (abst) . . . 760
Barton I: *See* O'Doherty M J et al.
Barton I K (letter) . . . 525
Barton I K, Streather C P, Hilton P J, Bradley R D
Successful Treatment of Severe Lactic Acidosis by Haemofiltration Using a Bicarbonate-Based Replacement Fluid . . . 368
Bartůňkova J (letter) . . . 913
Basile C: *See* Rizzi D et al.
Basile C (abst) . . . 787
Basolo B (abst) . . . 767, 768, 804
Bassa P (abst) . . . 814
Bateman A M S, Larner A J, McCartney S A, Rifkin I R
Rhabdomyolysis Associated with Lithium-Induced Hyperosmolal State . . . 203
Bateman J M, Morgans B, Rainford D J
Flexible Urethrocystoscopy in Nephrological Investigation . . . 159
Batlle D C (abst) . . . 755
Batsford S (abst) . . . 901
Battisti P: *See* Cugini P et al.
Baur S (abst) . . . 825
Baurmeister U, Vienken J, Grassmann A
Biocompatibility and Membrane Development . . . S317
Bayram A (abst) . . . 830
Bazzato G (abst) . . . 789
Beaman M (abst) . . . 224
Beaufils H (abst) . . . 783
Beavis M J: *See* Topley N et al.
Beavis M J (abst) . . . 812
Beccari M: *See* Castiglione A et al.
Belardi P (abst) . . . 775
Belch J J F (abst) . . . 223, 744, 902
Beleil O M (letter) . . . 747
Bell G M (abst) . . . 780, 792, 908
Bell P R F: *See* Nicholson M L et al.
Bell P R F (abst) . . . 904
Beltrame G (abst) . . . 775, 805
Ben Hamida F (abst) . . . 815
Ben Hmida M (abst) . . . 783
Benazzi E: *See* Civati G et al.
Bending M R: *See* Kwan J T C et al.
Benhamou P Y (abst) . . . 785, 790
Benigni A: *See* Remuzzi A et al.
Bennett S E (abst) . . . 904
Bennhold I (abst) . . . 826
Bennis D (abst) . . . 769
Benziane A (abst) . . . 792, 799
Berg K J, Holdaas H, Endresen L, Fauchald P, Hartmann A, Pran T, Solbu D
Effects of Isradipine on Renal Function in Cyclosporin-Treated Renal Transplanted Patients . 725
Bergström J (abst) . . . 809
Berland Y (abst) . . . 779
Berman S (abst) . . . 759, 760, 798
Bermejo M (abst) . . . 777
Bernheim J (abst) . . . 753, 789, 791, 820
Bernis C (letter) . . . 675
Berthoux F: *See* Guerin C et al.
Berthoux F (abst) . . . 772, 835
Bertocchio P: *See* Mege J L et al.
Bertoli S (abst) . . . 772
Bestard J (abst) . . . 820
Betriu M A (abst) . . . 822
Bevan B (abst) . . . 300

Bevington A (abst) . . . 904
Beyne P: *See* Hillion D et al.
Bhatnager D (abst) . . . 838
Bianchi M (abst) . . . 770
Bianchi S (abst) . . . 793
Biddlestone L R (abst) . . . 296
Biesenbach G (abst) . . . 769
Biesenbach G, Stöger H, Zazgornik J
Successful Pregnancy of Twins in a Renal Transplant Patient with Wegener's Granulomatosis . . . 139
Bigazzi R (abst) . . . 793
Billip-Tomecka Z: *See* Gellert R et al.
Bilsland D (abst) . . . 225
Birkner T (abst) . . . 764
Birmelé B (letter) . . . 151
Birnbaum M (abst) . . . 826
Biselli L (abst) . . . 837
Bisschop P: *See* Wens R et al.
Blaehr H: *See* Langhoff E et al.
Bláha J (letter) . . . 913
Blanchier D: *See* Pengloan J et al.
Blanco A (abst) . . . 839
Boccardo P: *See* Remuzzi A et al.
Bocchino G (abst) . . . 769, 774
Bochenek A, Religa Z, Kustosz R, Wnuk-Wojnar A-M, Wnuk R, Wojnar J, Woś S, Wites M, Zembala M, Spyt T, Kokot F
Improved Biocompatibility of Extracorporeal Circulation by the Use of Auto-Oxygenation . . . S375
Bock H A: *See* Brunner F P et al.
Böcker G (abst) . . . 803
Bodrogi T (abst) . . . 829
Boero R (abst) . . . 769, 774, 804
Boeschoten E W (abst) . . . 812
Bogdańska-Straszyńska B: *See* Gellert R et al.
Boim M A (abst) . . . 784, 789
Boland A (abst) . . . 757
Boland R (abst) . . . 757
Bomanji J (abst) . . . 298
Bondatti F (abst) . . . 786
Bone J M (abst) . . . 219, 740, 743, 791, 792
Bonello F (abst) . . . 775, 805
Bonet J (abst) . . . 810
Bonete R: *See* Chauveau P et al.
Bongrand P: *See* Mege J L et al.
Bonino F (abst) . . . 800
Bonnin R (abst) . . . 372
Bonomini V: *See* Stefoni S et al.
Bonomini V
Introducing the Biology of Bioincompatibility in Dialysis . . . S21
Bonucci E (abst) . . . 786
Borca M (abst) . . . 775
Borgatti P P, Lusenti T, Franco V, Anelli A, Brancaccio D
Guyon's Syndrome in a Long-Term Haemodialysis Patient . . . 734
Borgel F (abst) . . . 785
Borgnino L C: *See* Stefoni S et al.
Borrás M (abst) . . . 810
Borrego F: *See* Selgas R et al.
Bosch F H: *See* Veltman G A M et al.
Bosch J P (abst) . . . 808
Bosch R J, Hernando N, Plaza J J, Casado S, Lopez-Novoa J M
Renal Transplantation and Red Blood Cell Sodium Transport: Role of Prednisone Treatment . . . 286
Bossinakou I (abst) . . . 803
Botella J (abst) . . . 819, 820
Botella J, Ghezzi P, Sanz-Moreno C, Milan M, Conz P, La Greca G, Ronco C
Multicentric Study on Paired Filtration Dialysis as a Short Highly Efficient Dialysis Technique . . . 715
Boudailliez B (abst) . . . 818
Bouillie M (abst) . . . 828
Bouillon R (abst) . . . 818
Boulangé M (abst) . . . 797
Boulton H (abst) . . . 816
Boulton-Jones J M: *See* Goddard I R et al.
Boulton-Jones J C (abst) . . . 297
Boulton-Jones J M (abst) . . . 69, 220, 745, 903
Boulton-Jones M: *See* Campbell J H et al.
Bouvier Ph (abst) . . . 782
Bover J (abst) . . . 372
Bowman A (abst) . . . 71
Bowmer C J: *See* Evans J H C et al.
Bowmer C J (abst) . . . 297
Bozzola G (abst) . . . 773
Brackett L (abst) . . . 808
Bradley R D: *See* Barton I K et al.
Brahm M (abst) . . . 821
Brancaccio D: *See* Borgatti P P et al.
Brancaccio D, Avanzini G, Padovese P, Gallieni M, Franceschetti S, Panzica F, Anelli A, Colantonio G, Martinelli D, Bugiani O
Desferrioxamine Infusion Can Modify EEG Tracing in Haemodialysed Patients . . . 264
Breen D: *See* O'Doherty M J et al.
Bren A F (abst) . . . 790
Briat C (abst) . . . 782
Bridoux F (abst) . . . 782
Briggs J D: *See* Gardiner D S et al.
Briggs J D: *See* McMillan M A et al.
Briggs J D (abst) . . . 71, 226, 742, 902, 909
Brillet G (abst) . . . 795
Brock J H: *See* Cannata J B et al.
Brock J H: *See* Fernández Menéndez M J et al.
Brocklebank J T: *See* Evans J H C et al.
Brocklebank J T (abst) . . . 297
Brouard R: *See* Hannedouche T et al.
Brown A L, Stephenson J R, Baker L R I, Tabaqchali S
Epidemiology of CAPD-Associated Peritonitis Caused by Coagulase-Negative Staphylococci . . . 643
Brown E A: *See* Davies S P et al.
Brown E A (abst) . . . 298
Brown G S: *See* Falkenhagen D
Brown I (abst) . . . 909
Brown J (abst) . . . 219, 742, 773, 774, 909
Brown J H (abst) . . . 789
Brown P A J (abst) . . . 218
Brown Z (abst) . . . 303
Brune T: *See* Wizemann V et al.
Brune T (abst) . . . 821
Brunetti B: *See* Balletta M et al.
Brunkhorst R: *See* Haubitz M et al.
Brunner F P: *See* Ehrich J H H et al.
Brunner F P: *See* Fassbinder W et al.
Brunner F P: *See* Geerlings W et al.
Brunner F P: *See* Rizzoni G et al.
Brunner F P: *See* Tufveson G et al.
Brunner F P (abst) . . . 751, 752, 902

Brunner F P, Bock H A, Hermle M, Thiel G, Mihatsch M J
Control of Hypertension by Verapamil Enhances Renal Damage in a Rat Remnant Kidney Model . . 420
Brunori G (abst) . . . . . 813
Brynger H: *See* Ehrich J H H et al.
Brynger H: *See* Fassbinder W et al.
Brynger H: *See* Tufveson G et al.
Bufano G, Ariano R, Pecchini P, Pecchini F
Haemodiafiltration Versus Paired Filtration Dialysis: Evaluation of *In Vivo* Solute Removal . . . . . S282
Bugiani O: *See* Brancaccio D et al.
Burden R P: *See* Innes A et al.
Burden R P (abst) . . . . . 71, 744, 773, 901
Burdon J: *See* Kwan J T C et al.
Burger H, Kootstra G, de Charro F, Leffers P
A Survey of Vascular Access for Haemodialysis in The Netherlands . . . . . 5
Burlet C (abst) . . . . . 797
Burns A (abst) . . . . . 900
Burston J (letter) . . . . . 912
Buscaroli A: *See* Stefoni S et al.
Businger J: *See* Sundal E et al.
Bygren P: *See* Saxena R et al.
Cacace G (abst) . . . . . 767, 777
Caglioti A (abst) . . . . . 763, 795
Caillette A (abst) . . . . . 838
Caimi F (abst) . . . . . 811
Cairns T: *See* Palmer A et al.
Cairns T D H (abst) . . . . . 300
Caix J (abst) . . . . . 789
Čakalaroski K: *See* Masin G et al.
Calderaro V (abst) . . . . . 755, 760, 785, 835
Calderón J (abst) . . . . . 809
Calemard E (abst) . . . . . 813
Caligara F (abst) . . . . . 816
Çaliçkan Ü (abst) . . . . . 830
Callard P (abst) . . . . . 769
Calne R: *See* Morris G E et al.
Cam G (abst) . . . . . 792, 799
Camaiora E: *See* Bandiani G et al.
Cambi V: *See* David S et al.
Cambi V (abst) . . . . . 799
Camerini C (abst) . . . . . 813
Cameron H (abst) . . . . . 909
Cameron J S: *See* Seron D et al.
Cameron J S (abst) . . . . . 761, 762, 766, 810, 900
Campbell J H, Warwick G, Boulton-Jones M, McLay A, Jackson B, Stevenson R D
Rapidly Progressive Glomerulonephritis and Nephrotic Syndrome Associated with *Mycoplasma pneumoniae* Pneumonia . . . . . 518
Campins M (abst) . . . . . 836
Campise M: *See* Casati S et al.
Campistol J M (abst) . . . . . 814, 837
Campo C: *See* Praga M et al.
Campo C (abst) . . . . . 839
Campos A (abst) . . . . . 778
Camussi G: *See* Tetta C et al.
Camussi G (abst) . . . . . 799
Canaud B (abst) . . . . . 799, 800, 815
Canavese C (abst) . . . . . 800
Cancarini G C (abst) . . . . . 813
Canino F: *See* David S et al.
Canino F (abst) . . . . . 799
Cannata J (abst) . . . . . 817
Cannata J B: *See* Fernández Menéndez M J et al.
Cannata J B (abst) . . . . . 815
Cannata J B, Diaz López J B
Insights into the Complex Aluminium and Iron Relationship . . . . . 605
Cannata J B, Gómez Alonso C, Fernández Menéndez M J, Fernández Soto I, McGregor S, Menéndez-Fraga P, Brock J H
Iron Uptake in Aluminium Overload: *In Vivo* and *In Vitro* Studies . . . . . 637
Cannella G, La Canna G, Sandrini M, Gaggiotti M, Nordio G, Movilli E, Mombelloni S, Visioli O, Maiorca R
Reversal of Left Ventricular Hypertrophy Following Recombinant Human Erythropoietin Treatment . . 31
Cantaluppi A (abst) . . . . . 810, 831
Cao-Huu T (abst) . . . . . 800
Caparrós J (abst) . . . . . 373
Capdevila L (abst) . . . . . 836
Capo C: *See* Mege J L et al.
Cappelli P (abst) . . . . . 785
Caralps A (abst) . . . . . 810
Caramelo C: *See* Ortiz A et al.
Caramelo C (abst) . . . . . 752
Caravaca F (abst) . . . . . 821
Carlini A (abst) . . . . . 759, 794
Carmody M (abst) . . . . . 298, 301
Carothers A D (abst) . . . . . 68, 297
Carozzi S (abst) . . . . . 810, 831
Carr E C: *See* Kwan J T C et al.
Carralda E (abst) . . . . . 296
Carrascosa T: *See* García-Martín F et al.
Carrascosa T (abst) . . . . . 823
Carriazo A: *See* Gentil M A et al.
Casado S: *See* Bosch R J et al.
Casado S (abst) . . . . . 752
Casals M (letter) . . . . . 374
Casanova P (abst) . . . . . 779
Casanova S (abst) . . . . . 762
Casati S, Campise M, Ponticelli C
Correction of Anaemia with Recombinant Human Erythropoietin Despite Low Serum Ferritin . . . . 452
Cashman S J: *See* Pusey C D et al.
Casino F G (abst) . . . . . 801
Castelao A M (abst) . . . . . 372
Castellanos G (abst) . . . . . 839
Castiglione A (abst) . . . . . 816
Castiglione A, Pagliaro P, Romagnoni M, Beccari M, Cavaliere G, Veneroni G, Sorgato G
Flow Cytometric Analysis of Leukocytes Eluted From Haemodialysers . . . . . S231
Castillo D: *See* Gentil M A et al.
Castillo D: *See* Martin-Malo A et al.
Castro F (abst) . . . . . 371
Castro M: *See* Martin-Malo A et al.
Cattell W R (abst) . . . . . 300, 796, 904
Catto G R D: *See* Jones M C et al.
Catto G R D (abst) . . . . . 225
Cavaliere G: *See* Castiglione A et al.
Cavalli G (abst) . . . . . 767
Cavallini M: *See* Cugini P et al.
Cavill I (abst) . . . . . 222
Cecchin E: *See* De Marchi S
Cecchin E (abst) . . . . . 760
Celendo M T (abst) . . . . . 758
Cernadas M R (abst) . . . . . 752

Cervos-Navarro J: *See* Miksits K et al.
Cesana P (abst) . . . . . 777
Chabra S C (abst) . . . . . 70
Chacón P (abst) . . . . . 372
Chalmers R J (abst) . . . . . 302
Chambers K (abst) . . . . . 302
Chan K W: *See* Chan M K et al.
Chan M K, Chan K W, Ng W L
Amelioration of Gentamycin Nephrotoxicity by Phospholipids . . . . . 608
Chan T M (abst) . . . . . 761, 766, 900
Chan T M, Lok A S F, Cheng I K P
Hepatitis C Infection Among Dialysis Patients: A Comparison Between Patients on Maintenance Haemodialysis and Continuous Ambulatory Peritoneal Dialysis . . . . . 944
Chana R S (abst) . . . . . 903
Chanliau J (abst) . . . . . 800
Chantler C (abst) . . . . . 299
Charania B: *See* Hartmann A et al.
Charra B (abst) . . . . . 813
Chauveau D (abst) . . . . . 763, 770
Chauveau P, Poignet J-L, Kuno T, Bonete R, Kerembrun A, Naret C, Delons S, Man N K, Rist E
Phosphate Removal Rate: A Comparative Study of Five High-Flux Dialysers . . . . . S2114
Chazot C (abst) . . . . . 813
Chazot I (abst) . . . . . 813
Chen C: *See* Xu J et al.
Chen C-H (abst) . . . . . 768
Chen N, Nusbaum P, Halbwachs-Mecarelli L, Lesavre P
Light-Chain Composition of Serum IgA1 and *In Vitro* IgA1 Production in IgA Nephropathy . . . . 846
Chen S C A (letter) . . . . . 73
Cheng I K P: *See* Chan T M et al.
Chensue S W (abst) . . . . . 303
Cheriex E (abst) . . . . . 803
Chicca S (abst) . . . . . 786
Chimata M (abst) . . . . . 765
Chollet-Martin S (abst) . . . . . 806
Chong G (abst) . . . . . 831
Chorh-Chuan Tan: *See* Wai-Choong Lye
Chossegros P (abst) . . . . . 838
Chotta K (abst) . . . . . 753
Choy A M (abst) . . . . . 66
Chugh K S: *See* Das T et al.
Ciccarelli M: *See* Zoccali C et al.
Cinotti G A (abst) . . . . . 786
Cioni L (abst) . . . . . 827
Cirit M (abst) . . . . . 830
Civati G (abst) . . . . . 757
Civati G, Guastoni C, Teatini U, Perego A, Perrino M L, Benazzi E, Minetti L
High-Flux Acetate Haemodialysis: A Single-Centre Experience . . . . . S275
Cizman B (abst) . . . . . 761
Clarke B F (abst) . . . . . 69
Claus R (abst) . . . . . 782
Clayton L (abst) . . . . . 908
Cledes J: *See* Gentric A
Clutterbuck E J (abst) . . . . . 294
Cochlin D (abst) . . . . . 908
Cochlin D L: *See* Macdougall I C et al.
Coen G (abst) . . . . . 786
Cohen N (abst) . . . . . 760, 798
Cohn M (abst) . . . . . 759, 760, 798
Colantonio G: *See* Brancaccio D et al.
Coleiro J (abst) . . . . . 740
Coles G A: *See* Macdougall I C et al.
Coles G A: *See* Topley N et al.
Coles G A (abst) . . . . . 67, 222, 811, 812, 908
Coles G (abst) . . . . . 812
Coli L: *See* Stefoni S et al.
Colina F (abst) . . . . . 839
Collart F: *See* Wens R et al.
Colussi G (abst) . . . . . 757, 770
Combe C (abst) . . . . . 789, 801
Comi N (abst) . . . . . 763
Conlon P (abst) . . . . . 298, 301
Constans J (abst) . . . . . 789, 801
Conte G: *See* Balletta M et al.
Conte G (abst) . . . . . 795
Conz P: *See* Botella J et al.
Cooper E H: *See* Turney J H et al.
Coppo R (abst) . . . . 754, 758, 759, 761, 762, 767, 770, 771, 777, 778
Cordonnier D (abst) . . . . . 785, 787, 790
Cordonnier D (letter) . . . . . 526
Cordy P E: *See* Muirhead N et al.
Coronel F (abst) . . . . . 754, 788, 823
Corradi B (abst) . . . . . 786
Cosci P (abst) . . . . . 786, 818
Cosyns J P (abst) . . . . . 777
Cotes P M: *See* Stevens J M et al.
Coto E (abst) . . . . . 769
Courtney J M (abst) . . . . . 224
Cowan P (abst) . . . . . 69
Crabtree J: *See* Davenport A et al.
Craig K (abst) . . . . . 739
Craig K C: *See* Swainson C P
Crellin D M (abst) . . . . . 218
Črepinko I: *See* Tomic Brzac H et al.
Crespo J M (abst) . . . . . 801
Cristina S (abst) . . . . . 772
Cristol J P (abst) . . . . . 799, 831
Critchley M (abst) . . . . . 740, 792
Cubero J J (abst) . . . . . 821
Cuevas J (abst) . . . . . 774
Cugini P, Cavallini M, Pozzilli P, Letizia C, Sepe M, Di Palma L, Battisti P
Circadian Rhythm of T-Lymphocyte Subsets, Cortisol and Cyclosporin in Kidney-Transplanted Subjects . . . . . 512
Cumming A D (abst) . . . . . 756, 906
Cunningham J (abst) . . . . . 831
Curatola A: *See* Zoccali C et al.
Curatola A (abst) . . . . . 794, 798
Curtis J (abst) . . . . . 791
Cuvelier R (abst) . . . . . 777
Cuzzola F (abst) . . . . . 794, 798
Czapla K (abst) . . . . . 220, 222
Dadak Ch (abst) . . . . . 781
Daelemans R A: *See* Nuyts G D et al.
Dagorn J C (abst) . . . . . 779
Daha M R (abst) . . . . . 787
Dal Canton A: *See* Memoli B et al.
Dal Canton A (abst) . . . . . 763, 795
Dal Col A (abst) . . . . . 757
Dalley-Yates P T (abst) . . . . . 302
Dallman M (abst) . . . . . 300
Dalton R N (abst) . . . . . 299

Daly T (abst) . . . 298
Damiani F (abst) . . . 824
Danielsen H (abst) . . . 832
Danpure C J: *See* Watts R W E et al.
Dardamanis M: *See* Elisaf M et al.
Darenkov A F, Yermolenko V M, Sinyukhin V N, Stetsyuk E A, Kochlov A P, Yarmolinski J S
Pathophysiological Effects of a Limulus Amoebocyte-Lysate-Positive Substance During Haemodialysis . . S362
Dargie H J (abst) . . . 226
Darnell A: *See* Poch E et al.
Darocha Z (abst) . . . 829
das Neves F C (abst) . . . 762
Das T, Gupta A, Sakhuja V, Gupta K L, Minz M, Chugh K S
Ocular Complications in Renal Allograft Recipients 649
Daum V (abst) . . . 799
Davenport A (abst) . . . 225, 226, 821, 902
Davenport A, Crabtree J, Androjna C, Will E J, Davison A M
Tumour Necrosis Factor Does Not Increase During Routine Cuprophane Haemodialysis in Healthy Well-Nourished Patients . . . 435
David S (abst) . . . 799
David S, Canino F, Ferrari M E, Cambi V
The Role of Adsorption in Beta$_2$-Microglobulin Removal . . . S264
Davies D R: *See* Al-Nawab M D et al.
Davies F (abst) . . . 908
Davies J E: *See* Poli de Figueiredo C E et al.
Davies M: *See* Topley N et al.
Davies M (abst) . . . 812, 903
Davies M E: *See* Macdougall I C et al.
Davies S J (abst) . . . 756, 905
Davies S P, Lacey L F, Kox W J, Brown E A
Pharmacokinetics of Cefuroxime and Ceftazidime in Patients with Acute Renal Failure Treated by Continuous Arteriovenous Haemodialysis . . . 971
Davison A M: *See* Davenport A et al.
Davison A M: *See* Goode N P et al.
Davison A M: *See* Turney J H et al.
Davison A M (abst) . . . 218, 219, 221, 225, 226, 742, 743, 763, 773, 774, 821, 836, 902, 905, 909
Dawes J: *See* Milford D V et al.
Dawnay A (abst) . . . 300
Dawnay A B S (abst) . . . 796, 904
Day J P (abst) . . . 816
Deal J E (abst) . . . 294
De Arriba G: *See* García-Martín F et al.
De Arriba G (abst) . . . 774, 781, 801, 823
Deary I J (abst) . . . 223
De Broe M E: *See* Nuyts G D et al.
Debusmann E R (abst) . . . 821
Debussche P (abst) . . . 798
de Charro F: *See* Burger H et al.
De Ferrari M E (abst) . . . 757, 770
De Filippi P G (abst) . . . 777
Deguchi N, Ohigashi T, Tazaki H, Handa M, Ikeda Y
Haemodialysis and Platelet Activation . . . S240
Deibert B: *See* Reichel H et al.
del Río G (abst) . . . 371
de la Torre B (abst) . . . 371
de la Villa I (abst) . . . 827
Delahousse M (abst) . . . 775
de Lange J J (abst) . . . 776
Delfino M: *See* Balletta M et al.
Dell'Aquilla R (abst) . . . 788
Delons S: *See* Chauveau P et al.
De Marchi S (abst) . . . 760
De Marchi S, Cecchin E
Asymptomatic Autoimmune Thyroiditis and Thyroid Dysfunction in Alport's Syndrome. A Report of Three Families . . . 79
De Marco S: *See* Rizzi D et al.
De Maria A (abst) . . . 813
Demaille J G (abst) . . . 813
Demanet C (abst) . . . 828
De Meo F (abst) . . . 778
Demol H (abst) . . . 777
Demoz M (abst) . . . 767, 818
den Hartog M (abst) . . . 823
den Hollander D (letter) . . . 748
den Ottolander G J H: *See* Stehouwer C D A et al.
den Ottolander G J H (abst) . . . 779
Denfler K (abst) . . . 839
Dennis M J: *See* Innes A et al.
Dennis M J (abst) . . . 71, 901
De Padova F (abst) . . . 787
De Paoli P (abst) . . . 760
De Pauw L: *See* Watts R W E et al.
de Précigout V (abst) . . . 789, 801
Derancourt J (abst) . . . 813
Deray G (abst) . . . 783, 795
Derfler K (abst) . . . 781, 807, 840
D'Errico M (abst) . . . 824
Derveniotis V (abst) . . . 822
de Salamanca R E (abst) . . . 823
Descamps-Latscha B: *See* Herbelin A et al.
de Sequera P (abst) . . . 774
De Simone W: *See* Memoli B et al.
De Smet R (abst) . . . 786, 788, 819
De Stefanis D (abst) . . . 767, 818
de Talancé N (abst) . . . 797
Deteix P (abst) . . . 828
Deuber H J: *See* Thews O et al.
De Vos J Y (abst) . . . 802
de Vries P M J M: *See* Kouw P M et al.
de Vries P M J M (abst) . . . 776
de Vries P M J M, Olthof C G, Solf A, Schuenemann B, Oe P L, Quellhorst E, Schneider H, Donker A J M
Fluid Balance During Haemodialysis and Haemofiltration: The Effect of Dialysate Sodium and a Variable Ultrafiltration Rate . . . 257
Devriendt J: *See* Wens R et al.
Dhole T N: *See* Kher V et al.
Diaz Lopez J B: *See* Cannata J B
Di Cillo M: *See* Pertosa G et al.
Di Cillo M (abst) . . . 768
Dick J (abst) . . . 740
Diez J (abst) . . . 787
Di Maggio A: *See* Rizzi D et al.
Dimeny E: *See* Tufveson G et al.
Dioudis C (abst) . . . 822
Di Palma L: *See* Cugini P et al.
Di Paolo B (abst) . . . 785
Dische F: *See* Palmer A et al.
Distler A: *See* Miksits K et al.
Djukanović Lj (abst) . . . 833
Dohil R (abst) . . . 299
Dolben J (abst) . . . 780
Dommergues J P (abst) . . . 776

Don B: *See* Kaysen G A et al.
Doñate T (abst) . . . 371
Donath R (abst) . . . 795
Dongradi G: *See* Haas T et al.
Donini U (abst) . . . 762, 901
Donker A J M: *See* de Vries P M J M et al.
Donker A J M: *See* Kouw P M et al.
Donker A J M: *See* Stehouwer C D A et al.
Donker A J M (abst) . . . 776, 779
Donnelly P K: *See* Nicholson M L et al.
Donnelly P K (abst) . . . 904
Donohoe J (abst) . . . 298, 301
Donovan K L, Thomas D M, Wheeler D C, Macdougall I C, Williams J D
Experience with a New Method for Percutaneous Renal Biopsy . . . 731
Dos Anjos R (abst) . . . 298
Dosquet P (abst) . . . 775
Douat N: *See* Wens R et al.
Doucet D (abst) . . . 795
Dousset B (abst) . . . 800
Dowlin J P, Agar J W M
Diclofenac-Associated Interstitial Mucinosis . . . 595
Downie I (abst) . . . 907
Downie T (abst) . . . 907
Dozio B (abst) . . . 811
Draibe S (abst) . . . 789
Dratwa M: *See* Wens R et al.
Drinovec J (abst) . . . 790
Driscoll J O (abst) . . . 302
Drosos A A (abst) . . . 781
Druet P: *See* Tournade H et al.
Druet P (abst) . . . 768
Du Cailar G (abst) . . . 793
Dubois M (abst) . . . 783, 795
Dunlay R: *See* Felsenfeld A J et al.
Durrant S T (abst) . . . 302
Durrington P N (abst) . . . 838
Dussol B (abst) . . . 779
Dyer P A (letter) . . . 600
Dyson E H (abst) . . . 219, 221, 836, 905
Dyson H (abst) . . . 763
Eadington D (abst) . . . 752
Eadington D W (abst) . . . 739, 904
Eastwood J B: *See* Pazianas M et al.
Eckardt K U (abst) . . . 906
Edmunds M (abst) . . . 302
Edmunds M E: *See* Thomson C R V et al.
Edmunds M E (abst) . . . 301, 910
Edwards A (abst) . . . 831
Edwards B D (abst) . . . 302
Eftaxias G (abst) . . . 752
Egido J (abst) . . . 765
Eher R (abst) . . . 836
Ehrich J H H: *See* Fassbinder W et al.
Ehrich J H H: *See* Geerlings W et al.
Ehrich J H H: *See* Rizzoni G et al.
Ehrich J H H: *See* Tufveson G et al.
Ehrich J H H (abst) . . . 751, 752, 771
Ehrich J H H, Rizzoni G, Brunner F P, Brynger H, Geerlings W, Fassbinder W, Raine A E G, Selwood N H, Tufveson G
Combined Report on Regular Dialysis and Transplantation of Children in Europe, 1989 . . . S137
Eiskjær H (abst) . . . 795, 832, 833
Ejskjaer H (abst) . . . 825
El Nahas A M (abst) . . . 304, 305
El Sayed A A (abst) . . . 304
Elisaf M (abst) . . . 752, 781, 908
Elisaf M, Tsianos E, Mavridis A, Dardamanis M, Pappas M, Siamopoulos K C
Antibodies Against Hepatitis C Virus (Anti-HCV) in Haemodialysis Patients: Association with Hepatitis B Serological Markers . . . 476
Ellory J C: *See* Poli de Figueiredo C E et al.
Elorriaga R (abst) . . . 817
Elseviers M M: *See* Nuyts G D et al.
Emancipator S N (abst) . . . 754, 758, 759, 768
Emmendorffer A (abst) . . . 766
Emoto Y: *See* Niwa T et al.
Endler M (abst) . . . 781
Endresen L: *See* Berg K J et al.
Erdoğan Y (abst) . . . 808, 830
Erkul I (abst) . . . 808, 830
Esbrit P (abst) . . . 756
Esnault V L M (abst) . . . 295, 900
Esparrago J (abst) . . . 821
Espinosa M (abst) . . . 809
Esposito C (abst) . . . 763
Esquerda A (abst) . . . 819
Evangelista M (abst) . . . 785
Evans C (abst) . . . 908
Evans D B: *See* Morris G E et al.
Evans D J: *See* Pusey C D et al.
Evans J H C (abst) . . . 297
Evans J H C, Brocklebank J T, Bowmer C J, Ng P C
Pharmacokinetics of Recombinant Human Erythropoietin in Children with Renal Failure . . . 709
Fabrizzi V (abst) . . . 781, 807, 840
Fahal I B (abst) . . . 743
Fahal I H: *See* Yaqoob M et al.
Faict D: *See* Topley N et al.
Faict D (abst) . . . 812
Faict D, Lameire N, Kesteloot D, Peluso F
Evaluation of Peritoneal Dialysis Solutions with Amino Acids and Glycerol in a Rat Model . . . 120
Fairbanks L D (abst) . . . 303
Falger S (abst) . . . 834
Falkenhagen D: *See* Schauer S et al.
Falkenhagen D: *See* Smollich B P et al.
Falkenhagen D, Brown G S
Clinical Evaluation of Three Haemodialysers Containing PMMA Membranes of Different Surface Area, with Special Attention to Thrombogenicity . . S243
Falkenhagen U (abst) . . . 782
Fan K S (abst) . . . 742
Farah N B, Roddie M, Lord R H H, Williams G
Ureteric Obstruction in Renal Transplants: The Role of Percutaneous Balloon Dilatation . . . 977
Farina D: *See* Bandiani G et al.
Fariña L A (abst) . . . 373
Farina M (abst) . . . 786, 804
Farinelli C C J (abst) . . . 795
Farnarier C: *See* Mege J L et al.
Fassbinder W: *See* Ehrich J H H et al.
Fassbinder W: *See* Geerlings W et al.
Fassbinder W: *See* Rizzoni G et al.
Fassbinder W: *See* Tufveson G et al.
Fassbinder W (abst) . . . 751, 752
Fassbinder W, Brunner F P, Brynger H, Ehrich J H H, Geerlings W, Raine A E G, Rizzoni G, Selwood N H, Tufveson G, Wing A J

Combined Report on Regular Dialysis and Transplantation in Europe, XX, 1989 . . . . . S15
Fauchald P: *See* Berg K J et al.
Fauchald P: *See* Hartmann A et al.
Favre H (abst) . . . . . 795, 798
Fdez-Fdez J (abst) . . . . . 819, 820
Fdez-Giron F (abst) . . . . . 819
Fedele A (abst) . . . . . 787
Feehally J: *See* Thomson C R V et al.
Feehally J (abst) . . . . . 302, 900, 901, 904
Feest T G (abst) . . . . . 782
Feliciangeli F: *See* Stefoni S et al.
Fell G S: *See* Fernández Menéndez M J et al.
Feller P (abst) . . . . . 813
Felsenfeld A (abst) . . . . . 819
Felsenfeld A J: *See* Martinez M E et al.
Felsenfeld A J, Rodriguez M, Dunlay R, Llach F
A Comparison of Parathyroid Gland Function in Haemodialysis Patients with Different Forms of Renal Osteodystrophy . . . . . 244
Fenwick M (abst) . . . . . 739, 910
Ferguson J (abst) . . . . . 225
Fernandez A (abst) . . . . . 822
Fernández E (abst) . . . . . 822
Fernindez I (abst) . . . . . 815, 817
Fernández J (abst) . . . . . 787
Fernández M (abst) . . . . . 829
Fernández Menéndez M J: *See* Cannata J B et al.
Fernández Menéndez M J, Fell G S, Brock J H, Cannata J B
Aluminium Uptake by Intestinal Cells: Effect of Iron Status and Precomplexation . . . . . 672
Fernández Soto I: *See* Cannata J B et al.
Fernández Vega F (abst) . . . . . 769
Fernando R L: *See* Wheeler D C et al.
Fernicola L (abst) . . . . . 761, 771
Ferrari G (abst) . . . . . 822
Ferrari M E: *See* David S et al.
Ferro M (abst) . . . . . 767
Fessi H (abst) . . . . . 806
Fialkow P J (abst) . . . . . 775
Filella X (abst) . . . . . 814
Fine L G (abst) . . . . . 304
Finn R: *See* Yaqoob M et al.
Finn R (abst) . . . . . 780
Fiorini I (abst) . . . . . 794
Fischer G (abst) . . . . . 826
Fischer H R A: *See* Stehouwer C D A et al.
Flatmark A: *See* Hartmann A et al.
Flavier J L (abst) . . . . . 800, 815
Fleming L W (abst) . . . . . 222, 743, 744
Fleming L W, Halls D J, Henderson I S, Mactier R A, Taylor J E, Stewart W K
Aluminium Content of Water for Injection Used with Recombinant Human Erythropoietin . . . . . 857
Fleming S (abst) . . . . . 741, 756, 906
Flemming S (abst) . . . . . 296
Fletcher L F (abst) . . . . . 223
Fleuru H: *See* Guerin C et al.
Fleury D (abst) . . . . . 782
Fliser D: *See* Ritz E et al.
Fliser D (abst) . . . . . 771
Fliser D (letter) . . . . . 600
Flower A J E: *See* Thomson C R V et al.
Fontanellas A (abst) . . . . . 823
Forbes C D (abst) . . . . . 744, 902
Forbes M A: *See* Turney J H et al.
Formica M (abst) . . . . . 804
Forneris G (abst) . . . . . 769, 804, 805
Foster M H (abst) . . . . . 761
Foulon M M (abst) . . . . . 787
Fournier A (abst) . . . . . 798, 815, 818
Fournier A (letter) . . . . . 676
Fowler I (abst) . . . . . 745
Fox J G (abst) . . . . . 745
Frampton G (abst) . . . . . 766, 900
Frampton G J (abst) . . . . . 761
Franceschetti S: *See* Brancaccio D et al.
Franceschini R (abst) . . . . . 767
Francioso A (abst) . . . . . 822
Franco V: *See* Borgatti P P et al.
Franz H E (abst) . . . . . 753
Franz M (abst) . . . . . 836
Freestone S (abst) . . . . . 739, 752
Frei U: *See* Haubitz M et al.
Frenken L (abst) . . . . . 823
Frier B M (abst) . . . . . 904
Friman S: *See* Nordén G et al.
Frisenette-Fich C: *See* Nordén G et al.
Frutos M: *See* Martinez M E et al.
Fučíkova T (letter) . . . . . 913
Fuiano G: *See* Balletta M et al.
Fuiano G (abst) . . . . . 763, 795
Fujii R (abst) . . . . . 802
Fujinami T (abst) . . . . . 809
Fujisawa K (abst) . . . . . 765
Fujishima M: *See* Onoyama K et al.
Fujishima M: *See* Sanai T et al.
Fujiwara Y (abst) . . . . . 797
Fukunaga M (abst) . . . . . 784, 797
Fünfstück R (abst) . . . . . 772
Furet Y (letter) . . . . . 151
Gabás J (letter) . . . . . 374
Gaggiotti M: *See* Cannella G et al.
Gaggiotti M (abst) . . . . . 826
Gago E (abst) . . . . . 769
Gahl G M: *See* Jörres A et al.
Gahl G M (abst) . . . . . 811
Gaillard G (abst) . . . . . 828
Galato R (abst) . . . . . 757
Gallego M J (abst) . . . . . 752
Gallego N (abst) . . . . . 777
Gallieni M: *See* Brancaccio D et al.
Gámez C (abst) . . . . . 783, 829, 832
Gammelgaard B: *See* Jespersen B et al.
Gammelgaard B (abst) . . . . . 816
Gans R O B (abst) . . . . . 779
Garay R (abst) . . . . . 776
Garcia C (abst) . . . . . 821
Garcia Canton C (letter) . . . . . 675
Garcia Labat F (abst) . . . . . 371
García Martín F (abst) . . . . . 801
García-Cañero R (abst) . . . . . 756
García-Martín F (abst) . . . . . 774, 781, 823
García-Martín F, De Arriba G, Carrascosa T, Moldenhauer F, Martin-Escobar E, Val J, Saiz F
Anticardiolipin Antibodies and Lupus Anticoagulant in End-Stage Renal Disease . . . . . 543
García-Ocaña A (abst) . . . . . 756
Gardiner D S (abst) . . . . . 742
Gardiner D S, Watson M A, Junor B J R, Briggs J D, More I A R, Lindop G B M

The Effect of Conversion from Cyclosporin to Azathioprine on Renin-Containing Cells in Renal Allograft Biopsies . . . 363
Garini G (abst) . . . 758
Garlick P J (abst) . . . 300
Garred L J (abst) . . . 800, 824
Garrett P J (letter) . . . 912
Garrido M C: *See* Poli de Figueiredo C E et al.
Garron M P: *See* Ortiz A et al.
Gascó J (abst) . . . 820
Gascon-Barré M (abst) . . . 768
Gaskin G (abst) . . . 296, 900
Gaskin G, Savage C O S, Ryan J J, Jones S, Rees A J, Lockwood C M, Pusey C D
Anti-neutrophil Cytoplasmic Antibodies and Disease Activity During Long-Term Follow-up of . . . 70 Patients with Systemic Vasculitis . . . 689
Gattarello G: *See* Mondelli M U et al.
Gaudiano V (abst) . . . 801
Gawin R (abst) . . . 305
Gea T (abst) . . . 819
Geerlings W: *See* Ehrich J H H et al.
Geerlings W: *See* Fassbinder W et al.
Geerlings W: *See* Rizzoni G et al.
Geerlings W: *See* Tufveson G et al.
Geerlings W (abst) . . . 751, 752
Geerlings W, Tufveson G, Brunner F P, Ehrich J H H, Fassbinder W, Landais P, Mallick N, Margreiter R, Raine A E G, Rizzoni G, Selwood N
Combined Report on Regular Dialysis and Transplantation in Europe XXI, 1990 . . . S45
Geffriaud C (abst) . . . 763
Gellert R, Billip-Tomecka Z, Hijaz H, Bogdańska-Straszyńska B, Małecka B, Siciński A
Intradialytic Erythrocyte Volume Changes . . . S310
Genderini A (abst) . . . 772
Genesca J (abst) . . . 836
Genin C (abst) . . . 772
Gentil M A (abst) . . . 838
Gentil M A, Carriazo A, Pavón M I, Rosado M, Castillo D, Ramos B, Algarra G R, Tejuca F, Bañasco V P, Milan J A
Comparison of Survival in Continuous Ambulatory Peritoneal Dialysis and Hospital Haemodialysis . . . 444
Gentric A, Cledes J
Immediate and Long-Term Prognosis in Acute Renal Failure in the Elderly . . . 86
Georgoussi E (abst) . . . 803
Gerdin B (abst) . . . 838
Gerlag P (abst) . . . 823
Germans H (abst) . . . 810
Gesualdo L (abst) . . . 768
Gesuete A (abst) . . . 824
Ghazali A (abst) . . . 815
Ghazalli R (abst) . . . 801
Ghezzi P: *See* Botella J et al.
Ghosh A K: *See* Kher V et al.
Giacchino F (abst) . . . 837
Giammaria U (abst) . . . 778
Giangrande A (abst) . . . 816
Gianoglio B (abst) . . . 754, 758, 759, 761, 762, 770, 771
Gibb L A (abst) . . . 66
Gibson I W (abst) . . . 907
Gibson M (abst) . . . 224
Gibson S M (abst) . . . 808
Gibson S P, Mosquera D
Five Years Experience with the Quinton Permcath for Vascular Access . . . 269
Gibson S P, Mosquera D A, O'Donnell M J, Odurny A
Streptokinase in the Treatment of Innominate-Vein Thrombosis in Association with Haemodialysis Catheter. Preservation of a Precious Arteriovenous Fistula . . . 206
Gilbert B (abst) . . . 802
Giles G R: *See* Kashi S H et al.
Gillett M P T: *See* Wheeler D C et al.
Gilroy M (abst) . . . 741
Giordano C (abst) . . . 755, 785, 835
Giordano R (abst) . . . 787
Giovane A (abst) . . . 835
Girardier L (abst) . . . 795
Giraudo G (abst) . . . 767, 775, 805
Giusti R (abst) . . . 759, 794
Gjorstrup P: *See* Palmer A et al.
Gladziwa U (abst) . . . 803
Glancey G R (abst) . . . 810
Glatzl J (abst) . . . 765
Gluck G: *See* Palmer A et al.
Gnant M (abst) . . . 834
Gobernado J M (abst) . . . 778
Goddard I R (abst) . . . 69, 220, 745
Goddard I R, Jackson R, Boulton-Jones J M
AL Amyloidosis: Therapeutic Response in Two Patients with Renal Involvement . . . 592
Godin M: *See* Hannedouche T et al.
Gokal R (abst) . . . 224, 789, 816, 838
Golik A (abst) . . . 759, 760
Gomez Alamillo C (abst) . . . 371
Gómez Alonso C: *See* Cannata J B et al.
Gomez Charri M (abst) . . . 754
Gómez E (abst) . . . 769
Gómez-Chiarri M (abst) . . . 765
González E (abst) . . . 765
González G (abst) . . . 372
González M T (abst) . . . 372
Gonzalo A (abst) . . . 770, 778
Goode N P (abst) . . . 218, 219, 763, 905
Goode N P, Shires M, Aparicio S R, Davison A M
Cationic Colloidal Gold – A Novel Marker for the Demonstration of Glomerular Polyanion Status in Routine Renal Biopsies . . . 923
Gordge M P, Leaker B R, Rylance P B, Neild G H
Haemostatic Activation and Proteinuria as Factors in the Progression of Chronic Renal Failure . . . 21
Gordon I (abst) . . . 907
Gorostidi M: *See* Peces R et al.
Gotheil C (abst) . . . 769
Gottsauner-Wolf M (abst) . . . 840
Gougerot-Pocidalo M A (abst) . . . 806
Gouldesbrough D R: *See* Kharbanda R et al.
Gouldesbrough D R: *See* Oliver T B et al.
Gouldesbrough D R (abst) . . . 68
Goulthard M G (abst) . . . 220
Goutcher E (abst) . . . 221
Gower P E (abst) . . . 298
Gowland G (abst) . . . 218
Gradowska L (abst) . . . 831
Graf H (abst) . . . 824
Graham S: *See* Thomson C R V et al.
Grandes S (abst) . . . 752
Granolleras C (abst) . . . 802, 824
Grant A C (abst) . . . 223

Grant I S (abst) . . . 221
Grassi R (abst) . . . 759
Grassman A: *See* Baurmeister U et al.
Grazioli L (abst) . . . 813
Grčevska L (abst) . . . 764
Green N J (abst) . . . 296
Greeves I (abst) . . . 909
Gregorini G (abst) . . . 773
Gregorio Marañon H G (abst) . . . 753
Gregson N (abst) . . . 766
Grekas D (abst) . . . 822
Grierson D (abst) . . . 297
Griffin A (abst) . . . 298
Grime J S (abst) . . . 740, 792
Griño J M (abst) . . . 372
Gris P (abst) . . . 777
Groeneveld A B J (abst) . . . 784
Grönhagen-Riska C (abst) . . . 764, 838
Gronow G (abst) . . . 839
Groussin A (abst) . . . 801
Grunewald J M (abst) . . . 753
Grunewald R W (abst) . . . 753
Grünfeld J P: *See* Hannedouche T et al.
Grünfeld J P (abst) . . . 763, 770
Gruteke P: *See* Kouw P M et al.
Grützmacher P (abst) . . . 817
Grzeszczak W (abst) . . . 807, 829, 831
Guarena C (abst) . . . 769
Guarnieri G (abst) . . . 813
Guastoni C: *See* Civati G et al.
Guastoni G (abst) . . . 757
Guérin C (abst) . . . 835
Guérin C, Pomier G, Laverne S, Fleuru H, Le Petit J C, Berthoux F
Renal Transplantation with a Current T Negative but Historical T and/or B Positive Cross-Match . . . 280
Guerrero A (abst) . . . 838
Guery J-C: *See* Tournade H et al.
Guida C C (abst) . . . 824
Guilbert B: *See* Tournade H et al.
Gulanikar A C, Jindal K K, Hirsch D J
Is Chronic Peritoneal Dialysis Safe in Patients with Intra-Abdominal Prosthetic Vascular Grafts? . . . 215
Gullo M (abst) . . . 763
Gupta A: *See* Das T et al.
Gupta A: *See* Kher V et al.
Gupta K L: *See* Das T et al.
Gürbilek M (abst) . . . 808, 830
Gurland H J: *See* Kröner G et al.
Gurland H J
Closing Remarks . . . S2126
Guse J (abst) . . . 744
Gutierrez J A (abst) . . . 372
Haas T: *See* Hillion D et al.
Haas T, Hillion D, Dongradi G
Phosphate Kinetics In Dialysis Patients . . . S2108
Hackeng W H L: *See* Stehouwer C D A et al.
Hackeng W H L (abst) . . . 779
Hadaya K (abst) . . . 790
Hagemann J: *See* Schaefer K et al.
Hahn H: *See* Miksits K et al.
Haidland A: *See* Schaefer R M et al.
Haites N E (abst) . . . 299
Hakim R M: *See* Schulman G
Halati A (abst) . . . 822
Halbhuber K J (abst) . . . 772
Halbwachs-Mecarelli L: *See* Chen N et al.
Halimi S (abst) . . . 785
Hallett I: *See* Macdougall I C et al.
Hällgren R (abst) . . . 838
Halls D J: *See* Fleming L W et al.
Halls D J (abst) . . . 743
Halma C (abst) . . . 787
Hamad S (abst) . . . 782
Hamanaka I: *See* Okutsu I et al.
Hamels J (abst) . . . 777
Handa M: *See* Deguchi N et al.
Hannedouche T, Brouard R, Godin M, Kleinknecht D, Paillard F, Grünfeld J P
Chronic effects of tertatolol on Renal Function in Hypertensive Patients with Mild Chronic Renal Failure . . . 252
Hansen H E (abst) . . . 832
Harmer A (abst) . . . 294
Harmer A W (abst) . . . 294
Harper P S (abst) . . . 908
Harper S J (abst) . . . 901, 904
Harris K P G (abst) . . . 905
Harrison D J: *See* Kharbanda R et al.
Harrison S P: *See* Laxton J C et al.
Hart P D (abst) . . . 831
Hartley B (abst) . . . 294, 762
Hartmann A: *See* Berg K J et al.
Hartmann A, Charania B, Sund S, Holdaas H, Fauchald P, Flatmark A
Interstitial Nephritis with Extensive Calcium Deposits as a Cause of Renal Allograft Failure . . . 984
Hartter E (abst) . . . 834
Harwood S M (abst) . . . 796, 904
Haskard D O: *See* Seron D et al.
Hastka J (abst) . . . 825
Hatogai H (abst) . . . 827
Hattersley J (abst) . . . 901
Haubitz M, Frei U, Rother U, Brunkhorst R, Koch K M
Cyclophosphamide Pulse Therapy in Wegener's Granulomatosis . . . 531
Hauck W: *See* Seyfert U T et al.
Hauser A C (abst) . . . 839, 840
Hay C (abst) . . . 791
Haycock G B (abst) . . . 298, 299
Haylor J (abst) . . . 304
Hazzan M (abst) . . . 782
Hé C J (abst) . . . 756
Heaf J G (abst) . . . 816
Heatley R V (abst) . . . 226
Hecht M (abst) . . . 782
Heidland A: *See* Paczek L et al.
Heidland A: *See* Schaefer R M et al.
Heidland A (abst) . . . 774
Helliwell T: *See* Yaqoob M et al.
Helmling E: *See* Seyfert U T et al.
Henderson I (abst) . . . 301, 744, 902
Henderson I S: *See* Fleming L W et al.
Henderson I S (abst) . . . 70, 222, 223, 743, 796
Hendry B M: *See* Poli de Figueiredo C E et al.
Herbelin A, Ureña P, Nguyen A T, Zingraff J, Descamps-Latscha B
Influence of First and Long-Term Dialysis on Uraemia-Associated Increased Basal Production of Interleukin-1 and Tumour Necrosis Factor alpha by Circulating Monocytes . . . 349

Herman K (abst) . . . 816
Hermle M: *See* Brunner F P et al.
Hernandez E: *See* Praga M et al.
Hernandez J (abst) . . . 820
Hernando L (abst) . . . 752, 765
Hernando N: *See* Bosch R J et al.
Herrero J A (abst) . . . 823
Herrero J (abst) . . . 754
Hesse U J (abst) . . . 835
Hestin D (abst) . . . 800
Hewitson T D: *See* Nakajima M et al.
Heyl K (abst) . . . 764
Hidaka S (abst) . . . 765
Hijaz H: *See* Gellert R et al.
Hiley C (abst) . . . 756, 905, 908
Hill C M (abst) . . . 220
Hill F G: *See* Milford D V et al.
Hillion D: *See* Haas T et al.
Hillion D, Haas T, Uzan M, Pertuiset N, Beyne P
Biocompatibility of PMMA Membranes Used in Haemofiltration and Haemodiafiltration: Beta$_2$-Microglobulin Removal and Release of Granulocyte Elastase . . . S284
Hilton P J: *See* Barton I K et al.
Hinglais N: *See* Tournade H et al.
Hintner H (abst) . . . 765
Hinwood M (abst) . . . 773
Hirao A (abst) . . . 826
Hirasawa Y (abst) . . . 802
Hirsch D J: *See* Gulanikar A C et al.
Hirsch D J, Jindal K K
Late Leaks in Peritoneal Dialysis Patients . . . 670
Hirschl M M (abst) . . . 839
Hobby P (abst) . . . 761, 900
Hodsman A B: *See* Muirhead N et al.
Hoitsma A J: *See* Merkus J W S et al.
Holdaas H: *See* Berg K J et al.
Holdaas H: *See* Hartmann A et al.
Holgersson J (abst) . . . 300
Holland M J: *See* Pusey C D et al.
Hollomby D J: *See* Muirhead N et al.
Hombrouckx R (abst) . . . 802
Honkanen E (abst) . . . 764, 838
Hori K: *See* Onoyama K et al.
Hori K: *See* Sanai T et al.
Hortal L (abst) . . . 822
Howie A J (abst) . . . 296, 909
Hruby Z (abst) . . . 764
Hsu C (abst) . . . 819
Huang C-C (abst) . . . 768
Huang Z: *See* Xu J et al.
Huarte Loza E (abst) . . . 371
Huber W (abst) . . . 840
Hudson S (abst) . . . 744
Hughes R T: *See* Stevens J M et al.
Hull W E (abst) . . . 833
Hüller M: *See* Stein G et al.
Hulme B (abst) . . . 222
Hunt L (abst) . . . 789
Hutchinson R M: *See* Thomson C R V et al.
Hutchinson S M W (abst) . . . 68
Hutchison A J (abst) . . . 224, 816
Hutten H: *See* Thews O et al.
Hutton R D: *See* Macdougall I C et al.
Hysek H (abst) . . . 781
Iannelli S: *See* Stefoni S et al.
Idee J M (abst) . . . 795
Iida N (abst) . . . 802
Ikeda C (abst) . . . 827
Ikeda M (abst) . . . 809
Ikeda Y: *See* Deguchi N et al.
Iliopoulou E (abst) . . . 803
Ilkenhans C (abst) . . . 780
Imada A (abst) . . . 802
Imagawa D (abst) . . . 826
Innes A (abst) . . . 71, 744, 773, 901
Innes A, Pal C R, Dennis M J, Ryan J J, Morgan A G, Burden R P
Post-Transplant Erythrocytosis and Immunosuppression with Cyclosporin: A Case-Control Study . . . 588
Introna Jr F: *See* Rizzi D et al.
Ironside J (abst) . . . 821
Ironside J W (abst) . . . 902
Irvine L (abst) . . . 224
Irving H C: *See* Kashi S H et al.
Irzyniec T (abst) . . . 790
Ishibashi M (abst) . . . 784, 797
Isidoro C (abst) . . . 767, 818
Isles C (abst) . . . 909
Isles C G (abst) . . . 69
Ito H (abst) . . . 765
Itoh H (abst) . . . 827
Ittel T H (abst) . . . 817
Ius A (abst) . . . 760
Ivanov A (abst) . . . 776
Ivanovski N: *See* Masin G et al.
Iványi B (letter) . . . 375
Iwadare M (abst) . . . 827
Iwamoto I (abst) . . . 802
Jackson B: *See* Campbell J H et al.
Jackson M J (abst) . . . 792
Jackson R: *See* Goddard I R et al.
Jackson R (abst) . . . 220
Jacob C (abst) . . . 800
Jacobs C (abst) . . . 783, 795
Jacquiaud C (abst) . . . 783
Jagietto R (abst) . . . 831
Jamieson N V: *See* Morris G E et al.
Jankova T, Tchankova P, Nenov D
Low Prekallikrein and High Angiotensin-Converting Enzyme Activity in Patients with Chronic Renal Failure on Haemodialysis . . . S36
Jaraba M: *See* Martin-Malo A et al.
Jardi R (abst) . . . 836
Jardin A (abst) . . . 740
Jarillo M D (abst) . . . 774, 801, 827
Jauregui-Adell J (abst) . . . 813
Jayne D R W (abst) . . . 295, 761
Jeffrey R F (abst) . . . 836
Jelonek A (abst) . . . 837
Jenkins D A S (abst) . . . 69, 756, 906
Jenkins H (abst) . . . 299
Jensen J D: *See* Jespersen B et al.
Jensen J D (abst) . . . 795, 825
Jensen T M: *See* Otte K E et al.
Jespersen B: *See* Lauridsen I N et al.
Jespersen B (abst) . . . 795, 832
Jespersen B, Jensen J D, Nielsen H K, Lauridsen I N, Andersen M J F, Poulsen J H, Gammelgaard B, Pedersen E B
Comparison of Calcium Carbonate and Aluminium

Hydroxide as Phosphate Binders on Biochemical Bone Markers, PTH(1–84) . . . 98
Jespersen B, Sørensen S S, Pedersen E B
Effect of Frusemide on Atrial Natriuretic Peptide, Guanosine Cyclic Monophosphate, Angiotensin II, Aldosterone, Vasopressin, Prostaglandin $E_2$ and Blood Volume in the Nephrotic Syndrome . . . 402
Jewkes R E (abst) . . . 298
Jiang J: *See* Xu J et al.
Jimenez F (abst) . . . 822
Jimenez M (abst) . . . 807, 827
Jindal K K: *See* Gulanikar A C et al.
Jindal K K: *See* Hirsch D J
Jing Y (abst) . . . 224
Joannidis M (abst) . . . 753, 765
Jofre R (abst) . . . 753
Johnston P (abst) . . . 221, 742, 773, 774, 909
Johnston R (abst) . . . 219
Jones D R E (abst) . . . 744
Jones J K (abst) . . . 906
Jones J M (abst) . . . 67
Jones M C (abst) . . . 218, 299, 741
Jones M C, Stewart K N, Propper D J, Catto G R D, Power D A
The Effect of Cyclosporin Administered During a Third-Party Blood Transfusion Protocol on Humoral Immune Responses . . . 125
Jones N F: *See* Al-Nawab M D et al.
Jones P W (abst) . . . 908
Jones S: *See* Gaskin G et al.
Jorens Ph G: *See* Nuyts G D et al.
Jørgensen K A: *See* Otte K E et al.
Jörres A (abst) . . . 811, 812
Jörres A, Jörres D, Topley N, Gahl G M, Mahiout A
Leukotriene Release from Peripheral and Peritoneal Leukocytes Following Exposure to Peritoneal Dialysis Solutions . . . 495
Jörres D: *See* Jörres A et al.
Julien M (abst) . . . 776
Junco E (abst) . . . 753
Jung W K (abst) . . . 799
Junor B J R: *See* Gardiner D S et al.
Junor B J R: *See* McGregor E et al.
Junor B J R: *See* McMillan M A et al.
Junor B J R (abst) . . . 71, 226, 742, 902, 909
Kaever V (abst) . . . 812
Kaiser W (letter) . . . 374
Kakuta S (abst) . . . 765
Kamata K (abst) . . . 765
Kameoka H (abst) . . . 784, 797
Kanfer A (abst) . . . 828
Kanfer A (letter) . . . 676
Kapadia F H (abst) . . . 221
Kaplan Pavlovčič S (abst) . . . 790
Kaplanski S: *See* Mege J L et al.
Kappeler A: *See* Sundal E et al.
Karamitsos K (abst) . . . 825
Karlberg I: *See* Nordén G et al.
Kashi S H, Lodge J P A, Giles G R, Irving H C
Ultrasonography of Renal Allografts: Collecting System Dilatation and Its Clinical Significance . . . 358
Kaskas B (abst) . . . 762
Kataoka H: *See* Sugisaki H et al.
Katbamna I (abst) . . . 296
Kawano Y (abst) . . . 826
Kawashima S (abst) . . . 826
Kaye M (letter) . . . 150
Kaysen G A, Don B, Schambelan M
Proteinuria, Albumin Synthesis and Hyperlipidaemia in the Nephrotic Syndrome . . . 141
Kazatchkine M D: *See* Maillet F
Kelleher J P (abst) . . . 907
Keller F (abst) . . . 833
Kendall R G (abst) . . . 796, 904
Kenouch S (abst) . . . 775
Keoplung M (abst) . . . 783
Kerembrun A: *See* Chauveau P et al.
Kerr P (abst) . . . 815
Kerr P T (abst) . . . 801
Kes P (abst) . . . 796
Kessler M (abst) . . . 800
Kessler M, Avila J M, Renoult E, Mathieu P
Reoperation for Secondary Hyperparathyroidism in Chronic Renal Failure . . . 176
Kesteloot D: *See* Faict D et al.
Khan A A (abst) . . . 743
Khan A (abst) . . . 838
Khana S K (abst) . . . 902
Kharbanda R, Lauder J, Thomson D, Gouldesbrough D R, Harrison D J
Heterogeneity of Glutathione S-Transferase Isoenzyme Expression in Renal Disease . . . 695
Kher V, Ghosh A K, Gupta A, Arora P, Dhole T N
Visceral Leishmaniasis: An Unusual Case of Fever in a Renal Transplant Recipient . . . 736
Khiraoui F (abst) . . . 763
Kincaid-Smith P: *See* Nakajima M et al.
King R (abst) . . . 821
King R F G (abst) . . . 902
Kingstone D: *See* Wheeler D C et al.
Kinugasa E (abst) . . . 814
Kizaki T (abst) . . . 296
Kjellstrand P (abst) . . . 812
Klančar J (abst) . . . 790
Klaus G (abst) . . . 817
Klause N (abst) . . . 839
Klauser R (abst) . . . 834, 836
Kleinknecht D: *See* Hannedouche T et al.
Kleinknecht D (abst) . . . 769, 776, 782
Klinkmann H: *See* Smollich B P et al.
Klinkmann H (abst) . . . 782
Knudsen F: *See* Otte K E et al.
Kobayashi N (abst) . . . 765
Koch K M: *See* Haubitz M et al.
Koch K M (abst) . . . 824, 826
Koch M: *See* Ritz E et al.
Kochlov A P: *See* Darenkov A F et al.
Koda Y: *See* Arakawa M et al.
Koene R A P: *See* Merkus J W S et al.
Koene R (abst) . . . 823
Koffman C G (abst) . . . 294
Kokot F: *See* Bochenek A et al.
Kokot F (abst) . . . 798, 829, 831
Kolonduck N (abst) . . . 776
Komen G C M (abst) . . . 812
König P (abst) . . . 753, 765
Konstantin P (abst) . . . 802
Kontessis P S (abst) . . . 803
Kooman J P (abst) . . . 803
Koomen G C M: *See* Struijk D G et al.
Koomen G C M (abst) . . . 811
Kootstra G: *See* Burger H et al.

Koram A (abst) . . . 296
Kornerup H J (abst) . . . 832
Koselj M (abst) . . . 790
Koshikawa S (abst) . . . 814
Kouw P (abst) . . . 803
Kouw P M (abst) . . . 776
Kouw P M, Olthof C G, Gruteke P, de Vries P M J M, Meijer J H, Oe P L, Schneider H, Donker A J M
Influence of High and Low Sodium Dialysis on Blood Volume Preservation . . . 876
Kouwenberg J H (abst) . . . 793
Kovarik J (abst) . . . 834, 836
Kox W J: *See* Davies S P et al.
Kozioł M: *See* Książek A
Kramer W: *See* Wizemann V et al.
Krause R (abst) . . . 826
Krautzig S (abst) . . . 802
Krediet R T: *See* Struijk D G et al.
Krediet R T (abst) . . . 784, 811, 812
Kronenberg F (abst) . . . 753
Kröner G, Stäbler A, Seiderer M, Moran J E, Gurland H J
$Beta_2$-Microglobulin-Related Amyloidosis Causing Atlantoaxial Spondylarthropathy with Spinal-Cord Compression in Haemodialysis Patients: Detection by MRI . . . S291
Kruppenbacher J (abst) . . . 834
Książek A, Kozioł M
Phagocytic Function of Neutrophils During Dialysis in Relation to Some Immunological Findings . . . S331
Kubara C (abst) . . . 305
Kudlacek T (abst) . . . 836
Kühn B (abst) . . . 772
Kühn R (abst) . . . 772
Kulzer P (abst) . . . 774
Kunitomo T: *See* Arakawa M et al.
Kunitomo T: *See* Sugisaki H et al.
Kunkel S L (abst) . . . 303
Kuno T: *See* Chauveau P et al.
Kunz F (abst) . . . 753
Kurilenko S (abst) . . . 791
Kuroda Y (abst) . . . 826
Kurz P (abst) . . . 817
Kusakari S (abst) . . . 808
Kustosz R: *See* Bochenek A et al.
Kuźniar J (abst) . . . 764
Kveder R (abst) . . . 790
Kwan J T C (abst) . . . 831
Kwan J T C, Carr E C, Neal A D, Burdon J, Raftery M J, Marsh F P, Barron J L, Bending M R
Carbamylated Haemoglobin, Urea Kinetic Modelling and Adequacy of Dialysis in Haemodialysis Patients 38
Kwasny H (abst) . . . 821
Labeeuw M (abst) . . . 838
La Canna G: *See* Cannella G et al.
Lace R (abst) . . . 770
Lacey L F: *See* Davies S P et al.
Ladefoged J: *See* Langhoff E et al.
Lafayette R (abst) . . . 791
Lagona C (abst) . . . 772
La Greca G: *See* Botella J et al.
Lalau J D (abst) . . . 798
Lamb E (abst) . . . 300
Lamb E J (abst) . . . 796, 904
Lameire N: *See* Faict D et al.
Lamm M E (abst) . . . 754, 759
Lancini L (abst) . . . 773
Landais P: *See* Geerlings W et al.
Landais P: *See* Rizzoni G et al.
Landais P (abst) . . . 751, 752, 770
Landriani N (abst) . . . 772
Lang C (abst) . . . 301
Lang C C (abst) . . . 66, 302, 796
Langhoff E, Blaehr H, Ladefoged J
Production of Prostaglandin $E_2$ by Macrophages in Uraemia . . . 966
Lao M (abst) . . . 831
Laraudiogoitia E (abst) . . . 822
Larner A J: *See* Bateman A M S et al.
Lasserre J J (abst) . . . 825
Lauder I (abst) . . . 901
Lauder J: *See* Kharbanda R et al.
Laurent G (abst) . . . 813
Laurent T (abst) . . . 838
Lauridsen I N: *See* Jespersen B et al.
Lauridsen I N: *See* Sørensen S S et al.
Lauridsen I N, Jespersen B, Thomsen K, Pedersen E B
Abnormal Glomerular and Tubular Response to Intravenous Frusemide in Patients with Chronic Glomerulonephritis . . . 466
Laurincova Z: *See* Sulkova S et al.
Lauriola V (abst) . . . 824
Lavarino G (abst) . . . 800
Laverne S: *See* Guerin C et al.
Lawrence S (letter) . . . 73
Lawson R S A (abst) . . . 302
Laxton J C, Harrison S P, Shaw A B
Assessment of Protein Intake in Early Progressive Renal Disease . . . 17
Layward L (abst) . . . 900, 901
Leaker B, Neild G H
Effect of Enalapril on Proteinuria and Renal Function in Patients with Healed Severe Crescentic Glomerulonephritis . . . 936
Leaker B R: *See* Gordge M P et al.
Lebranchu Y (letter) . . . 151
Le Carpentier J E (abst) . . . 305
Lee H A (letter) . . . 912
Lee M (abst) . . . 752
Lee M R (abst) . . . 68, 739
Lee S J (abst) . . . 296, 909
Leffers P: *See* Burger H et al.
Leimenstoll G (abst) . . . 764
Lemaître V (abst) . . . 782
Lemoine R (abst) . . . 828
Leonardis D (abst) . . . 794
Le Petit J C: *See* Guérin C et al.
Lerche D: *See* Meier W et al.
Lerma J L (abst) . . . 765
Lesavre P: *See* Chen N et al.
Lesavre P (abst) . . . 763
Leski M (abst) . . . 828
Letizia C: *See* Cugini P et al.
Leunissen K M L (abst) . . . 803
Lew S Q (abst) . . . 808
Lhotta K (abst) . . . 765
Lian J-D (abst) . . . 768
Liaño F (abst) . . . 783, 807, 827, 829
Liberek T (abst) . . . 811
Libetta C: *See* Balletta M et al.
Libetta C: *See* Memoli B et al.
Ličina A (abst) . . . 790

Lindholm B (abst) . . . 809
Lindop G B M: *See* Gardiner D S et al.
Lindop G M B (abst) . . . 907
Linß W: *See* Schauer S et al.
Lipkin G W (abst) . . . 796, 904
Litherland J C (abst) . . . 224
Llach F: *See* Felsenfeld A J et al.
Lloveras J-J: *See* Pusey C D et al.
Lockwood C M: *See* Gaskin G et al.
Lockwood C M: *See* Pusey C D et al.
Lockwood C M (abst) . . . 295, 761, 900
Loddo M (abst) . . . 839
Lodge J P A: *See* Kashi S H et al.
Lok A S F: *See* Chan T M et al.
Lomeña F (abst) . . . 814
López Farré A (abst) . . . 752
López Larrea C (abst) . . . 769
Lopez T (abst) . . . 801
Lopez-Novoa J M: *See* Bosch R J et al.
Lopez-Rivas A: *See* Selgas R et al.
Lopot F
Is Urea Kinetic Modelling an Appropriate Tool for Guiding Ultrashort High-Flux Dialysis Therapy? . . S386
Lord R H H: *See* Farah N B et al.
Lorho R (abst) . . . 831
Lou L M (abst) . . . 372
Lowe G D O (abst) . . . 224
Lozano L (abst) . . . 774, 827
Lu Y-S (abst) . . . 768
Luciak M, Trznadel K
Free Oxygen Species Metabolism During Haemodialysis with Different Membranes . . . . . S366
Lucie N P: *See* McMillan M A et al.
Lumlertgul D (abst) . . . 783
Lupton E (abst) . . . 224
Lusenti T: *See* Borgatti P P et al.
Luu T (abst) . . . 768
McCartney S A: *See* Bateman A M S et al.
McClelland P (abst) . . . 219, 743, 791
McColl K E L (abst) . . . 902
McConnell K M: *See* Rolton H A et al.
McConnell K N (abst) . . . 220
McCool B (abst) . . . 808
McDicken I (abst) . . . 791
Macdougall A I: *See* Rolton H A et al.
Macdougall A I (abst) . . . 220, 222, 223, 224, 744
Macdougall I C: *See* Donovan K L et al.
Macdougall I C (abst) . . . 67, 222
Macdougall I C, Davies M E, Hallett I, Cochlin D L, Hutton R D, Coles G A, Williams J D
Coagulation Studies and Fistula Blood Flow During Erythropoietin Therapy in Haemodialysis Patients . 862
McGladdery S (abst) . . . 297
MacGreggor I: *See* Milford D V et al.
McGregor A (abst) . . . 780, 792, 908
McGregor E (abst) . . . 222, 226, 909
McGregor E, Stewart G, Junor B J R, Rodger R S C
Successful Use of Recombinant Human Erythropoietin in Pregnancy . . . 292
McGregor S: *See* Cannata J B et al.
Macia M (abst) . . . 788, 822
McKay N (abst) . . . 299
McKay P (abst) . . . 222
Mackenzie R: *See* Topley N et al.
Mackenzie R (abst) . . . 812
Mackenzie S J (abst) . . . 221
McLaren M (abst) . . . 744, 902
McLay A: *See* Campbell J H et al.
McLay A L C (abst) . . . 220
McLean A (abst) . . . 903
McLenachan J M (abst) . . . 226
McLeod A M (abst) . . . 218
MacLeod A M (abst) . . . 225, 741
McLeod I A (abst) . . . 744
MacLeod R I (letter) . . . 228
MacMahon S H (abst) . . . 902
McMillan M A (abst) . . . 222, 224, 744
McMillan M A, Muirhead C S M, Lucie N P, Briggs J D, Junor B J R
Autoimmune Haemolytic Anaemia Related to Cyclosporin with ABO-Compatible Kidney Donor and Recipient . . . 57
McNamara E (abst) . . . 298
Macnicol A M (abst) . . . 68, 297, 770
Macnicol A M, Wright A F, Watson M L
Education and Attitudes in Families with Adult Polycystic Kidney Disease . . . 27
McNurlan M A (abst) . . . 300
MacRae K D: *See* Pazianas M et al.
Mactier R A: *See* Fleming L W et al.
Mactier R A (abst) . . . 70, 71, 222, 743, 796
MacTier R (abst) . . . 301
Madaio M P (abst) . . . 761
Madsen S (abst) . . . 832
Maduell F (abst) . . . 787
Maeda K: *See* Niwa T et al.
Maffei S (abst) . . . 775, 805
Magri F (abst) . . . 811
Magri P (abst) . . . 763
Mahiout A: *See* Jörres A et al.
Maillet F, Kazatchkine M D
Specific Antibodies Enhance Alternative Complement Pathway Activation by Cuprophan . . 193
Main I (abst) . . . 801
Main J, Thomas T H, Wilkinson R
Haemodialysis: Effects on White and Red Blood Cell Sodium Content and Transport . . . 91
Maiorca R: *See* Cannella G et al.
Maiorca R (abst) . . . 773, 813, 826
Maistre G (abst) . . . 795
Maiza A (abst) . . . 302
Majka S (abst) . . . 829
Makó J: *See* Taraba I et al.
Mal F (abst) . . . 769
Malberti F (abst) . . . 786, 804, 818
Malberti F, Surian M
Ionised Calcium Changes and Parathyroid Hormone Secretion in Haemodiafiltration in Relation to Substitution Fluid Calcium Content . . . S2104
Małecka B: *See* Gellert R et al.
Malfi B (abst) . . . 837
Mall G (abst) . . . 790
Mallamaci F: *See* Zoccali C et al.
Mallamaci F (abst) . . . 794, 796
Mallick N: *See* Geerlings W et al.
Mallick N: *See* Rizzoni G et al.
Mallick N (abst) . . . 751, 752
Mallick N P (abst) . . . 789
Malluche H H (abst) . . . 817
Maltby P (abst) . . . 740, 792
Man N K: *See* Chauveau P et al.
Mancini E (abst) . . . 804, 806

Mancini F: *See* Mondelli M U et al.
Mandolfo S (abst) . . . 786
Mangiarotti G (abst) . . . 804
Manili L (abst) . . . 813, 826
Manno C: *See* Pertosa G et al.
Manzione A (abst) . . . 837
Marangi A L (abst) . . . 787
Marcén R (abst) . . . 807, 827, 832
Marco J (abst) . . . 820
Mardaras J (abst) . . . 822
Marfella C: *See* Pertosa G et al.
Marfella C (abst) . . . 768
Margreiter R: *See* Geerlings W et al.
Margreiter R: *See* Rizzoni G et al.
Margreiter R (abst) . . . 751, 752
Mariano F: *See* Tetta C et al.
Marinoso M L (abst) . . . 372
Marley N J E (letter) . . . 912
Marofka F (letter) . . . 375
Marr J (abst) . . . 840
Marsh F P: *See* Kwan J T C et al.
Marsh F P (abst) . . . 831
Martelli S (abst) . . . 769, 774
Martín-Escobar E: *See* García-Martín F et al.
Martín-Escobar E (abst) . . . 781, 823
Martín-Malo A (abst) . . . 819
Martín-Malo A, Castillo D, Castro M, Pérez R, Rios A, Jaraba M, Aljama P
Biocompatibility of Dialysis Membranes: A Comparative Study . . . S255
Martina G (abst) . . . 768, 774, 777, 804
Martinelli D: *See* Brancaccio D et al.
Martínez A (abst) . . . 753
Martinez Cercós R (abst) . . . 371
Martinez E (abst) . . . 371
Martinez F (abst) . . . 783
Martinez M E (abst) . . . 809
Martinez M E, Rodriguez M, Frutos M, Felsenfeld A J
Effect of Aluminium on Osteocalcin Production in the Rat . . . 851
Martinson E (abst) . . . 812
Marwah T (abst) . . . 785
Marzoll I: *See* Stein G et al.
Masin G, Polenaković M, Ivanovski N, Atanasov N, Olivera S, Čakalaroski K
Hypersensitivity Reactions to Ethylene Oxide: Clinical Experience . . . S350
Mason H (abst) . . . 780, 792, 908
Massara C (abst) . . . 775, 805
Massry S G (abst) . . . 788
Mastrangelo F, Alfonso L, Rizzelli S, Aprile M, Sandri L
Anaemia in High-Efficiency Dialysis . . . S2116
Matamoros N (abst) . . . 820
Mateos J (abst) . . . 838
Mateos M L (abst) . . . 832
Mathews D C: *See* Nakajima M et al.
Mathieu P: *See* Kessler M et al.
Matkovics B (abst) . . . 829
Maurel G (abst) . . . 798
Maurizi J (abst) . . . 787
Maurouard C (abst) . . . 818
Mavridis A: *See* Elisaf M et al.
Mavridis A (abst) . . . 781
Mayer T W (abst) . . . 791
Mazuecos A: *See* Praga M et al.
Mazzaferro S (abst) . . . 786
Mazzucco G (abst) . . . 754, 758, 759, 767
Meccariello S: *See* Memoli B et al.
Mege J L (abst) . . . 805
Mege J L, Olmer M, Purgus R, Bertocchio P, Farnarier C, Kaplanski S, Capo C, Bongrand P
Haemodialysis Membranes Modulate Chronically the Production of TNFalpha, IL1beta and IL6 . . . 868
Mehls O (abst) . . . 791, 797, 817
Mei E (abst) . . . 759
Meier W, Paulitschke M, Lerche D, Schmidt G, Zoellner K
Action of rHuEpo on Mechanical Membrane Properties of Red Blood Cells in Children with End-Stage Renal Disease . . . 110
Meijer J H: *See* Kouw P M et al.
Memoli B, Libetta C, Rampino T, De Simone W, Meccariello S, Stangherlin P, Dal Canton A, Andreucci V E
Interleukin-6 Production of Uraemic Haemodialysed Patients: Effects of Different Membranes . . . S296
Menegatti E (abst) . . . 767, 778
Menendez P (abst) . . . 815, 817
Menendez-Fraga P: *See* Cannata J B et al.
Menheere P (abst) . . . 803
Merkus J W S, Hoitsma A J, Koene R A P
Detrimental Effect of Acute Renal Failure on the Survival of Renal Allografts: Influence of Total Ischaemia Time and Anastomosis Time . . . 881
Mertes P M (abst) . . . 797
Méry J Ph (abst) . . . 775, 806
Mesiti A (abst) . . . 818
Messina M (abst) . . . 837
Messineo L (abst) . . . 794
Meulders Q (abst) . . . 756
Meyer G (abst) . . . 791
Miall P A (abst) . . . 796, 904
Michael J (abst) . . . 296, 899, 906, 909
Michelacci Y (abst) . . . 789
Mihatsch M J: *See* Brunner F P et al.
Miksits K, Stoltenburg G, Neumayer H-H, Spiegel H, Schaal K P, Cervós-Navarro J, Distler A, Stein H, Hahn H
Disseminated Infection of the Central Nervous System Caused by *Nocardia farcinica* . . . 209
Mila J (abst) . . . 820
Milan J A: *See* Gentil M A et al.
Milan M: *See* Botella J et al.
Milcent T: *See* Schillinger F et al.
Milford D V, Staten J, MacGreggor I, Dawes J, Taylor C M, Hill F G
Prognostic Markers in Diarrhoea-Associated Haemolytic-Uraemic Syndrome: Initial Neutrophil Count, Human Neutrophil Elastase and Von Willebrand Factor Antigen . . . 232
Milutinovic J (abst) . . . 775
Mimran A (abst) . . . 793
Mimura N (abst) . . . 805
Minakuchi J (abst) . . . 826
Minetti L: *See* Civati G et al.
Minetti L (abst) . . . 757, 770
Minz M: *See* Das T et al.
Mion C (abst) . . . 799, 800, 813, 815, 831
Miranda B: *See* Selgas R et al.
Mistry C (abst) . . . 811
Mitchell A (abst) . . . 222

Mittermair C (abst) . . . 766
Mitzner S: *See* Smollich B P et al.
Miyazawa Y (abst) . . . 827
Modai D (abst) . . . 759, 760, 798
Modi K S: *See* Rolton H A et al.
Modoni S (abst) . . . 824
Mohácsi G (letter) . . . 375
Möhring K (abst) . . . 833
Moldenhauer F: *See* Garcia-Martin F et al.
Moldenhauer F (abst) . . . 823
Molina S: *See* Selgas R et al.
Molino A (abst) . . . 767, 818
Moliz M (abst) . . . 752
Mombelloni S: *See* Cannella G et al.
Mombelloni S (abst) . . . 826
Mondelli M U, Smedile V, Piazza V, Villa G, Barbieri C, Gattarello G, Mancini F, Raimondo G
Abnormal Alanine Aminotransferase Activity Reflects Exposure to Hepatitis C Virus in Haemodialysis Patients . . . 480
Monnens L A H: *See* Schröder C H et al.
Monneret-Vautrin D A (abst) . . . 800
Montagnac R: *See* Schillinger F et al.
Montanaro A (abst) . . . 787
Montoliu J (abst) . . . 822
Montoyo C: *See* Praga M et al.
Montoyo C (abst) . . . 832
Montrucchio G: *See* Tetta C et al.
Moore-Prince S M (abst) . . . 808
Moorhead J F: *See* Wheeler D C et al.
Moorhead J F (abst) . . . 903
Moorhouse J (abst) . . . 904
Morales J M: *See* Praga M et al.
Morales J M (abst) . . . 832, 839
Moran J E: *See* Kröner G et al.
Moran M J (abst) . . . 823
More I A (abst) . . . 742
More I A R: *See* Gardiner D S et al.
More I A R (abst) . . . 907
Morey A (abst) . . . 820
Morgan A C (abst) . . . 901
Morgan A G: *See* Innes A et al.
Morgan A G (abst) . . . 71, 744, 773
Morgans B: *See* Bateman J M et al.
Moriconi L (abst) . . . 827
Morinière Ph (abst) . . . 815, 818
Morlans M (abst) . . . 836
Morley A R: *See* Thompson S J
Morley A R (letter) . . . 227
Morozumi K (abst) . . . 809
Morris G E, Jamieson N V, Small J, Evans D B, Calne R
Cadaveric Renal Transplantation in Elderly Recipients: Is it Worthwhile? . . . 887
Morris K I (abst) . . . 226
Morris K P (abst) . . . 220
Morsli R (abst) . . . 815
Morton M (abst) . . . 296
Mosaico A (abst) . . . 794
Mosconi G: *See* Stefoni S et al.
Mosquera D: *See* Gibson S P
Mosquera D A: *See* Gibson S P et al.
Mostacci S D (abst) . . . 801
Motomura K: *See* Sanai T et al.
Motoyoshi K (abst) . . . 826
Motta M (abst) . . . 759
Motwani J G (abst) . . . 66, 302, 739, 740, 910
Mouneimne A (abst) . . . 787
Mourad G (abst) . . . 831
Moutabarrik A (abst) . . . 784, 797
Moutsopoulos H M (abst) . . . 781, 908
Movilli E: *See* Cannella G et al.
Movilli E (abst) . . . 826
Moya J L (abst) . . . 807, 827
Mühlbacher F (abst) . . . 834
Muirhead C S M: *See* McMillan M A et al.
Muirhead N, Hodsman A B, Hollomby D J, Cordy P E
The Role of Aluminium and Parathyroid Hormone in Erythropoietin Resistance in Haemodialysis Patients 342
Mukhtar A (abst) . . . 299
Mulas L (abst) . . . 759
Müller C (abst) . . . 811
Müller M: *See* Schmidtmann S et al.
Muller S (abst) . . . 901
Munoz J: *See* Selgas R et al.
Muñoz J (abst) . . . 814
Muñoz-Gómez J (abst) . . . 814
Murchison J T (abst) . . . 741
Murdock I A (abst) . . . 298
Murray L (abst) . . . 297
Musa A R (letter) . . . 747
Muxi A (abst) . . . 814
Myers B D (abst) . . . 791
Nádasdy T (letter) . . . 375
Nagai T (abst) . . . 814
Nagao M: *See* Arakawa M et al.
Nagasawa T (abst) . . . 901
Nagase (abst) . . . 765
Nakabayashi K (abst) . . . 901
Nakajima M, Hewitson T D, Mathews D C, Kincaid-Smith P
Platelet-Derived Growth Factor Mesangial Deposits in Mesangial IgA Glomerulonephritis . . . 11
Nakamura K (abst) . . . 765
Nakamura M (abst) . . . 827
Nakashima Y (abst) . . . 814
Nanbu M (abst) . . . 808
Nand N (letter) . . . 227, 228
Nanni-Costa A: *See* Stefoni S et al.
Napodano P (abst) . . . 772
Naranjo J (abst) . . . 819
Naranjo P (abst) . . . 754
Naret C: *See* Chauveau P et al.
Nasini M G (abst) . . . 810, 831
Naumann G (abst) . . . 782
Navarro A: *See* Ortiz A et al.
Neal A D: *See* Kwan J T C et al.
Nedrud J (abst) . . . 758
Negrette J J (abst) . . . 224
Neidermayer W (abst) . . . 764, 839
Neild G H: *See* Gordge M P et al.
Neild G H: *See* Leaker B
Neild G H (abst) . . . 303
Neilson E G (abst) . . . 757
Németh I (abst) . . . 829
Nenov D: *See* Jankova T et al.
Neuberger J (abst) . . . 899
Neumayer H-H: *See* Miksits K et al.
Neverov N (abst) . . . 776
Newbold K M (abst) . . . 296
Newstead C G (letter) . . . 600
Newton K E (abst) . . . 225

Ng L L: *See* Poli de Figueiredo C E et al.
Ng P C: *See* Evans J H C et al.
Ng W L: *See* Chan M K et al.
Nguyen A T: *See* Herbelin A et al.
Nicholson F (letter) . . . . . 525
Nicholson M L, Donnelly P K, Veitch P S, Bell P R F
Anti-Rejection Therapy in Renal Transplantation: Use of the Monoclonal Antibody OKT3 . . . . . 275
Nicolini M A: *See* Bandiani G et al.
Nielsen H K: *See* Jespersen B et al.
Nielsen P K (abst) . . . . . 821
Nieto J (abst) . . . . . 827
Nigra M (abst) . . . . . 774
Nimmo G R (abst) . . . . . 221
Ninomiya S: *See* Okutsu I et al.
Nivet H (letter) . . . . . 151
Niwa T, Emoto Y, Maeda K, Uehara Y, Yamada N, Shibata M
Oral Sorbent Suppresses Accumulation of Albumin-Bound Indoxyl Sulphate in Serum of Haemodialysis Patients . . . . . 105
Noblins M (abst) . . . . . 776
Nochy D: *See* Tournade H et al.
Nochy D (abst) . . . . . 775
Noël L H (abst) . . . . . 763
Nonnast Daniel B (abst) . . . . . 824
Nordén G, Friman S, Frisenette-Fich C, Persson H, Karlberg I
Renal Transplantation in the Bardet-Biedl Syndrome, a Form of Laurence-Moon-Biedl Syndrome . . . . . 982
Nordin M (abst) . . . . . 812
Nordio G: *See* Cannella G et al.
Notghi A (abst) . . . . . 72
Nowack R: *See* Ritz E et al.
Nowack R (abst) . . . . . 791
Nowotny Ch (abst) . . . . . 781
Nujumi A M (abst) . . . . . 902
Nunan T O: *See* O'Doherty M J et al.
Nusbaum P: *See* Chen N et al.
Nussberger J (abst) . . . . . 798
Nuyts G D, Daelemans R A, Jorens Ph G, Elseviers M M, Van de Vyver F L, De Broe M E
Does Lead Play a Role in the Development of Chronic Renal Disease? . . . . . 307
Nyländen P (abst) . . . . . 838
O'Doherty M J, Breen D, Page C, Barton I, Nunan T O
Lung $^{99m}$Tc DTPA Transfer in Renal Disease and Pulmonary Infection . . . . . 582
O'Donnell M J: *See* Gibson S P et al.
O'Driscoll M (abst) . . . . . 740, 792
Odurny A: *See* Gibson S P et al.
Oe P L: *See* de Vries P M J M et al.
Oe P L: *See* Kouw P M et al.
Oe P L (abst) . . . . . 784
Offermann G (abst) . . . . . 833
Ogata A (abst) . . . . . 784
Ogg C S (abst) . . . . . 810
Ogura Y (abst) . . . . . 805
Ohigashi T: *See* Deguchi N et al.
Oikawa T (abst) . . . . . 809
Okada H (abst) . . . . . 765
Okubo M (abst) . . . . . 765, 808
Okuda S: *See* Sanai T et al.
Okutsu I (abst) . . . . . 814
Okutsu I, Ninomiya S, Takatori Y, Hamanaka I, Takemura T, Otsubo K, Otsubo O
Endoscopic Management of Shoulder Pain in Long-Term Haemodialysis Patients . . . . . 117
Olaizola I (abst) . . . . . 815, 817
Oliveira D B G: *See* Porter J et al.
Oliver A (abst) . . . . . 371
Oliver D O: *See* Stevens J M et al.
Oliver T B, Gouldesbrough D R, Swainson C P
Acute Crescentic Glomerulonephritis Associated with Antiglomerular Basement Membrane antibody in Alport's Syndrome After Second Transplantation 893
Olivera S: *See* Masin G et al.
Olivetti L (abst) . . . . . 813
Olmer M: *See* Mege J L et al.
Olmer M (abst) . . . . . 805
Olsen S (abst) . . . . . 832
Olthof C G: *See* de Vries P M J M et al.
Olthof C G: *See* Kouw P M et al.
Olthof C G (abst) . . . . . 776
Omeñaca M (abst) . . . . . 372
Ong A C M (abst) . . . . . 903
Onoyama K: *See* Sanai T et al.
Onoyama K, Hori K, Osato S, Fujishima M
Haemodynamic Effect of Recombinant Human Erythropoietin on Hypotensive Haemodialysis Patients . . . . . 562
Oochi N: *See* Sanai T et al.
Opatrný Jr K, Opatrný K, Vít L, Racek J, Válek A
What are the Factors Contributing to the Changes in Tissue-Type Plasminogen Activator During Haemodialysis? . . . . . S326
Opatrný K: *See* Opatrný Jr K et al.
Ordi J: *See* Poch E et al.
Ormos J (letter) . . . . . 375
Orofino L (abst) . . . . . 832
Orte L (abst) . . . . . 777, 778
Orth S (abst) . . . . . 757
Ortíz A (abst) . . . . . 765
Ortiz A, Garron M P, Navarro A, Rodriguez-Barbero J M, Aguilera B, Caramelo C
Ischaemic Hepatic Necrosis and Intestinal Infarction in a Haemodialysis Patient . . . . . 521
Ortuña J (abst) . . . . . 807
Ortuño J (abst) . . . . . 777, 778, 783, 827, 829, 832
Orvos H (letter) . . . . . 375
Osato S: *See* Onoyama K et al.
Osato S: *See* Sanai T et al.
Osman E M (letter) . . . . . 747
Ošrić V (abst) . . . . . 806
Ota K: *See* Klinkmann H et al.
Ota K
Biocompatibility and Capability of Haemopurification Systems: Review and Future Development . . . . . S286
Otsubo K: *See* Okutsu I et al.
Otsubo K (abst) . . . . . 814
Otsubo O: *See* Okutsu I et al.
Otsubo O (abst) . . . . . 805, 814
Otte K E, Jensen T M, Knudsen F, Antonsen S, Jørgensen K A
Does the Method of Heparinisation Influence the Biocompatibility of Dialysis Membranes? . . . . . 62
Oulès R (abst) . . . . . 802, 824
Oviasu E (abst) . . . . . 900
Owens D R (abst) . . . . . 780

Pacitti A (abst) . . . . . 775, 800, 804, 805
Packard C (abst) . . . . . 69, 297
Paczek L: *See* Schaefer R M et al.
Paczek L, Schaefer R M, Heidland A
Dialysis Membranes Decrease Immunoglobulin and Interleukin-6 Production by Peripheral Blood Mononuclear Cells *In Vitro* . . . . . S341
Padovese P: *See* Brancaccio D et al.
Page C: *See* O'Doherty M J et al.
Pagliaro P: *See* Castiglione A et al.
Paillard F: *See* Hannedouche T et al.
Pal C R: *See* Innes A et al.
Pal C R (abst) . . . . . 71
Pallot J L (abst) . . . . . 782
Palmer A, Cairns T, Dische F, Gluck G, Gjorstrup P, Parsons V, Welsh K, Taube D
Treatment of Rapidly Progressive Glomerulonephritis by Extracorporeal Immunoadsorption, Prednisolone and Cyclophosphamide . . . . . 536
Palmer T (abst) . . . . . 294
Palomero B (abst) . . . . . 781
Palop L (abst) . . . . . 822
Pamphile R (abst) . . . . . 818
Panzica F: *See* Brancaccio D et al.
Paolini F (abst) . . . . . 804, 806
Papadimitriou M (abst) . . . . . 758, 825
Papagalanis N D (abst) . . . . . 752
Papoz L (abst) . . . . . 785
Pappas M: *See* Elisaf M et al.
Pappas M (abst) . . . . . 781
Parera M (abst) . . . . . 778
Parida S (abst) . . . . . 906
Parigori P (abst) . . . . . 803
Parlongo S: *See* Zoccali C et al.
Parlongo S (abst) . . . . . 794, 798
Parrish A H (abst) . . . . . 808
Parry-Jones D (abst) . . . . . 67
Parsons V: *See* Palmer A et al.
Pascual J (abst) . . . . . 777, 783, 807, 827, 829
Pasqueli M (abst) . . . . . 786
Pasquier R: *See* Tournade H et al.
Passerini P: *See* Ponticelli C
Patrick A W (abst) . . . . . 69
Patterson D (abst) . . . . . 219, 791
Paul J (abst) . . . . . 372
Paulitschke M: *See* Meier W et al.
Pauwels E K J (abst) . . . . . 787
Pavlović D: *See* Tomic Brzać H et al.
Pavón M I: *See* Gentil M A et al.
Pazianas M, Eastwood J B, MacRae K D, Phillips M E
Racial Origins and Primary Renal Diagnosis in 771 Patients with End-Stage Renal Disease . . . . . 931
Pearson J D (abst) . . . . . 295, 899
Pecchini F: *See* Bufano G et al.
Pecchini P: *See* Bufano G et al.
Peces R, Sánchez L, Gorostidi M, Alvarez J
Minimal Change Nephrotic Syndrome Associated With Hodgkin's Lymphoma . . . . . 155
Pechianer Ch (abst) . . . . . 753
Pedersen E B: *See* Jespersen B et al.
Pedersen E B: *See* Lauridsen I N et al.
Pedersen E B: *See* Sørensen S S et al.
Pedersen E B: *See* Tietze I N
Pedersen E B (abst) . . . . . 795, 825, 832, 833
Peiffer B (abst) . . . . . 797
Pelletier L: *See* Tournade H et al.
Peltenburg H G (abst) . . . . . 803
Peluso F: *See* Faict D et al.
Peluso F: *See* Topley N et al.
Peluso F (abst) . . . . . 812
Pengloan J (letter) . . . . . 151
Pengloan J, Petit A, Thibaut G, Blanchier D, Bardos P
Biocompatibility of Dialyser Membranes: Rôles of Membranes and of Patients . . . . . S259
Penketh A R L (abst) . . . . . 776
Peraldi M N (abst) . . . . . 756
Perdomo M (abst) . . . . . 822
Perego A: *See* Civati G et al.
Pereira P (abst) . . . . . 838
Perez R: *See* Martín-Malo A et al.
Perez R (abst) . . . . . 753
Perna A F (abst) . . . . . 788
Pernaute R (abst) . . . . . 372
Perotta U: *See* Bandiani G et al.
Perrino M L: *See* Civati G et al.
Perry G (abst) . . . . . 900
Perry G J (abst) . . . . . 761, 766
Persaud J: *See* Wheeler D C et al.
Persaud J W (abst) . . . . . 903
Persson H: *See* Nordén G et al.
Pertosa G, Marfella C, Tarantino E A, Di Cillo M, Manno C, Russo R, Schena F P
Involvement of Peripheral Blood Monocytes in Haemodialysis: *In Vivo* Induction of Tumour Necrosis Factor Alpha . . . . . S218
Pertuiset N: *See* Hillion D et al.
Peruzzi L . . . . . 754
Peruzzi L (abst) . . . . . 758, 759, 761, 762, 770, 771
Peters J R (abst) . . . . . 780
Petersen M (abst) . . . . . 812
Petersen M M: *See* Topley N et al.
Petersen M M (abst) . . . . . 812
Petit A: *See* Pengloan J et al.
Petris C (abst) . . . . . 752
Petronić V (abst) . . . . . 833
Phillips G (abst) . . . . . 744
Phillips M E: *See* Pazianas M et al.
Phillips M E (abst) . . . . . 298
Piatosa B (abst) . . . . . 837
Piazza V: *See* Mondelli M U et al.
Picciotto G (abst) . . . . . 767, 777
Piccoli G (abst) . . . 754, 758, 759, 761, 767, 768, 769, 775, 777, 778, 804, 818
Piccoli G B (abst) . . . . . 775, 804, 805
Piera C (abst) . . . . . 814
Piera L (abst) . . . . . 836
Piera Ll (abst) . . . . . 372
Piers Ll (abst) . . . . . 373
Pignatelli P M (abst) . . . . . 68, 297
Pinedo B (abst) . . . . . 801, 827
Pinelli G (abst) . . . . . 797
Pirson Y (abst) . . . . . 770, 777
Pizarro J (abst) . . . . . 821
Plant W D (abst) . . . . . 745
Plaza C (abst) . . . . . 822
Plaza J J: *See* Bosch R J et al.
Poccia G (abst) . . . . . 778
Poch E, Almirall J, Torras A, Ordi J, Darnell A, Revert L
Rapidly Progressive Glomerulonephritis and Systemic Vasculitis in Non-Hodgkin Lymphoma . . 51

Pødenphant J (abst) . . . 816
Podjarny E (abst) . . . 753, 789, 791, 820
Pohanka E (abst) . . . 836
Poignet J-L: *See* Chauveau P et al.
Polat M (abst) . . . 830
Polenaković M: *See* Masin G et al.
Polenaković M (abst) . . . 764
Poli de Figueiredo C E, Ng L L, Garrido M C, Davies J E, Ellory J C, Hendry B M
Leukocyte Intracellular pH and Na/H Antiporter Activity in Uraemia and Type I Diabetes Mellitus . 615
Pollini J (abst) . . . 782
Pollock M (abst) . . . 824
Polner K: *See* Taraba I et al.
Pomer S (abst) . . . 833
Pomeranz A (abst) . . . 789, 791
Pomeranz M (abst) . . . 789
Pomier G: *See* Guérin C et al.
Pompa G (abst) . . . 824
Ponticelli C: *See* Casati S et al.
Ponticelli C, Passerini P
Alkylating Agents and Purine Analogues in Primary Glomerulonephritis with Nephrotic Syndrome . . . 381
Ponz E (abst) . . . 814, 837
Popp-Snijders C (abst) . . . 779
Porcellini G (abst) . . . 771
Porcellini M G (abst) . . . 770
Porter J, Wang W M, Oliveira D B G
Chylous Ascites and Continuous Ambulatory Peritoneal Dialysis . . . 659
Portolés J (abst) . . . 754
Postlethwaite R J (abst) . . . 296
Postorino M (abst) . . . 794
Potaux L (abst) . . . 801
Pottinger B E (abst) . . . 295, 899
Poulsen J H: *See* Jespersen B et al.
Pound S E (abst) . . . 68, 297
Pouteil-Noble C (abst) . . . 838
Power D A: *See* Jones M C et al.
Power D A (abst) . . . 299, 300, 741
Power D (abst) . . . 218
Pozzato M (abst) . . . 767
Pozzilli P: *See* Cugini P et al.
Prabhu P (abst) . . . 743
Praga M (abst) . . . 832
Praga M, Andres A, Hernandez E, Montoyo C, Mazuecos A, Campo C, Morales J M, Rodicio J L
Tubular Dysfunction in Nephrotic Syndrome: Incidence and Prognostic Implications . . . 683
Prahbu P (abst) . . . 221
Pran T: *See* Berg K J et al.
Prats D (abst) . . . 788
Precht K: *See* Schmidtmann S et al.
Prescott M (abst) . . . 816
Prescott M C (abst) . . . 789
Price R G (abst) . . . 906
Pringle J H (abst) . . . 901
Propper D J: *See* Jones M C et al.
Propper D J (abst) . . . 225
Puccini R (abst) . . . 827
Pulitano R (abst) . . . 762
Purgus R: *See* Mege J L et al.
Purgus R (abst) . . . 805
Pusey C (abst) . . . 296, 900
Pusey C D: *See* Gaskin G et al.
Pusey C D, Holland M J, Cashman S J, Sinico R A, Lloveras J-J, Evans D J, Lockwood C M
Experimental Autoimmune Glomerulonephritis Induced by Homologous and Isologous Glomerular Basement Membrane in Brown-Norway Rats . . . 457
Qian T: *See* Xu J et al.
Quagliuolo L (abst) . . . 835
Quaranta S (abst) . . . 758
Quarello F (abst) . . . 769, 775, 804, 805
Quattrocchio G (abst) . . . 767, 777, 818
Quellhorst E: *See* de Vries P M J M et al.
Quereda C (abst) . . . 777, 778, 827
Quesada J (abst) . . . 809
Quirós J (abst) . . . 765
Quoidbach A (abst) . . . 777
Raafat F (abst) . . . 907
Rabczyński J (abst) . . . 764
Racek J: *See* Opatrný Jr K et al.
Radeke H H (abst) . . . 766
Raftery M J: *See* Kwan J T C et al.
Rahilly M (abst) . . . 741
Rahman A R A (abst) . . . 66
Rahman A R (abst) . . . 302
Raidis P C (abst) . . . 825
Raimondo G: *See* Mondelli M U et al.
Raine A E G: *See* Ehrich J H H et al.
Raine A E G: *See* Fassbinder W et al.
Raine A E G: *See* Geerlings W et al.
Raine A E G: *See* Rizzoni G et al.
Raine A E G (abst) . . . 751, 752, 796, 902, 904
Rainford D J: *See* Bateman J M et al.
Rambausek M: *See* Weinreich T et al.
Ramirez M (abst) . . . 836
Ramos B: *See* Gentil M A et al.
Rampino T: *See* Memoli B et al.
Ranieri E (abst) . . . 768
Ransley P G (abst) . . . 907
Rasmussen N: *See* Saxena R et al.
Ratcliffe P J (abst) . . . 906
Rathaus M (abst) . . . 753, 789, 791, 820
Ratti C (abst) . . . 774
Ravelli M (abst) . . . 826
Rawlinson C E (abst) . . . 295
Rayner H (abst) . . . 801
Reddingius R E: *See* Schröder C H et al.
Rees A (abst) . . . 296, 303
Rees A J: *See* Gaskin G et al.
Rees A J (abst) . . . 900
Reichel H, Deibert B, Schmidt-Gayk H, Ritz E
Calcium Metabolism in Early Chronic Renal Failure: Implications for the Pathogenesis of Hyperparathyroidism . . . 162
Religa Z: *See* Bochenek A et al.
Rembold-Schuster I (abst) . . . 797
Remuzzi A, Boccardo P, Benigni A
*In Vitro* Platelet Adhesion to Dialysis Membranes . S236
Renoult E: *See* Kessler M et al.
Repetti E (abst) . . . 769, 774
Resch K (abst) . . . 766
Revert L: *See* Poch E et al.
Revert L (abst) . . . 814, 837
Reyna A (abst) . . . 761, 771
Reynolds J (abst) . . . 296
Ribstein J (abst) . . . 793
Richard M J (abst) . . . 787
Richard M J (letter) . . . 526
Richards N (abst) . . . 899

Richards N T (abst) . . . . . 909
Riesco A (abst) . . . . . 752
Rifkin I R: *See* Bateman A M S et al.
Rigden S P A (abst) . . . . . 294
Rincón B (letter) . . . . . 675
Ringoir S (abst) . . . . . 786, 788, 819, 829
Riñon C: *See* Selgas R et al.
Rios A: *See* Martín-Malo A et al.
Rist E: *See* Chauveau P et al.
Ritrovato G (abst) . . . . . 824
Ritz E: *See* Reichel H et al.
Ritz E: *See* Stein G et al.
Ritz E: *See* Weinreich T et al.
Ritz E (abst) . . . . . 757, 771, 780, 790, 791, 817
Ritz E (letter) . . . . . 600
Ritz E, Nowack R, Fliser D, Koch M, Tschöpe W
Type II Diabetes Mellitus: Is the Renal Risk Adequately Appreciated? . . . . . 679
Rivera F (abst) . . . . . 778
Rivera M (abst) . . . . . 778
Rizzelli S: *See* Mastrangelo F et al.
Rizzetto M (abst) . . . . . 800
Rizzi D, Basile C, Di Maggio A, Sebastio A, Introna Jr F, Rizzi R, Scatizzi A, De Marco S, Smialek J E
Clinical Spectrum of Accidental Hemlock Poisoning: Neurotoxic Manifestations, Rhabdomyolysis and Acute Tubular Necrosis . . . . . 939
Rizzi R: *See* Rizzi D et al.
Rizzoni G: *See* Ehrich J H H et al.
Rizzoni G: *See* Fassbinder W et al.
Rizzoni G: *See* Geerlings W et al.
Rizzoni G: *See* Tufveson G et al.
Rizzoni G (abst) . . . . . 751, 752
Rizzoni G, Ehrich J H H, Brunner F P, Geerlings W, Fassbinder W, Landais P, Mallick N, Margreiter R, Raine A E G, Selwood N, Tufveson G
Combined Report on Regular Dialysis and Transplantation of Children in Europe . . . . . S431
Roberts E (abst) . . . . . 299
Roberts N: *See* Yaqoob M et al.
Roberts R (abst) . . . . . 297
Robinson M I (abst) . . . . . 67
Roccatello D (abst) . . . 754, 758, 759, 761, 762, 767, 768, 771, 777, 778, 818
Rocha J L (abst) . . . . . 838
Rodá M (abst) . . . . . 371
Roddie M: *See* Farah N B et al.
Rodger R S C: *See* McGregor E et al.
Rodger R S C (abst) . . . . . 71, 223, 224, 226, 742, 909
Rodicio J L: *See* Praga M et al.
Rodicio J L (abst) . . . . . 832, 839
Rodriguez J C (abst) . . . . . 822
Rodriguez M: *See* Felsenfeld A J et al.
Rodriguez M: *See* Martinez M E et al.
Rodríguez M (abst) . . . . . 819
Rodriguez Paterna E (abst) . . . . . 832
Rodriguez-Barbero J M: *See* Ortiz A et al.
Rodriguez-Iturbe B (abst) . . . . . 901
Rodriquez-Algarra G (abst) . . . . . 838
Roger S D (letter) . . . . . 73
Rollino C (abst) . . . . . 767, 768, 771, 778
Rolton H A, McConnell K M, Modi K S, Macdougall A I
The Effect of Vitamin C Intake on Plasma Oxalate in Patients on Regular Haemodialysis . . . . . 440
Romagnoni M: *See* Castiglione A et al.
Romano G (abst) . . . . . 795
Rombolà G (abst) . . . . . 757, 770
Romero M (letter) . . . . . 374
Ronco C: *See* Botella J et al.
Ronda N (abst) . . . . . 900
Rondeau E (abst) . . . . . 756
Rondeau E (letter) . . . . . 676
Ropolo R (abst) . . . . . 767, 777
Rosado M: *See* Gentil M A et al.
Rossi M (abst) . . . . . 804, 806
Roth P (abst) . . . . . 817
Rother U: *See* Haubitz M et al.
Rotunno M (abst) . . . . . 837
Round A (abst) . . . . . 782
Rovigatti R (abst) . . . . . 789
Rowe P A (abst) . . . . . 71, 902
Roy-Chaudhury P (abst) . . . . . 218, 299, 300
Rubin E (abst) . . . . . 768
Ruder H (abst) . . . . . 840
Ruedin P (abst) . . . . . 828
Rugman F (abst) . . . . . 219, 791
Russell G I (abst) . . . . . 301, 910
Russo D (abst) . . . . . 795
Russo R: *See* Pertosa G et al.
Rust P F (abst) . . . . . 775
Rustom R (abst) . . . . . 740, 792
Ryan J (abst) . . . . . 296
Ryan J J: *See* Gaskin G et al.
Ryan J J: *See* Innes A et al.
Ryan J J (abst) . . . . . 71, 901
Rych S (abst) . . . . . 834
Rychlik G (abst) . . . . . 837
Rylance P B: *See* Gordge M P et al.
Sabater J (abst) . . . . . 777, 783
Sabbatini M (abst) . . . . . 754
Sacks S (abst) . . . . . 297, 300
Saíz F: *See* Garcia-Martin F et al.
Saiz F (abst) . . . . . 781, 823
Sakhuja V: *See* Das T et al.
Salamero P (abst) . . . . . 822
Salit M (abst) . . . . . 810, 831
Salnitro F: *See* Zoccali C et al.
Salnitro F (abst) . . . . . 796
Salomone M (abst) . . . . . 775, 804, 805
Salter D M (abst) . . . . . 745
Sambrook P (abst) . . . . . 224
San A: *See* Selçuk Y et al.
Sanai T, Okuda S, Onoyama K, Motomura K, Hori K, Osato S, Oochi N, Fujishima M
Advantage of Early Initiation of Aluminium Hydroxide Administration for the Prevention of Experimental Progressive Renal Disease . . . . . 330
Sánchez A (abst) . . . . . 754, 788
Sanchez Casado E (abst) . . . . . 821
Sanchez Casajus A (abst) . . . . . 371
Sánchez J (abst) . . . . . 774
Sánchez L: *See* Peces R et al.
Sánchez M (abst) . . . . . 774, 801, 827
Sánchez-Ortega F (abst) . . . . . 781
Sanchez-Sicilia L: *See* Selgas R et al.
Sandoval L E (abst) . . . . . 808
Sandri L: *See* Mastrangelo F et al.
Sandrini W: *See* Cannella G et al.
Sanguedolce V (abst) . . . . . 805
Sanjuan A (abst) . . . . . 372

Sansone G (abst) . . . 754
Santarsia G (abst) . . . 801
Santini G (abst) . . . 760
Santoro A (abst) . . . 804, 806, 822
Santos J L (abst) . . . 823
Santos M F F (abst) . . . 784
Santos O F P (abst) . . . 784
Sanz-Guajardo D (abst) . . . 819, 820
Sanz-Moreno C: *See* Botella J et al.
Sanz-Moreno C (abst) . . . 819, 820
Sardella D (abst) . . . 786
Sardella M (abst) . . . 771
Sarrias X (letter) . . . 374
Sategna C (abst) . . . 762
Sauter M (abst) . . . 840
Savage C O S: *See* Gaskin G et al.
Savage C O S (abst) . . . 295, 899
Savage J M (abst) . . . 220
Savazzi G (abst) . . . 758
Savin M (abst) . . . 806, 833
Saxena R, Bygren P, Rasmussen N, Wieslander J
Circulating Autoantibodies in Patients with Extracapillary Glomerulonephritis . . . 389
Scanziani R (abst) . . . 811
Scaroina F (abst) . . . 769, 774
Scatizzi A: *See* Rizzi D et al.
Schaal K P: *See* Miksits K et al.
Schaefer F (abst) . . . 797, 840
Schaefer K: *See* Stein G et al.
Schaefer K, Scheer J, Asmus G, Umlauf E, Hagemann J, von Herrath D
The Treatment of Uraemic Hyperphosphataemia with Calcium Acetate and Calcium Carbonate: A Comparative Study . . . 170
Schaefer R (abst) . . . 774
Schaefer R M: *See* Paczek L et al.
Schaefer R M, Paczek L, Heidland A
Cytokine Production by Monocytes During Haemodialysis . . . S214
Suppression of Beta$_2$-Microglobulin Release from Lymphocytes by Dialysis Membranes . . . S353
Schäfer R: *See* Wizemann V et al.
Schambelan M: *See* Kaysen G A et al.
Schärer K (abst) . . . 797, 840
Schauer M (abst) . . . 799
Schauer S, Stein G, Süss J, Falkenhagen D, Linß W
Phagocytosis Activity of Polymorphonuclear Cells of Normal Persons and Dialysis Patients is Influenced by Different Dialysis Membranes . . . S335
Scheer J: *See* Schaefer K et al.
Schena F P: *See* Pertosa G et al.
Schena F P (abst) . . . 768
Schenn G (abst) . . . 834
Schiavone M G (abst) . . . 787
Schillinger D: *See* Schillinger F et al.
Schillinger F, Schillinger D, Montagnac R, Milcent T
Post Catheterisation Vein Stenosis in Haemodialysis: Comparative Angiographic Study of 50 Subclavian and 50 Internal Jugular Accesses . . . 722
Schindler R (abst) . . . 766, 811, 812
Schmidt G: *See* Meier W et al.
Schmidt H (abst) . . . 782
Schmidt R (abst) . . . 782
Schmidt-Gayk H: *See* Reichel H et al.
Schmidtmann S, Müller M, von Baehr R, Precht K
Changes of Antioxidative Homeostasis in Patients on Chronic Haemodialysis . . . S371
Schmiedeke T (abst) . . . 901
Schneider A: *See* Stein G et al.
Schneider H: *See* de Vries P M J M et al.
Schneider H: *See* Kouw P M et al.
Schneider H (abst) . . . 776
Schneidewind J: *See* Smollich B P et al.
Schor N (abst) . . . 784, 789
Schrder T (abst) . . . 835
Schröder C H, Reddingius R E, van Dreumel J A M, Theeuwes A G M, Monnens L A H
Transcapillary Ultrafiltration and Lymphatic Absorption During Childhood Continuous Ambulatory Peritoneal Dialysis . . . 571
Schuenemann B: *See* de Vries P M J M et al.
Schulman G, Hakim R M
Recent Advances in the Biocompatibility of Haemodialysis Membranes . . . S210
Schulpin A (abst) . . . 817
Schulz W: *See* Thews O et al.
Schütterle G: *See* Wizemann V et al.
Schwarz A (abst) . . . 833
Schwarzbeck A (abst) . . . 825
Schweizer C (letter) . . . 600
Schweizer Ch (abst) . . . 771
Scigalla P (abst) . . . 826
Scivittaro V (abst) . . . 768
Scoble J E (abst) . . . 903
Scolari M P: *See* Stefoni S et al.
Scorza D (abst) . . . 772
Sebastio A: *See* Rizzi D et al.
Sedlacek P (abst) . . . 807
Segarra A (abst) . . . 372, 373
Segoloni G: *See* Tetta C et al.
Segoloni G (abst) . . . 805
Segoloni G P (abst) . . . 837
Seiderer M: *See* Kröner G et al.
Seignalet J (abst) . . . 831
Selçuk Y, San A, Bakan E, Yiğitoğlu R
Plasma Atrial Natriuretic Peptide and its Relation to the Renin-Angiotensin-Aldosterone System in Patients with Chronic Renal Failure . . . 557
Selgas R, Lopez-Rivas A, Miranda B, Muñoz J, Riñon C, Borrego F, Molina S, Sanchez-Sicilia L
Characterisation of the Mitogenic-Induced Capacity of Peritoneal Effluent on Human and Mice Fibroblasts in Culture . . . 44
Selwood N: *See* Geerlings W et al.
Selwood N H: *See* Ehrich J H H et al.
Selwood N H: *See* Fassbinder W et al.
Selwood N H: *See* Rizzoni G et al.
Selwood N H: *See* Tufveson G et al.
Selwood N H (abst) . . . 751, 752, 902
Sena L M (abst) . . . 761
Sennesael J (abst) . . . 828
Sepe M: *See* Cugini P et al.
Sepe V (abst) . . . 763, 795
Serfoglia G (abst) . . . 762
Seron D, Cameron J S, Haskard D O
Expression of VCAM-1 in the Normal and Diseased Kidney . . . 917
Serrano P (abst) . . . 832
Serrano S (abst) . . . 372
Serre A F (abst) . . . 828
Servillo L (abst) . . . 835
Sethi D (abst) . . . 298

Setoain J (abst) . . . 814
Severgina E (abst) . . . 776
Seyfarth M (abst) . . . 782
Seyfert U T, Helmling E, Hauck W, Skroch D, Albert W
Comparison of Blood Biocompatibility During Haemodialysis with Cuprophane and Polacrylonitrile Membranes . . . 428
Seymour J (abst) . . . 223
Sferopoulos G (abst) . . . 752
Shah K J (abst) . . . 907
Shaked U (abst) . . . 760
Shaldon S (abst) . . . 824
Shallcross T (abst) . . . 226
Shanks J B (abst) . . . 220
Sharfi A A (letter) . . . 747
Shaw A B: *See* Laxton J C et al.
Shenouda M (abst) . . . 815
Shepherd J (abst) . . . 69, 297
Shibata M: *See* Niwa T et al.
Shibata T (abst) . . . 805
Shirai D (abst) . . . 802
Shires M: *See* Goode N P et al.
Shires M (abst) . . . 218, 219, 763, 905
Short C D (abst) . . . 838
Shu K-H (abst) . . . 768
Siamopoulos K C: *See* Elisaf M et al.
Siamopoulos K C (abst) . . . 752, 781, 908
Sibai R (abst) . . . 782
Siciński A: *See* Gellert R et al.
Sicuso C (abst) . . . 798
Sidira E (abst) . . . 758
Sieberth H G (abst) . . . 817
Sierra Carpio M (abst) . . . 371
Simada T (abst) . . . 827
Simin N (abst) . . . 806
Simon P (abst) . . . 792, 799
Simpson J G (abst) . . . 218
Simpson K (abst) . . . 224
Singh I (abst) . . . 304
Sinico R A: *See* Pusey C D et al.
Sinyukhin V N: *See* Darenkov A F et al.
Sioulis A (abst) . . . 822
Sirajeddine K (abst) . . . 787, 790
Sirajeddine K (letter) . . . 526
Sirivanichae C (abst) . . . 783
Skovbon H (abst) . . . 833
Skroch D: *See* Seyfert U T et al.
Slapak M (letter) . . . 748
Slesak J (abst) . . . 764
Small J: *See* Morris G E et al.
Smedile V: *See* Mondelli M U et al.
Smellie W S A, Warwick G L
Primary Hyperlipidaemia is Not Associated with Increased Urinary Albumin Excretion . . . 398
Smialek J E: *See* Rizzi D et al.
Smit W M (abst) . . . 784
Smith A F (abst) . . . 70
Smith E (abst) . . . 301
Smith N (abst) . . . 907
Smits P J H (abst) . . . 793
Smollich B P, Falkenhagen D, Schneidewind J, Mitzner S, Klinkmann H
Importance of Endotoxins in High-Flux Dialysis . . S383
Smye S (abst) . . . 902
Smyth E (abst) . . . 298
Snell M E (abst) . . . 907
Solá R (abst) . . . 373
Solbiati L (abst) . . . 816
Solbu D: *See* Berg K J et al.
Solé M (abst) . . . 814, 837
Solf A: *See* de Vries P M J M et al.
Sonoda T (abst) . . . 784, 797
Sørensen A W (abst) . . . 832
Sørensen S S: *See* Jespersen B et al.
Sørensen S S (abst) . . . 832, 833
Sørensen S S, Lauridsen I N, Thomsen K, Pedersen E B
Effect of Two Regimens of Intravenous Amino Acid Infusion on Renal Haemodynamics, Renal Tubular Function and Sodium and Water Homeostatic Hormones in Healthy Humans . . . 410
Sorgato G: *See* Castiglione A et al.
Soria C (abst) . . . 777
Sorrell T C (letter) . . . 73
Soutif C (abst) . . . 782
Souweine B (abst) . . . 828
Spencer S (abst) . . . 301
Spencer S J (abst) . . . 900
Sperschneider H: *See* Stein G et al.
Spiegel H: *See* Miksits K et al.
Splendiani G (abst) . . . 778
Spongano M (abst) . . . 804, 806, 822
Spulzaro P (abst) . . . 760
Spurio A (abst) . . . 786
Spyt T: *See* Bochenek A et al.
Sraer J D (abst) . . . 756
Sraer J-D (letter) . . . 676
Srinivas K (abst) . . . 776
Stäbler A: *See* Kröner G et al.
Staines N A (abst) . . . 761
Stallone C (abst) . . . 824
Stamatakis G (abst) . . . 806
Stangherlin P: *See* Memoli B et al.
Stanojević M (abst) . . . 806, 833
Stanziale P (abst) . . . 763
Starzyk J (abst) . . . 807
Staten J: *See* Milford D V et al.
Steenweg L (abst) . . . 811
Stefoni S, Nanni-Costa A, Buscaroli A, Coli L, Feliciangeli F, Mosconi G, Scolari M P, Iannelli S, Borgnino L C, Bonomini V
Cellular Immunology in Regular Dialysis: A Biological Model for Biocompatibility Evaluation . S24
Stehouwer C D A (abst) . . . 779
Stehouwer C D A, Fischer H R A, Hackeng W H L, den Ottolander G J H, Donker A J M
Diurnal Variation in Urinary Protein Excretion in Diabetic Nephropathy . . . 238
Stein G: *See* Schauer S et al.
Stein G (abst) . . . 772
Stein G, Schneider A, Thoß K, Ritz E, Schaefer K, Hüller M, Sperschneider H, Marzoll I
$Beta_2$-Microglobulin Serum Concentration and Associated Amyloidosis in Dialysis Patients . . . S357
Stein H: *See* Miksits K et al.
Steiner G (abst) . . . 836
Steininger R (abst) . . . 834
Stekkinger P: *See* Struijk D G et al.
Stephenson J R: *See* Brown A L et al.
Stetsyuk E A: *See* Darenkov A F et al.
Stevens J M, Auer J, Strong C A, Hughes R T,

Oliver D O, Winearls C G, Cotes P M
Stepwise Correction of Anaemia by Subcutaneous Administration of Human Recombinant Erythropoietin in Patients with Chronic Renal Failure . . . 487
Stevenson R D: *See* Campbell J H et al.
Stewart G: *See* McGregor E et al.
Stewart K N: *See* Jones M C et al.
Stewart K N (abst) . . . 218, 741
Stewart M J (abst) . . . 220
Stewart R (abst) . . . 69
Stewart W (abst) . . . 301
Stewart W K: *See* Fleming L W et al.
Stewart W K (abst) . . . 70, 222, 223, 225, 743, 744, 796, 902
Stippel D (abst) . . . 834
Stockdale H R (abst) . . . 740, 792
Stockenhuber F (abst) . . . 834, 839
Stockl F (abst) . . . 901
Stöger H: *See* Biesenbach G et al.
Stojković D (abst) . . . 833
Stoltenburg G: *See* Miksits K et al.
Stošović M (abst) . . . 806
Strada A (abst) . . . 826
Strange R C (abst) . . . 756, 905, 908
Strauch M (abst) . . . 825
Strauss B J G (abst) . . . 801
Streather C P: *See* Barton I K et al.
Strieter R M (abst) . . . 303
Stroes E S G (abst) . . . 779
Strong C A: *See* Stevens J M et al.
Strongman R S (abst) . . . 218
Struijk D G (abst) . . . 811, 812
Struijk D G, Bakker J C, Krediet R T, Koomen G C M, Stekkinger P, Arisz L
Effect of Intraperitoneal Administration of Two Different Batches of Albumin Solutions on Peritoneal Solute Transport in CAPD Patients . . . 198
Struthers A (abst) . . . 301
Struthers A D (abst) . . . 66, 302, 739, 740, 796, 910
Suassuna J (abst) . . . 762
Suganuma T (abst) . . . 809
Sugiasaki Y (abst) . . . 901
Sugisaki H, Yamada K, Kataoka H, Kunitomo T
Long-Term Observation on Renal-Osteodystrophy-Related Parameters in Dialysis Patients . . . S299
Sugito K (abst) . . . 809
Sulaiman S M (letter) . . . 747
Sulkova S, Laurincova Z, Válek A
Haemofiltration or Haemodialysis in Aluminium elimination? . . . S33
Sulková S (letter) . . . 913
Suma C (abst) . . . 787
Sund S: *See* Hartmann A et al.
Sundal E, Businger J, Kappeler A
Treatment of Transfusion-Dependent Anaemia of Chronic Renal Failure with Recombinant Human Erythropoietin . . . 955
Sundaram S (abst) . . . 224
Sunder-Plassmann G (abst) . . . 807, 840
Surian M: *See* Malberti F
Surian M (abst) . . . 786, 804, 811, 818
Süss J: *See* Schauer S et al.
Suzuki F (abst) . . . 805
Suzuki M (abst) . . . 802
Suzuki Y: *See* Arakawa M et al.
Swainson C P: *See* Oliver T B et al.
Swainson C P (abst) . . . 72, 739, 752, 904
Swainson C P, Craig K C
Effects of Atrial Natriuretic Peptide (99–126) in Chronic Renal Disease in Man . . . 336
Sweeting V (abst) . . . 70
Swoboda K (abst) . . . 781, 807, 840
Szewczyk Z (abst) . . . 764
Tabaqchali S: *See* Brown A L et al.
Tagliazucchi A: *See* Bandiani G et al.
Takatori Y: *See* Okutsu I et al.
Takaue Y (abst) . . . 826
Takemura T: *See* Okutsu I et al.
Takizawa Y (abst) . . . 814
Tamer N (abst) . . . 808, 830
Tan C C (abst) . . . 906
Tanaka Y (abst) . . . 802
Taraba I: *See* Walter J
Taraba I (appreciation) . . . 231
Taraba I, Polner K, Makó J
Biocompatibility Study on Cuprophane and Polysulphone Dialysers . . . S322
Tarantino E A: *See* Pertosa G et al.
Tareyeva I (abst) . . . 776
Taube D: *See* Palmer A et al.
Taylor C M: *See* Milford D V et al.
Taylor C M (abst) . . . 899, 906
Taylor J (abst) . . . 744, 902
Taylor J E: *See* Fleming L W et al.
Taylor J E (abst) . . . 70, 222, 223, 743
Tazaki H: *See* Deguchi N et al.
Tchankova P: *See* Jankova T et al.
Teatini U: *See* Civati G et al.
Teixidó J (abst) . . . 810
Tejedor A (abst) . . . 753
Tejuca F: *See* Gentil M A et al.
Telerman-Toppet N: *See* Wens R et al.
Telli H H (abst) . . . 830
Temple R M (abst) . . . 70, 223
ten Dam M A G J (abst) . . . 779
ten Kate R W (abst) . . . 779
Teppo A-M (abst) . . . 764
Terada R: *See* Arakawa M et al.
Teruel J L (abst) . . . 783, 807, 827, 829, 832
Testa H J (abst) . . . 789
Testa H T (abst) . . . 302
Tetta C (abst) . . . 799
Tetta C, Segoloni G, Mariano F, Montrucchio G, Turello E, Camussi G
Leukocyte-Derived Mediators and Biocompatibility S224
Thea A (abst) . . . 800
Theeuwes A G M: *See* Schröder C H et al.
Thews O, Deuber H J, Hutten H, Schulz W
Theoretical Approach and Clinical Application of Kinetic Modelling in Dialysis . . . 180
Thibaut G: *See* Pengloan J et al.
Thiel G: *See* Brunner F P et al.
Thijs L G (abst) . . . 784
Thoenes W (abst) . . . 765
Thomas D M: *See* Donovan K L et al.
Thomas N: *See* Topley N et al.
Thomas T (abst) . . . 221
Thomas T H: *See* Main J et al.
Thomas T H (abst) . . . 67
Thompson R J (abst) . . . 744
Thompson S J, Morley A R
Glomerulocystic Kidney Disease Associated with

Haemolytic-Uraemic Syndrome . . . . . 131
Thomsen K: *See* Lauridsen I N et al.
Thomsen K: *See* Sørensen S S et al.
Thomson A W (abst) . . . . . 225
Thomson C R V, Graham S, Hutchinson R M, Flower A J E, Edmunds M E, Feehally J
Sezary Cell Lymphoma Following Cyclosporin Immunosuppression for Renal Transplantation . . . 896
Thomson D: *See* Kharbanda R et al.
Thomson N M (abst) . . . . . 801
Thoß K: *See* Stein G et al.
Tibi L (abst) . . . . . 70
Tietze I N, Pedersen E B
Effect of Fish Protein Supplementation on Aminoacid Profile and Nutritional Status in Haemodialysis Patients . . . . . 948
Tira P (abst) . . . . . 773
Toffoletto P P (abst) . . . . . 789
Tomic Brzać H, Pavlović D, Črepinko I
Spontaneous Inflammation-Induced Remission of Parathyroid Tumour in Secondary Hyperparathyroidism . . . . . 134
Tomson C R V (abst) . . . . . 302
Tönshoff B (abst) . . . . . 791
Toothill C (abst) . . . . . 225
Topley N: *See* Jörres A et al.
Topley N (abst) . . . . . 811, 812, 903
Topley N, Mackenzie R, Petersen M M, Beavis M J, Williams D, Thomas N, Faict D, Peluso F, Coles G A, Davies M, Williams J D
*In Vitro* Testing of a Potentially Biocompatible Continuous Ambulatory Peritoneal Dialysis Fluid . 574
Torán D (abst) . . . . . 820
Torchio M (abst) . . . . . 767
Tornero F (abst) . . . . . 754, 788, 823
Törnroth T (abst) . . . . . 838
Torralbo A (abst) . . . . . 754
Torras A: *See* Poch E et al.
Torregrosa V (abst) . . . . . 814
Torres A (abst) . . . . . 819
Torronteras R (abst) . . . . . 838
Touraine J L (abst) . . . . . 838
Tourkantonis A (abst) . . . . . 822
Tournade H, Guery J-C, Pasquier R, Nochy D, Hinglais N, Guilbert B, Druet P, Pelletier L
Experimental Gold-Induced Autoimmunity . . . . 621
Toussaint C: *See* Watts R W E et al.
Tovar J L (abst) . . . . . 373
Traindl O (abst) . . . . . 834, 836
Tran D D (abst) . . . . . 784
Tranaeus A (abst) . . . . . 809
Traver J A (letter) . . . . . 675
Trepo C (abst) . . . . . 838
Tricot F (abst) . . . . . 787
Triolo G (abst) . . . . . 800
Trznadel K: *See* Luciak M
Tsakiris D (abst) . . . . . 825
Tschöpe W: *See* Ritz E et al.
Tsianos E: *See* Elisaf M et al.
Tsubakihara Y (abst) . . . . . 802
Tsukamoto Y (abst) . . . . . 808
Tufveson G: *See* Ehrich J H H et al.
Tufveson G: *See* Fassbinder W et al.
Tufveson G: *See* Geerlings W et al.
Tufveson G: *See* Rizzoni G et al.
Tufveson G (abst) . . . . . 751, 752, 838
Tufveson G, Brynger H, Dimeny E, Brunner F P, Ehrich J H H, Fassbinder W, Geerlings W, Rizzoni G, Selwood N H, Wing A J
Renal Transplantation in Diabetic Patients with or Without Simultaneous Pancreatic Transplantation 1986 . . . . . 1
Tulloch I A (abst) . . . . . 903
Turello E: *See* Tetta C et al.
Túri S (abst) . . . . . 829
Türk S (abst) . . . . . 808, 830
Turner N (abst) . . . . . 296
Turney J H, Davison A M, Forbes M A, Cooper E H
Hyaluronic Acid in End-Stage Renal Failure Treated by Haemodialysis: Clinical Correlates and Implications . . . . . 566
Tweedale P M (abst) . . . . . 70
Ubeda I (abst) . . . . . 788
Uccello F (abst) . . . . . 754
Ueda S (abst) . . . . . 814
Uehara Y: *See* Niwa T et al.
Ulman J (abst) . . . . . 829
Ulrich W (abst) . . . . . 834
Umlauf E: *See* Schaefer K et al.
Ungaro B: *See* Balletta M et al.
Ureña P: *See* Herbelin A et al.
Uzan M: *See* Hillion D et al.
v Hirschheydt G (abst) . . . . . 811
v Poelgeest A E (abst) . . . . . 793
Vaerman J P (abst) . . . . . 777
Val J: *See* Garcia-Martin F et al.
Val J (abst) . . . . . 823
Valderrabano F (abst) . . . . . 753
Válek A: *See* Opatrný Jr K et al.
Válek A: *See* Sulkova S et al.
Válek A (letter) . . . . . 913
Valkouma D (abst) . . . . . 822
Vallery-Radot C H (abst) . . . . . 769
Vallés M (abst) . . . . . 373
Vallières S (abst) . . . . . 768
van Bortel L (abst) . . . . . 803
Van Dam M (abst) . . . . . 300
Van de Vyver F L: *See* Nuyts G D et al.
van der Meulen J (abst) . . . . . 784
Van der Niepen P (abst) . . . . . 828
van der Plas-Cats M B: *See* Veltman G A M et al.
van Dreumel J A M: *See* Schröder C H et al.
Vanel T (abst) . . . . . 813
van Es L A (abst) . . . . . 787
Vanhille Ph (abst) . . . . . 782
van Hooff J P (abst) . . . . . 803
Vanholder R (abst) . . . . . 786, 788, 819, 829
Van Landschoot N (abst) . . . . . 788
van Leusen R: *See* Veltman G A M et al.
van Lier H (abst) . . . . . 823
Van't Hoff W G (abst) . . . . . 299
Vanziro A (abst) . . . . . 778
Varagunam M (abst) . . . . . 899
Varga I (abst) . . . . . 829
Varghese Z: *See* Wheeler D C et al.
Varghese Z (abst) . . . . . 903
Vassiliou S (abst) . . . . . 822
Veenstra J (abst) . . . . . 784
Vega N (abst) . . . . . 822
Veitch P S: *See* Nicholson M L et al.
Veitch P S (abst) . . . . . 904
Vela C (abst) . . . . . 782

Veljović R (abst) . . . . . 806, 833
Veltman G A M, Bosch F H, van der Plas-Cats M B, van Leusen R
Urine Cytology as a Screening Method for Transitional-Cell Carcinoma in Dialysis Patients with Analgesic Nephropathy . . . . . 346
Vendeville B (abst) . . . . . 768
Veneroni G: *See* Castiglione A et al.
Venning M C (abst) . . . . . 70
Verbeelen D (abst) . . . . . 828
Vercellone A (abst) . . . . . 775, 800, 804, 805, 837
Verdier J M (abst) . . . . . 779
Verrier Jones K (abst) . . . . . 297, 299
Versolato C (abst) . . . . . 789
Veys N (abst) . . . . . 829
Vial M C (abst) . . . . . 768
Vidal M T (abst) . . . . . 373
Vidal-Barraquer F (abst) . . . . . 371
Vidaur F (abst) . . . . . 755
Vienken J: *See* Baurmeister U et al.
Vienken J (abst) . . . . . 799
Vila J (abst) . . . . . 372, 836
Vilardell M (abst) . . . . . 372
Villa G: *See* Mondelli M U et al.
Villafruela J J (abst) . . . . . 783
Villalta D (abst) . . . . . 760
Villamor N (abst) . . . . . 837
Villavicencio H (abst) . . . . . 373
Villemot J P (abst) . . . . . 797
Visioli O: *See* Cannella G et al.
Vít L: *See* Opatrný Jr K et al.
Vites N P (abst) . . . . . 789
Vlahakos D V (abst) . . . . . 761
Vogt A (abst) . . . . . 901
von Albertini B (abst) . . . . . 808
von Baehr R: *See* Schmidtmann S et al.
von Herrath D: *See* Schaefer K et al.
Vora J (abst) . . . . . 780
Vychytil A (abst) . . . . . 834
Wahlqvist M (abst) . . . . . 801
Wai-Choong Lye, Chorh-Chuan Tan
Multiple Arterial Thromboses in Nephrotic Syndrome . . . . . 55
Waldherr G (abst) . . . . . 797
Waldherr R (abst) . . . . . 780, 901
Walls J (abst) . . . . . 301, 302, 904, 905, 910
Walsh J (abst) . . . . . 298
Walter J, Taraba I
Dialysis Hypersensitivity . . . . . S347
Walther U (abst) . . . . . 797, 840
Wamser P (abst) . . . . . 834
Wang C: *See* Xu J et al.
Wang W M: *See* Porter J et al.
Ward M K (abst) . . . . . 70
Ward M K (letter) . . . . . 227, 228
Warwick G: *See* Campbell J H et al.
Warwick G (abst) . . . . . 69, 297
Warwick G L: *See* Smellie W S A
Waterloos M A (abst) . . . . . 788
Watschinger B (abst) . . . . . 834, 836
Watson M A: *See* Gardiner D S et al.
Watson M L: *See* Macnicol A M et al.
Watson M L (abst) . . . . . 68, 297
Watts R W E, Danpure C J, De Pauw L, Toussaint C
Combined Liver-Kidney and Isolated Liver Transplantations for Primary Hyperoxaluria Type 1: The European Experience . . . . . 502
Weber B K (abst) . . . . . 300
Weber Ch (abst) . . . . . 833
Weetman A P (abst) . . . . . 295
Weih M (abst) . . . . . 757
Weinreich T, Rambausek M, Ritz E
Is Control of Secondary Hyperparathyroidism Optimal with the Currently Used Calcium Concentration in the CAPD Fluid? . . . . . 843
Weinreich Th (abst) . . . . . 757
Weissenberg N (abst) . . . . . 834
Weissgarten J (abst) . . . . . 759, 760, 798
Welham J (abst) . . . . . 224
Wells A (abst) . . . . . 838
Welsh K: *See* Palmer A et al.
Welsh K I (abst) . . . . . 294
Weng D (abst) . . . . . 224
Wens R, Devriendt J, Collart F, Dratwa M, Bisschop P, Telerman-Toppet N, Douat N
Rhinocerebral Mucormycosis in Haemodialysis Patients Treated with Desferrioxamine: Possible Role of Recent Surgery as an Additional Risk Factor . . 656
Werner E (abst) . . . . . 817
Werter C J P (abst) . . . . . 779
Westeel P F (abst) . . . . . 798, 818
Westwick J (abst) . . . . . 303
Wheeler D C: *See* Donovan K L et al.
Wheeler D C (abst) . . . . . 903
Wheeler D C, Fernando R L, Gillett M P T, Zaruba J, Persaud J, Kingstone D, Varghese Z, Moorhead J F
Characterisation of the Binding of Low-Density Lipoproteins to Cultured Rat Mesangial Cells . . . 701
White R H R (abst) . . . . . 907
Wicks A C B (abst) . . . . . 901
Widera W (abst) . . . . . 798
Wieçek A (abst) . . . . . 798, 829, 831
Wieczorek L (abst) . . . . . 826
Wienand P (abst) . . . . . 834, 835
Wieslander A (abst) . . . . . 812
Wieslander J: *See* Saxena R et al.
Wijnen J A G (abst) . . . . . 803
Wildhalm K (abst) . . . . . 840
Wilkie M (abst) . . . . . 831
Wilkinson R: *See* Main J et al.
Wilkinson R (abst) . . . . . 67, 70, 221
Will E (abst) . . . . . 821
Will E J: *See* Davenport A et al.
Will E J (abst) . . . . . 225, 226, 743, 836, 902
Williams A J (abst) . . . . . 908
Williams D: *See* Topley N et al.
Williams D G (abst) . . . . . 294, 900
Williams D J (abst) . . . . . 67
Williams G: *See* Farah N B et al.
Williams J D: *See* Donovan K L et al.
Williams J D: *See* Macdougall I C et al.
Williams J D: *See* Topley N et al.
Williams J D (abst) . . . . . 222, 780, 811, 812, 903
Williams P S (abst) . . . . . 219, 743, 791
Wills E J (abst) . . . . . 221
Wilson S J (abst) . . . . . 218
Winearls C G: *See* Stevens J M et al.
Wing A J: *See* Fassbinder W et al.
Wing A J: *See* Tufveson G et al.
Wing A J (abst) . . . . . 902
Winney R J (abst) . . . . . 70, 223, 741, 745
Wites M: *See* Bochenek A et al.

Wizemann V, Brune T, Kramer W, Schäfer R, Schütterle G
Recombinant Human Erythropoietin Expressed in C-127 Mouse Cells: Efficacy, Side-Effects and Cardiovascular Actions . . . . . S2122
Wnuk R: *See* Bochenek A et al.
Wnuk-Wojnar A-M: *See* Bochenek A et al.
Woittiez A J J (abst) . . . . . 793
Wojnar J: *See* Bochenek A et al.
Wojtacha D R (abst) . . . . . 756, 906
Wolf G (abst) . . . . . 757, 761
Wongmekiat O (abst) . . . . . 783
Woo J (abst) . . . . . 225
Woolf A S (abst) . . . . . 304
Woś S: *See* Bochenek A et al.
Wright A F: *See* Macnicol A M et al.
Wright A F (abst) . . . . . 68, 297
Wu Y: *See* Xu J et al.

Xin C: *See* Xu J et al.
Xu J, Qian T, Xin C, Wu Y, Huang Z,
Protective Role of BCG in the Rabbit Model of Mesangial Proliferative Glomerulonephritis . . . . 554
Xu J, Qian T, Jiang J, Chen C, Huang Z, Wang C
Clinical studies in the Use of BCG and Levamisole in the Treatment of Glomerulonephritis . . . . . 548
Yamada K: *See* Sugisaki H et al.
Yamada N: *See* Niwa T et al.
Yanagisawa E (abst) . . . . . 827
Yaqoob M (abst) . . . . . 219, 780, 791, 792, 908
Yaqoob M, Ahmad R, Roberts N, Helliwell T
Low-Dose Desferrioxamine Test for the Diagnosis of Aluminium-Related Bone Disease in Patients on Regular Haemodialysis . . . . . 484
Yaqoob M, Fahal I H, Finn R
Obstructive Nephropathy Due to Pseudomyxoma Peritonei and its Management by Cystic Obliteration and Urinary Diversion . . . . . 60
Yarmolinski J S: *See* Darenkov A F et al.
Yeksan F N (abst) . . . . . 830
Yeksan M (abst) . . . . . 808, 830
Yermolenko V M: *See* Darenkov A F et al.
Yiğitoğlu R: *See* Selçuk Y et al.
Yokota K (abst) . . . . . 805
Yoshiara S (abst) . . . . . 907
Yoshida A (abst) . . . . . 809
Yoshizaki K (abst) . . . . . 784
Zabel P (abst) . . . . . 764
Zaruba J: *See* Wheeler D C et al.
Zazgornik J: *See* Biesenbach G et al.
Zazgornik J (abst) . . . . . 769
Zech P (abst) . . . . . 838
Zeier M (abst) . . . . . 774
Zembala M: *See* Bochenek A et al.
Zingraff J: *See* Herbelin A et al.
Zlabinger G J (abst) . . . . . 836
Zmirou D (abst) . . . . . 785
Zoccali C (abst) . . . . . 794, 796, 798
Zoccali C, Mallamaci F, Ciccarelli M, Parlongo S, Salnitro F, Curatola A
The Reflex Control of Vasopressin in Haemodialysis Patients . . . . . 631
Zoellner K: *See* Meier W et al.
Zucchelli A (abst) . . . . . 762
Zucchelli P (abst) . . . . . 762, 804, 806, 822

# *Subject Index to Volume 6*


ACE Inhibitors
in acute renal failure (abst) . . . 782
in chronic renal failure (abst) . . . 754
in diabetic nephropathy (abst) . . . 776
in haemodialysis (abst) . . . 809
in potassium management (abst) . . . 754
in renal failure (abst) . . . 793
in renovascular hypertension (abst) . . . 793
renal haemodynamic response (abst) . . . 69
Acetate-Free Biofiltration
calcium in (abst) . . . 804
uraemic acidosis (abst) . . . 806
vs Bicarbonate Dialysis (abst) . . . 801
Acetate Haemodialysis with High-Flux Dialysers (HAHD) . . . S275
Acidosis
ammoniagenic pathways in (abst) . . . 753
in uraemia (abst) . . . 757, 806
Acute Arterial Occlusion in acute renal failure (abst) . 783
Acute Renal Failure
ACE inhibitors in (abst) . . . 782
acute arterial occlusion in (abst) . . . 783
ceftazidime in . . . 971
cefuroxime in . . . 971
continuous arteriovenous haemodialysis (CAVHD) in . . . 971
determinants of mortality in (abst) . . . 784
gallopamil in (abst) . . . 783
immediate and long-term prognosis in the elderly . . 86
in bronchogenic squamous cell carcinoma (letter) . . 911
in IgA nephropathy (abst) . . . 220
in renal transplantation . . . 881
intensive therapy unit (book review) . . . 378
organ system failure (OSF) in (abst) . . . 784
prospective study (abst) . . . 782
rapidly progressive glomerulonephritis in . . . 536
review of meeting (book review) . . . 527
sepsis in (abst) . . . 784
Acute Tubular Necrosis in hemlock poisoning . . . 939
Acyclovir
in cytomegalovirus disease (letter) . . . 525
nephrotoxicity (abst) . . . 784
Adenosine Triphosphate (ATP) in CAPD (abst) . . . 221
Adriamycin
in chronic renal disease . . . 330
in glomerulopathies in rats (abst) . . . 791
in pregnancy (abst) . . . 789
Adult Polycystic Kidney Disease (APKD) . . . 27, 933
(abst) . . . 68, 297
cerebral haemorrhagic attacks in (abst) . . . 778
AIDS and hepatitis . . . S427
AL Amyloid, renal function in (abst) . . . 69
AL Amyloidosis
colchicine in . . . 592
melphalan in . . . 592
prednisolone in . . . 592
Alanine in primary hyperoxaluria type 1 (PH1) . . . 502
Alanine Aminotransferase in haemodialysis . . . 480
Albumin
in CAPD . . . 198
in CAPD (abst) . . . 300
urinary excretion in primary hyperlipidaemia . . . 398
Albumin-Bound Indoxyl Sulphate . . . 105
Albumin Excretion Rate, diurnal variation in . . . 238
Albumin Synthesis in nephrotic syndrome . . . 141
Albumin Synthesis Rates in nephrotic syndrome (abst) 300
Albuminuria and polyunsaturated fatty acid (PUFA) (abst) . . . 903
Alcohol Liver Cirrhosis and IgA Nephropathy (abst) . 759
Aldosterone
effect of amino acid infusion . . . 410
effect of ANF (abst) . . . 302
effect of frusemide in nephrotic syndrome . . . 402
Alkaline Phosphatase . . . 98
Alkalosis, ammoniagenic pathways in (abst) . . . 753
Alkylating Agents in primary glomerulonephritis with nephrotic syndrome . . . 381
Allograft Rejection
effect of OKT3 . . . 275
interleukin 2 (IL2) in (abst) . . . 300
1 Alpha OH Vitamin D3 in hyperparathyroidism (abst) 818
Alpha-1-Antitrypsin (α-1-AT)
in vasculitis (abst) . . . 764
Alpha-Granule Fraction in Systemic Vasculitis (abst) . 762
Alpha-Ketoglutarate Dehydrogenase
in chronic renal failure (abst) . . . 788
Alport's Syndrome . . . 79, 893
fibronectin in (abst) . . . 760
IgA in (abst) . . . 760
renal transplantation in . . . 893
Aluminium
and iron overload (abst) . . . 819
and iron relationship . . . 605
effect on osteocalcin production . . . 851
effect on recombinant human erythropoietin resistance . . . 857
in erythropoietin resistance in haemodialysis . . . 342
in haemodialysis . . . S33
in haemofiltration . . . S33
in osteomalacia . . . 851
in recombinant human erythropoietin (abst) . . . 743
in renal failure (book review) . . . 377
uptake and iron status . . . 672
uptake by intestinal cells . . . 672

uptake by mononuclear phagocytic system (abst) . . 218
Aluminium Absorption and iron stores (abst) . . . . 817
Aluminium Hydroxide in chronic renal disease . . 98, 330
Aluminium Mobilisation in renal allograft (abst) . . 225
Aluminium Overload
and rHuEpo (abst) . . . . . 821
desferrioxamine in (abst) . . . . . 817
iron uptake in . . . . . 637
Aluminium-Related Bone Disease (ABD) . . . . . 484
Aluminium Tissue Stores and bacterial sepsis (abst) . 225
Amino Acid Infusion microalbuminuria in (abst) . . . 770
Amino Acid Profile in haemodialysis . . . . . 948
Amino Acids
in CAPD solutions . . . . . 120
in uraemia (abst) . . . . . 785
infusion in healthy humans . . . . . 410
non-nitric oxide-donor (abst) . . . . . 752
Ammoniagenesis and proteinuria (abst) . . . . . 792
Ammoniagenic Pathways
in acidosis (abst) . . . . . 753
in alkalosis (abst) . . . . . 753
Amyloid from $\beta_2$-microglobulin . . . . . 117
Amyloidosis
$\beta_2$-microglobulin . . . . . S357, S291
$\beta_2$-microglobulin (abst) . . . . . 814
diagnosis (abst) . . . . . 814
diagnosis of dialysis-related (abst) . . . . . 814
dialysis-associated (abst) . . . . . 745
in end-stage renal failure . . . . . S131
in long-term dialysis . . . . . 734
uraemic, in HD and CAPD (abst) . . . . . 813
AN69 Membrane in Haemodialysis (abst) . . . . . 799
Anaemia
chronic . . . . . 31
in chronic renal failure . . . . . 955
in chronic renal function (abst) . . . . . 222
in dialysis . . . . . S2116
in end-stage renal failure in children . . . . . 709
in haemodialysis (abst) . . . . . 809, 823
management of . . . . . S419
recombinant human erythropoietin in . . . . . 452, 487
recombinant human erythropoietin in (book review) 602
transfusion-dependent . . . . . 955
Analgesic Nephrology (book review) . . . . . 74
Analgesic Nephropathy in dialysis . . . . . 346
ANF effect on aldosterone (abst) . . . . . 302
Angiotensin II
(abst) . . . . . 66
and intracellular pH changes (abst) . . . . . 755
and vasodilator prostaglandins (abst) . . . . . 910
effect of amino acid infusion . . . . . 410
effect of frusemide in nephrotic syndrome . . . . . 402
effect of lithium (abst) . . . . . 752
in chronic protein loading (abst) . . . . . 910
in collagen type I synthesis (abst) . . . . . 757
in type I diabetes mellitus (abst) . . . . . 904
receptor blockage (abst) . . . . . 791
Angiotensin II Induced Antinatriuresis
indomethacin in (abst) . . . . . 740, 910
Angiotensin-Converting Enzyme (ACE)
in chronic renal failure (CRF) . . . . . S36
Ankylosing Spondylitis
in IgA glomerulonephritis (abst) . . . . . 772
Antgiotensin II Infusion, lithium in (abst) . . . . . 7398
Anticardiolipin Antibodies
in end-stage renal disease (ESRD) . . . . . 543
Anticoagulants, effect on cell-mediated factors (abst) . 808
Anti-Endomysium Antibodies in IgA Nephropathy
(abst) . . . . . 762
Antiendothelial Cell Antibodies (AECA)
in IgA disease (abst) . . . . . 766
in IgA nephropathy (abst) . . . . . 900
in microscopic vasculitis (MPA) (abst) . . . . . 766
in systemic lupus erythematosus (abst) . . . . . 766
in systemic lupus erythematosus (SLE) (abst) . . . 900
in systemic vasculitis (abst) . . . . . 295, 900
Anti-Entactin Antibodies
in extracapillary glomerulonephritis . . . . . 389
Antiepithelial cell antibody (AEC)
in renal transplantation (abst) . . . . . 294
Antifreeze Poisoning (abst) . . . . . 220
Antiglomerular Basement Membrane (Anti-GBM)
in rapidly progressive glomerulonephritis and acute
renal failure . . . . . 536
Antiglomerular Basement Membrane Antibodies . 621, 893
Anti-Goodpasture (Anti-NC1)
in extracapillary glomerulonephritis . . . . . 389
Antimyeloperoxidase Antibodies
in glomerulonephritis (abst) . . . . . 778
in systemic vasculitis (abst) . . . . . 295
Antineutrophil Cytoplasmic Antibodies (ANCA)
in extracapillary glomerulonephritis . . . . . 389
in glomerulonephritis (abst) . . . . . 296, 778
in systemic vasculitis . . . . . 689
in systemic vasculitis (abst) . . . . . 295
in vasculitis (abst) . . . . . 764
in Wegener's granulomatosis (abst) . . . . . 763
Antineutrophil Cytoplasmic Autoantibodies (ANCA)
in NCGN (abst) . . . . . 773
Antioxidant Enzymes (abst) . . . . . 905
Antiphospholipid Antibodies in Haemodialysis (abst) . 801
Anti-Pig Antibody and B Cell Lines (abst) . . . . . 300
Anti-Self Class II T-Cells . . . . . 621
Antithrombogenic Continuous Ultrafiltration System
(ACUS) . . . . . S249
Antithyroid Antibodies . . . . . 79
Aplastic Bone Disease Without Aluminium (ABD) . . 244
Apolipoprotein
in CAPD (abst) . . . . . 838
in renal transplantation (abst) . . . . . 838
Aprotinin, renal tubular degradation (abst) . . . . . 740
Arachidonate Cyclo-Oxygenase in Glomerular Immune
Injury . . . . . 662
Arachidonic Acid, epithelial uptake of (abst) . . . . 755
L-Arginine, renal effect (abst) . . . . . 752
Arginine Vasopressin . . . . . 631
effect of amino acid infusion . . . . . 410
effect of frusemide in nephrotic syndrome . . . . . 402
Arterial Pressure
in uraemia (abst) . . . . . 794
Arteriovenous Fistula, preservation of . . . . . 206
Arteriovenous Proteses for Haemodialysis (abst) . . . 371
Arteroivenous Shunt . . . . . 5
Aspirin in increase in haematocrit (abst) . . . . . 822
AST-120 . . . . . 105
Atlantoaxial Spondylarthropathy
in haemodialysis . . . . . S291
Atrial Natriuretic Factor (ANF)
(abst) . . . . . 66
in renal transplantation (abst) . . . . . 301
Atrial Natriuretic Peptide
(abst) . . . . . 740

and glomerular filtration rate (GFR) (abst) . . . . 301
and radiocontrast-induced nephropathy (abst) . . . 795
effect of amino acid infusion . . . . . 410
effect of frusemide in nephrotic syndrome . . . . . 402
effect of kidney mass vs kidney function (abst) . . . 798
in chronic renal disease . . . . . 336
in chronic renal failure . . . . . 557
in chronic renal failure (abst) . . . . . 796
in glomerular hyperfiltration (abst) . . . . . 798
in heart transplantation (abst) . . . . . 797
in hypertension (abst) . . . . . 795, 796, 798
in renal transplantation (abst) . . . . . 796, 904
in uraemia (abst) . . . . . 794
salt excretion by (abst) . . . . . 795
Autoantibodies, correlation against neutrophil cytoplasm components (NCC) (abst) . . . . . 762
Autoantibodies to Endothelial Cells in Systemic Vasculitis (abst) . . . . . 761
Autoantibodies to Neutrophil Granulocytes Cytoplasm (ANCA) in systemic vasculitis (abst) . . . . . 767
Autoimmune Glomerulopathy . . . . . 621
Autoimmune Haemolytic Anaemia, cyclosporin in . . 57
Autoimmunity . . . . . 79
Autonomic Nervous System in dialysis (abst) . . . . 822
Autonomic Neuropathy . . . . . 631
Autooxygenation Technique
of cardiopulmonary bypass . . . . . S375
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
genetic counselling in (abst) . . . . . 769
genetic study (abst) . . . . . 781
intracranial aneurysm rupture in (abst) . . . . . 770
intrafamilial phenotypic expression (abst) . . . . . 775
Autovaccination
in urinary tract infection (abst) . . . . . 782
Azathioprine
and renal allograft survival (abst) . . . . . 71
effect on renin-containing cells in renal allograft biopsies . . . . . 363
in renal transplantation (abst) . . . . . 832, 835, 836
**B** Cell Lines and Anti-Pig Antibody (abst) . . . . . 300
B Cell Polyclonal Activation . . . . . 621
Bacterial Sepsis and aluminium tissue stores (abst) . . 225
Bacteriuria in pregnancy (abst) . . . . . 297
Bardet-Biedl syndrome, renal transplantation in . . . 982
Bartter's Syndrome, differential diagnosis (abst) . . . 770
BCG
in glomerulonephritis . . . . . 548
in mesangial proliferative glomerulonephritis . . . 554
Benign Hypertensive Nephrosclerosis
proteinuria in (abst) . . . . . 773
$\beta_2$-Microglobulin
adsorption of . . . . . S286
adsorption role in removal of . . . . . S264
amyloid from . . . . . 117
amyloidosis . . . . . S291
and amyloidosis . . . . . S357
effects of uraemic serum (abst) . . . . . 814
excretion rate . . . . . 238
$^{131}$I scintigraphy for dialysis amyloidosis (abst) . . . 814
in dialysis . . . . . S261
in dialysis-related amyloidosis (abst) . . . . . 814
in end-stage renal disease (abst) . . . . . 813
in glomerulonephritis (abst) . . . . . 768
in haemodialysis . . . . . S218
removal by PMMA BK membrane . . . . . S269
removal in haemofiltration and haemodiafiltration . S284
removal in high-flux acetate haemodialysis . . . . . S275
serum concentration . . . . . S357
suppression of release from lymphocytes . . . . . S353
Bicarbonate-based Replacement Fluid in Haemofiltration . . . . . 368
Bicarbonate Dialysate, quality of (abst) . . . . . 805
Bicarbonate Dialysis vs Acetate-Free Biofiltration (abst) . . . . . 801
Biocompatibility
and hypersensitivity reactions . . . . . S347
and leukocyte-derived mediators . . . . . S224
and membrane development . . . . . S317
in dialysis . . . . . S21
of cuprophane haemodialyser membranes . . . . . 62
of dialysis membranes . . . . . S255, S259, S296
of haemodialysis membranes . . . . . S210, S231
of PMMA membranes . . . . . S284
Biocompatibility Evaluation, biological model for . . S24
Biomass Obstruction in Haemodialysis (abst) . . . . 744
Blood Biocompatibility in haemodialysis . . . . . 428
Blood Compatibility of PMMA-Containing Dialysers . S243
Blood-Membrane Interactions . . . . . S210, S224
Blood Pressure and rHuEpo in haemodialysis (abst) . 829
in chronic renal disease . . . . . 336
in haemodialysis (abst) . . . . . 803
in haemodialysis (letter) . . . . . 374
in renal failure (abst) . . . . . 67
Blood Pressure Profile in Haemodialysis (abst) . . . . 792
Blood Transfusion
cyclosporin in . . . . . 125
effect of rapamycin on MHC Class I response (abst) 225
effect on oxygen dissociation curve (abst) . . . . . 825
elective pretransplant (abst) . . . . . 901
Blood Volume
effect of frusemide in nephrotic syndrome . . . . . 402
influence of high and low sodium dialysis . . . . . 876
intradialytic control (abst) . . . . . 806
BMA031 and cytokine release (abst) . . . . . 836
Bone Biopsy in renal transplantation (abst) . . . . . 372
Bone Histomorphometry in Uraemic Osteodystrophy (abst) . . . . . 816
Bone Marrow, effect of rHuEpo (abst) . . . . . 823
Bone Marrow Transplantation
graft-versus-host disease (GVHD) in (letter) . . . . 675
Bone Mineral Content . . . . . 98
Bronchogenic Squamous Cell Carcinoma
acute renal failure in (letter) . . . . . 911
Brown-Norway Rats . . . . . 457
C-Reactive Protein (CRP) in vasculitis (abst) . . . . 764
$Ca^{2+}/H^+$ Exchange Activity (abst) . . . . . 755
Calcitonin and serum calcium (abst) . . . . . 819
Calcitriol
effect on glucose intolerance in uraemia (abst) . . . 808
effect on osteocalcin production . . . . . 851
in CAPD (abst) . . . . . 809
in chronic renal failure (abst) . . . . . 786
in hyperparathyroidism (abst) . . . . . 817, 818
in osteitis fibrosa (abst) . . . . . 818
in renal failure (abst) . . . . . 819
in uraemic hyperphosphataemia . . . . . 170
Calcium
and calcitonin relationship (abst) . . . . . 819
and iron overload (abst) . . . . . 819
in acetate-free biofiltration (abst) . . . . . 804
in CAPD . . . . . 843

in CAPD (abst) . . . 809
in chronic renal failure (abst) . . . 796
in haemodiafiltration . . . S2104
in haemodiafiltration (abst) . . . 804, 815
in haemodialysis (abst) . . . 815
in renal allograft failure . . . 984
in renal transplantation (abst) . . . 831
interstitial nephritis . . . 984
Calcium Absorption Test (abst) . . . 816
Calcium Acetate
in haemodialysis (abst) . . . 815
in uraemic hyperphosphataemia . . . 170
Calcium Antagonists
effect on serum erythropoietin (abst) . . . 822
in renal transplantation (abst) . . . 832
Calcium Carbonate . . . 98
in CAPD (abst) . . . 224, 745
in dialysis (abst) . . . 818
in haemodialysis (abst) . . . 815
in uraemic hyperphosphataemia . . . 170
lithostathine in crystal growth (abst) . . . 779
Calcium Channel Blockers
in renal failure . . . 420
in renal transplantation (abst) . . . 839, 904
Calcium Dialysate in CAPD (abst) . . . 224
Calcium Haemodialysis . . . 244
Calcium Metabolism
in chronic renal failure . . . 162
in hypertension (abst) . . . 794
Calmodulin Dependent Mechanisms in $Cl^-$ Transport (abst) . . . 755
CAPD . . . 5, 44
5-year survival rate (abst) . . . 745
adenosine triphosphate (ATP) in (abst) . . . 221
albumin in . . . 198
albumin in (abst) . . . 300
anterior abdominal wall leaks (abst) . . . 224
apolipoprotein in (abst) . . . 838
calcitriol in (abst) . . . 809
calcium carbonate in (abst) . . . 224, 745
calcium dialysate in (abst) . . . 224
calcium in . . . 843
calcium in (abst) . . . 809
chylous ascites in . . . 659
dialysate leakage in . . . 670
hepatitis C in . . . 944
host defence, nutrition and ultrafiltration (book review) . . . 377
hyperthyroidism in . . . 843
in chronic renal failure . . . 487
*in vitro* testing of potentially biocompatible fluid . . . 571
interleukin-6 in (abst) . . . 811
Kt/V and protein catabolic rate (abst) . . . 809
leukotriene release in . . . 495
lymphatic absorption in . . . 571
lymphatic absorption in (abst) . . . 811
magnesium carbonate in (abst) . . . 745
magnesium in (abst) . . . 221
$1,25(OH)_2D3$ in (abst) . . . 810
peritoneal drainage in (abst) . . . 810
peritoneal function in (abst) . . . 810
peritoneal solute transport in . . . 198
peritoneal transport characteristics (abst) . . . 812
peritonitis in . . . 495, 643, 659
PG and PCT (abst) . . . 811
rHuEpo in (abst) . . . 821
solution evaluation . . . 120
statistics on . . . S421
survival comparison with centre haemodialysis . . . 444
survival data . . . S124
transcapillary ultrafiltration in . . . 571
tumour necrosis factor alpha (abst) . . . 811
uraemic amyloidosis in (abst) . . . 813
Captopril
(abst) . . . 776
in chronic heart failure (abst) . . . 739, 910
in glomerulopathies in rats (abst) . . . 791
renal haemodynamic response (abst) . . . 69
Carbamylated Haemoglobin (CarHb) . . . 38
Carboplatin nephrotoxicity (abst) . . . 783
Cardiac Death
in renal failure (abst) . . . 771
Cardiac Structures, effect of Epo (abst) . . . 827
Cardiopulmonary Bypass
auto-oxygenation technique of . . . S375
Cardiovascular Disease
in haemodialysis (abst) . . . 807
thallium myocardial perfusion imaging for (abst) . . . 789
Catheters, Quinton Permcath . . . 269
Cationic Colloidal Gold . . . 923
in glomerular basement membrane (GBM) (abst) . . . 219
in renal biopsy (abst) . . . 905
Ceftazidime in acute renal failure . . . 971
Cefuroxime in acute renal failure . . . 971
Cell Basement Membrane Adhesion in Renal Tubular Epithelium (abst) . . . 741
Cell-Mediated Factors, effect of anticoagulants (abst) . . . 808
Cellular Immunology in dialysis . . . S24
Cellulose Acetate Membranes (abst) . . . 806
Central Nervous System, disseminated infection . . . 209
Central Venous Catheter . . . 269
Cerebral Haemorrhagic Attacks in Adult Polycystic Kidney Disease (abst) . . . 778
Chimeric Kidney, functioning mammalian (abst) . . . 303
Chronic Heart Failure, captopril in (abst) . . . 739, 910
Chronic Renal Disease
adriamycin in . . . 330
aluminium hydroxide in . . . 330
atrial natriuretic peptide (ANP) in . . . 336
blood pressure in . . . 336
extracellular fluid volume in . . . 336
Chronic Renal Failure
ACE inhibitors in (abst) . . . 754
alpha-ketoglutarate dehydrogenase in (abst) . . . 788
anaemia in . . . 955
angiotensin-converting enzyme (ACE) in . . . S36
atrial natriuretic peptide in . . . 557
atrial natriuretic peptide in (abst) . . . 796
calcium in (abst) . . . 796
calcium metabolism in . . . 162
CAPD in . . . 487
diet in (abst) . . . 789
Fc-receptor function in (abst) . . . 787
glutathione system in children (abst) . . . 829
glycosaminoglycans in (abst) . . . 789
growth and endocrine changes in children and adolescents (book review) . . . 749
haemoglobin oxidation in children (abst) . . . 829
haemostasis in . . . 21
hyperparathyroidism in . . . 162, 176
hyperparathyroidism in (abst) . . . 372
hypertension in . . . 252

incidence of (abst) . . . 909
lead in . . . 307
Liddle syndrome in (abst) . . . 776
measurement of rHuEpo in (abst) . . . 828
nutrition in (abst) . . . 789
photosensitivity disorders in (abst) . . . 225
pituitary-gonadal axis in (abst) . . . 807
plumbism in (abst) . . . 788
prekallikrein in . . . S36
progression of (abst) . . . 743
proteinuria in . . . 21
recombinant human erythropoietin in . . . 955
renin-angiotensin-aldosterone system in . . . 557
renovascular disease (abst) . . . 786
serum little gastrin in (abst) . . . 796
serum procollagen type I C-term in (abst) . . . 786
Chronic Renal Function, anaemia in (abst) . . . 222
Chylous Ascites in CAPD . . . 659
Circadian Rhythm in kidney transplantation . . . 512
Circulating Autoantibodies . . . 389
Cisplatin nephrotoxicity (abst) . . . 783
$Cl^-/HCO_3^-$ Anion Exchanger in Uraemia (abst) . . . 787
Coagulase-Negative Staphylococci . . . 643
Cognitive Function
in recombinant erythropoietin therapy (abst) . . . 223
Colchicine in AL amyloidosis . . . 592
Collagen Type I Synthesis, angiotensin II in (abst) . . . 757
Complement
cuprophane effect on alternative pathway . . . 193
Complement C4-Deficiency (abst) . . . 765
Computer Simulation in dialysis . . . 180
Congenital Nephrotic Syndrome (abst) . . . 220
Congestive Heart Failure, effect of rHuEpo in (abst) . . . 825
Coniine in hemlock poisoning . . . 939
Constipation in Urinary Tract Abnormalities in
Children (abst) . . . 299
Contact Phase Activation in haemodialysis (abst) . . . 224
Continuous Arteriovenous Haemodialysis (CAVHD)
in acute renal failure . . . 971
Continuous Arteriovenous Haemofiltration/Dialysis
(CAVH/D) in multi-organ failure (abst) . . . 221
Continuous Cycling Peritoneal Dialysis (CCPD)
in anaemic children . . . 487
Continuous Veno-Venous Haemofiltration (CVVH)
versus haemodialysis (abst) . . . 220
Converting Enzyme Inhibitors (CEIs) in Urinary
Albumin Excretion (abst) . . . 793
Coracoacromial Ligament, endoscopic resection of . . . 117
Cortisol in kidney transplantation . . . 512
Creatinine
and hypertension (abst) . . . 219
assay interferance effects (abst) . . . 740
in uraemia (abst) . . . 904
Creatinine Excretion Rate, diurnal variation . . . 241
Creatinine Phosphokinase
by red-cell fragmentation (abst) . . . 802
Cremophor EL (CEL) nephrotoxicity (abst) . . . 839
Crescentic Glomerulonephritis . . . 893
Cryoglobulinaemia
monocyte-macrophage functions in (abst) . . . 767
Cuprophan Haemodialysis Membrane . . . 868
Cuprophan Membranes (abst) . . . 806
Cuprophane Dialysers . . . S322
Cuprophane Haemodialysis
tumour necrosis factor in . . . 435
Cuprophane Membranes . . . 428
biocompatibility of . . . 62
effect on alternative complement pathway activation 193
free oxygen species metabolism . . . S366
Cyclophosphamide
in rapidly progressive glomerulonephritis . . . 536
in SLE (abst) . . . 70
in vasculitis (abst) . . . 70
in Wegener's granulomatosis . . . 531
pulse therapy . . . 531
Cyclosporin
and Endothelin (abst) . . . 68
effect on endothelin secretion (abst) . . . 797
effect on luteinising hormone (abst) . . . 797
effect on renin-containing cells in renal allograft
biopsies . . . 363
effects on renal function . . . 324
in autoimmune haemolytic anaemia . . . 57
in erythrocytosis (abst) . . . 71
in haemolysis . . . 57
in hypertension (abst) . . . 838
in kidney transplantation . . . 512
in long-term graft survival . . . S415
in lymphoglobulin therapy (abst) . . . 835
in nephrotic syndrome (letter) . . . 150
in nephrotoxicity (abst) . . . 777
in post-transplant erythrocytosis . . . 588
in renal transplantation . . . 725, 881, 896
in renal transplantation (abst) . . . 72, 301, 372, 796, 832, 835, 836, 839, 904
in renal transplantation (letter) . . . 374
in third-party blood transfusion protocol . . . 125
in tubular dysfunction (abst) . . . 302
interaction with ticlopidine (letter) . . . 150
nephrotoxicity (abst) . . . 68, 832, 839
Cyclosporin Nephrotoxicity vs renal rejection (abst) . . . 833
Cysteamine in cystinosis (abst) . . . 299
Cystic Obliteration . . . 60
Cystinosis
combined report . . . S143
cysteamine in (abst) . . . 299
phosphocysteamine in (abst) . . . 299
Cytokine Release
and BMA031 (abst) . . . 836
and monoclonal antibodies (abst) . . . 836
Cytokines
in haemodialysis . . . S214
in substitutive extracorporeal treatments . . . S226
Cytomegalovirus
infection in renal transplantation (abst) . . . 372
Cytomegalovirus Disease
in renal transplantation (letter) . . . 525
Cytomegalovirus Infection
in renal transplantation (abst) . . . 834
Cytoplasmic Lipid Inclusions
renal biopsies (abst) . . . 776
15-Deoxyspergualin (DSP) in Lupus Nephritis (abst) . . . 765
Desferrioxamine
effect of iron status (abst) . . . 815
in aluminium overload (abst) . . . 817
in haemodialysis . . . 264, S33
in mucormycosis . . . 656
low-dose test . . . 484
Diabetes Mellitus
in end-stage renal disease (abst) . . . 785
insulin-dependent, microalbuminuria in (abst) . . . 778
type I

angiotensin II in (abst) . . . 904
diabetic nephropathy in (abst) . . . 779
leukocyte inracellular pH and Na/H antiporter activity in . . . 615
lithium in (abst) . . . 904
renal function decline (abst) . . . 790
type II
(abst) . . . 909
in renal failure (abst) . . . 780
proximal tubular dysfunction (abst) . . . 774
red cell Na/Li countertransport in (abst) . . . 769
renal clearance of insulin and C-peptide in (abst) . 779
renal function decline (abst) . . . 790
renal haemodynamics (abst) . . . 780
renal risk . . . 679
vasoactive and natriuretic hormones in (abst) . . 798
Diabetic Glomerulosclerosis in Type II Diabetes Mellitus . . . 679
Diabetic Nephropathy . . . 1, 932
ACE inhibitors (abst) . . . 776
growth hormone in (abst) . . . 304
in type I diabetes mellitus (abst) . . . 779
insulin-like growth factor-1 (IGF-1) (abst) . . . 304
urinary protein excretion in . . . 238
urinary protein excretion in (abst) . . . 776
with nephrotic syndrome (abst) . . . 769
Diabetic Patients
fructosamine measurement in (abst) . . . 803
renal biopsies in (abst) . . . 769
Diabetic Rats
inner medullary collecting duct cells (abst) . . . 753
Dialysate Sodium, effect on fluid balance . . . 257
Dialysis
adequacy of . . . 38
adequacy of (abst) . . . 801
anaemia in . . . S2116
analgesic nephropathy in . . . 346
autonomic nervous system in (abst) . . . 822
$\beta_2$-microglobulin in . . . S261
bioincompatibility in . . . S21
calcium carbonate in (abst) . . . 818
cellular immunology in . . . S24
combined reports . . . S15, S137
combined reports (abst) . . . 751, 752
computer simulation in . . . 180
excessive (abst) . . . 800
hepatitis C in (abst) . . . 298
hepatitis C infection in . . . 944
high-risk conditions (abst) . . . 805
histamine release in (abst) . . . 800
in children, erythropoietin (Epo) in (abst) . . . 297
Interleukin-2 R in . . . S261
international symposium (book review) . . . 527
kinetic modelling in . . . 180
magnesium hydroxide in (abst) . . . 818
musculoskeletal symptoms in (abst) . . . 744
parathyroid hormone in (abst) . . . 817
patient's guide to (book review) . . . 152
peritoneal access (book review) . . . 750
polymorphonuclear functions in (letter) . . . 912
see also Recombinant Human Erythropoietin
short high-efficiency (abst) . . . 808
tumour necrosis factor in . . . S261
vascular access (book review) . . . 750
Dialysis Amyloidosis
($^{99m}$TC(V)DMSA) uptake in (abst) . . . 298
Dialysis Equipment
re-use and schedules . . . S18
Dialysis Membranes
and $\beta_2$-microglobulin suppression . . . S353
biocompatibility of . . . S255, S259, S296
effect on phagocytosis activity . . . S335
influence on immunoglobulins and interleukin-6 . . S341
platelet adhesion to . . . S236
Diarrhoea-Associated Haemolytic-Uraemic Syndrome 232
Diclofenac and interstitial mucinosis . . . 595
Diet in chronic renal failure (abst) . . . 789
1,25-Dihydroxyvitamin D3 [1,25$(OH)_2$D3] . . . 162
in uraemic hyperphosphataemia . . . 171
Diltiazem in glomerulopathies in rats (abst) . . . 791
Direct Dialysis Quantification and Urea Kinetics (abst) 801
Disabilities, incidence of . . . S433
Diurnal Variation in albumin excretion rate . . . 238
DNA Synthesis *in vivo* . . . S25, S27
Drug Monitoring (book review) . . . 74
Duodenal Lamina Propria
in IgA nephropathy, J-Chain mRNA in (abst) . . . 901
Echocardiography in haemodialysis (abst) . . . 807
EDTA-ERA Diagnostic Codes (letter) . . . 524
EEG, effects of desferrioxamine . . . 264
Effective Renal Plasma Flow (ERPF) . . . 252
in non-insulin-dependent diabetes mellitus (abst) . . 780
Elderly Persons, renal replacement in . . . S425
Enalapril
effect on glomerulosclerosis (abst) . . . 790
effect on renal function . . . 936
in glomerulonephritis . . . 936
in proteinuria . . . 936
Endogenous Digoxin-Like Immunoreactivity (EDLI) . 286
Endoscopic Resection of coracoacromial ligament . . 117
Endothelin
and Cyclosporin (abst) . . . 68
in kidney allograft recipients (abst) . . . 834
in renal allograft rejection (abst) . . . 834
in uraemia (abst) . . . 794
Endothelin Secretion
cyclosporin A effect on (abst) . . . 797
FK506 effect on (abst) . . . 797
Endotoxins
effect on tumour necrosis factor alpha (abst) . . . 805
in high-flux dialysis . . . S383
End-Stage Renal Disease . . . 931
anticardiolipin antibodies in . . . 543
$\beta_2$-microglobulin in (abst) . . . 813
diabetes mellitus in (abst) . . . 785
Epo in (abst) . . . 302
glomerulonephritis in (abst) . . . 780
haemodialysis in . . . S418
hydrocarbons in (abst) . . . 780
hyperparathyroidism in (abst) . . . 817
lupus anticoagulant in . . . 543
myocardial infarction in (abst) . . . 902
primary renal diagnosis in . . . 931
racial origin in . . . 931
recombinant human erythropoietin in . . . 342
End-Stage Renal Failure
amyloidosis in . . . S131
haemodialysis in . . . 566
*Heliobacter pylori* in (abst) . . . 226
hyaluronic acid in . . . 566
IgA nephropathy in . . . S134
in children, anaemia in . . . 709

in Kartagener's syndrome (letter) . . . 747
leukocyte Na/H antiporter in . . . 615
paediatric (abst) . . . 296
renal insufficiency in (letter) . . . 600
Entactin in extracapillary glomerulonephritis . . . 389
Epidermal Growth Factor Receptor (abst) . . . 218
Epithelial Cell Adhesion Molecule (abst) . . . 296
Epsiaminocaproic acid (EACA) in $HgCl_2$ nephropathy (abst) . . . 764
Erythrocyte Sodium Content and Transport . . . 91
Erythrocytes
in glomerulonephritis (abst) . . . 772
in kidney biopsy (abst) . . . 772
intradialytic volume changes . . . S310
Erythrocytosis
cyclosporin in (abst) . . . 71
in renal transplantation (letter) . . . 675
post-transplant . . . 588
Erythropoietin
in haemodialysis (abst) . . . 70
in myeloma (abst) . . . 70
Erythropoietin Concentration and haemoglobin (abst) 222
Erythropoietin (EPO) . . . S440
and iron deficiency in (abst) . . . 222
in dialysis in children (abst) . . . 297
Erythropoietin Messenger RNA (abst) . . . 906
Erythropoietin Therapy
plasma acute-phase proteins in (abst) . . . 222
Ethylene Glycol Poisoning (abst) . . . 220
Ethylene Oxide hypersensitivity reactions . . . S350, S347
Experimental Autoimmune Glomerulonephritis (EAG) 457
Extracellular Fluid Volume (EFV) (abst) . . . 776
Extracellular Fluid Volume in Chronic Renal Disease . 336
Extracellular Volume Control
natriuresis in (abst) . . . 795
natriuretic hormones in (abst) . . . 795
Extracellular Volume Expansion
and parathyroid hormone (abst) . . . 794
Extracorporeal Immunoadsorption
in rapidly progressive glomerulonephritis . . . 536
False Aneurysm of Thyrocervical Trunk (letter) . . . 747
Fc-Receptor Function in Chronic Renal Failure (abst) 787
Felodipine in renal transplantation (abst) . . . 833
Ferritin in anaemia correction . . . 452
Fibrinolysis in haemodialysis (abst) . . . 224
Fibroblasts Growth . . . 44
Fibronectin
in Alport's syndrome (abst) . . . 760
in glomerular synthesis of inflammatory markers (abst) . . . 765
Fibronectin Synthesis (abst) . . . 299
Fine-Needle Ethanol Injection in Hyperparathyroidism (abst) . . . 816
Fish Oil and Transepithelial Ion Transport (abst) . . . 835
Fish Protein Supplementation in haemodialysis . . . 948
Fistula Blood Flow in erythropoietin therapy . . . 862
FK506
effect on endothelin secretion (abst) . . . 797
tubular cells toxicity (abst) . . . 784
Flexible Urethrocystoscopy . . . 159
Flow cytofluorimetry . . . S231
Flow Cytometry Evaluations . . . S25
Fluid Balance and Hypotension . . . 257
Focal Glomerulosclerosis . . . 21, 330
Focal Segmental Glomerulosclerosis . . . S440
in recurrence rate (letter) . . . 375
Focal Segmental Glomerulosclerosis (abst) . . . 296
Focal Segmental Sclerosis (FSGS)
glomerular sclerotic areas in (abst) . . . 763
Free Oxygen Species Metabolism in haemodialysis . . S366
Fructosamine Measurement in Diabetic Patients (abst) 803
Frusemide
in chronic glomerulonephritis . . . 466
in nephrotic syndrome . . . 402
Frusemide-Induced Natriuresis (abst) . . . 739, 910
Gallopamil in acute renal failure (abst) . . . 783
Genetic Counselling . . . 27
in autosomal dominant polycystic kidney disease (ADPKD) (abst) . . . 769
Gentamicin
effect of phospholipids on nephrotoxicity induced by 608
nephrotoxicity of (book review) . . . 601
Glomerular and Interstitial Diseases
T-lymphocyte infiltration in (abst) . . . 764
Glomerular Basement Membrane (GBM) . . . 457
cationic colloidal gold in (abst) . . . 219
Glomerular Charge Aberrations
in renal biopsy (abst) . . . 905
Glomerular Disease T-lymphocyte infiltration (abst) . 764
Glomerular Epithelial Cell Endocytosis in Systemic Lupus Erythematosus . . . 316
Glomerular Filtration Rate (GFR) . . . 252
and atrial natriuretic peptide (ANP) (abst) . . . 301
assessment of (abst) . . . 777
effect of amino acid infusion . . . 410
in chronic glomerulonephritis . . . 466
in haemorrhagic fever with renal syndrome (HFRS) (abst) . . . 781
in non-insulin-dependent diabetes mellitus (abst) . . 780
Glomerular Haematuria in IgA nephropathy (abst) . . 220
Glomerular Hyperfiltration
atrial natriuretic peptide (ANP) in (abst) . . . 798
Glomerular Immune Injury
arachidonate cyclo-oxygenase in . . . 662
lipoxygenase in . . . 662
Glomerular Leukocyte Number (abst) . . . 905
Glomerular Morphometry
in reflux nephropathy (abst) . . . 907
Glomerular Permselectivity . . . 141
in reflux nephropathy (abst) . . . 770
Glomerular Polyanion Status . . . 923
Glomerular Thromboxane, effect of Epo (abst) . . . 820
Glomerular Visceral Epithelial Cells (GVECs) . . . 316
Glomerulocystic Disease
in haemolytic-uraemic syndrome . . . 131
Glomerulonephritis
abnormal glomerular and tubular response to intravenous frusemide in . . . 466
alkylating agents in . . . 381
and neoplasms (abst) . . . 774
antineutrophil cytoplasm antibodies (ANCA) in (abst) . . . 296
atypical membranous (abst) . . . 772
BCG in . . . 548
$\beta_2$-microgobulin in (abst) . . . 768
enalapril in . . . 936
erythrocytes in (abst) . . . 772
experimental autoimmune . . . 457
extracapillary . . . 389
growth factors in (abst) . . . 218
hydrocarbons in (abst) . . . 792
hypertension in (abst) . . . 219, 773

IgE in (abst) . . . 768
immunosuppressive therapy in . . . 381
in end-stage renal disease (abst) . . . 780
in *Mycoplasma pneumoniae* pneumonia . . . 518
in non-Hodgkin lymphoma . . . 51
in type II diabetes mellitus (abst) . . . 780
interleukin-2 in (abst) . . . 768
interleukin-6 in (abst) . . . 766
levamisole in . . . 548
mesangial proliferative . . . 554
purine analogues in . . . 381
rapidly progressive . . . 536
rapidly progressive (abst) . . . 778
reviews on (book review) . . . 377
Glomerulosclerosis . . . 21
enalapril effect on (abst) . . . 790
focal and segmental . . . S144
pathogenesis of (abst) . . . 905
Glucagon, effect of amino acid infusion . . . 410
Glucose Intolerance in uraemia (abst) . . . 808
Glucose Polymer Dialysis Fluids (abst) . . . 811
Gludopa nephrotoxicity (abst) . . . 68
Glutathione in CRF (abst) . . . 829
Glutathione S-Transferase (GST) Isoenzyme Expression in Renal Disease . . . 695
Glutathione-S-Transferase (GST) (abst) . . . 756, 905
Glycerol in CAPD solutions . . . 120
Glycosaminoglycans in chronic renal failure (abst) . . . 789
Glycosylation Products
effects on glomerular haemodynamics (abst) . . . 754
Glyoxylate Aminotransferase
in primary hyperoxaluria type 1 (PH1) . . . 502
Gold, glomerular charge marker in glomerular anionic sites (abst) . . . 763
Gold-Induced Autoimmunity . . . 621
Goodpasture Antigen (abst) . . . 296
Goodpasture Syndrome
in extracapillary glomerulonephritis . . . 389
Gout, lead in (abst) . . . 371
Graft-Versus-Host Disease (GVHD) in Bone-Marrow Transplantation (letter) . . . 675
Granular Gingivitis
and Wegener's granulomatosis (letter) . . . 228
Growth after Menarche . . . S437
Growth and Development Study . . . S431
Growth Hormone . . . S439
and prostaglandins (abst) . . . 791
effect of amino acid infusion . . . 410
in diabetic nephropathy (abst) . . . 304
Guanosine Cyclic Monophosphate (cGMP)
effect of frusemide in nephrotic syndrome . . . 402
Guyon's Syndrome in haemodialysis . . . 734
Haemodiafiltration
biocompatibility of PMMA membranes in . . . S284
calcium in . . . S2104
calcium in (abst) . . . 804, 815
Kt/V in (abst) . . . 804
parathyroid hormone (PTH) in . . . S2104
two-chamber . . . 715
vs. paired filtration dialysis . . . S282
Haemodialysers, leukocytes eluted from . . . S231
Haemodialysis
ACE inhibitors in (abst) . . . 809
adequacy of dialysis . . . 38
alanine aminotransferase in . . . 480
aluminium in . . . S33
aminoacid profile in . . . 948
AN69 membrane in (abst) . . . 799
anaemia in (abst) . . . 809, 823
antiphospholipid antibodies in (abst) . . . 801
arteriovenous protheses for (abst) . . . 371
atlantoaxial spondylarthropathy in . . . S291
$\beta_2$-microglobulin in . . . S218
biomass obstruction in (abst) . . . 744
blood biocompatibility in . . . 428
blood pressure in (abst) . . . 803
blood pressure in (letter) . . . 374
blood pressure profile in (abst) . . . 792
calcium acetate in (abst) . . . 815
calcium carbonate in (abst) . . . 815
calcium in (abst) . . . 815
cardiovascular disease in (abst) . . . 807
comparative angiographic study of subclavian and internal jugular accesses . . . 722
contact phase activation in (abst) . . . 224
contamination of dialysis water and dialysate (abst) . . . 799
cytokines in . . . S214
desferrioxamine in . . . 264, S33
diagnosis of aluminium-related bone disease in . . . 484
dry weight in (abst) . . . 803
duration of treatment (abst) . . . 807
echocardiography in (abst) . . . 807
EEG tracing in . . . 264
effects on white and red blood cell sodium content and transport . . . 91
erythropoietin in (abst) . . . 70
fibrinolysis in (abst) . . . 224
fish protein supplementation in . . . 948
fluid balance in . . . 257
free oxygen species metabolism in . . . S366
Guyon's syndrome in . . . 734
hand examination in (abst) . . . 813
heparin in . . . 62
hepatitis C in . . . 944
hepatitis C in (abst) . . . 371
hepatitis C virus (HCV) in . . . 476
hepatitis C virus in . . . 480
high and low sodium dialysate . . . 876
high-flux acetate . . . S275
hyperparathyroidism in (abst) . . . 70
hypersensitivity reactions to . . . S347
hypotension in . . . 562
hypotension in (abst) . . . 802
IL-1 alpha in (abst) . . . 807
IL-1 beta in . . . 868
IL-1 in . . . 349
IL-6 in . . . 868, S218, S296
in end-stage renal disease . . . S418
in end-stage renal failure . . . 566
intestinal infarction in . . . 521
ischaemic hepatic necrosis in . . . 521
Kt/V and protein catabolic rate (abst) . . . 809
limulus amoebocyte-lysate-positive substance in . . . S362
monocytes in . . . S214, S218
neutropenia . . . S331
nutritional status in . . . 948
omega-3 fatty acids in (letter) . . . 526
parathyroid-gland function in . . . 244
phagocytosis in (abst) . . . 829
phosphate removal in . . . S2114
plasma oxalate in . . . 440
plasminogen activator in . . . S326

platelet activation in . . . . . S240
polycystic kidney disease (PCKD) in (abst) . . . . 809
post catheterisation vein stenosis in . . . . . 722
prescribing (book review) . . . . . 528
pruritus in . . . . . 105
reactive oxygen species (ROS) in . . . . . S371
recombinant human erythropoietin in . . . . . 562, 862
recombinant human erythropoietin in (abst) . . . . 902
renal osteodystrophy in . . . . . S299
rhinocerebral mucormycosis in . . . . . 656
role of aluminium and parathyroid hormone in . . . 342
see also Recombinant Human Erythropoietin
shoulder pain in . . . . . 117
silastic twin catheters in (abst) . . . . . 799
spinal-cord compression in . . . . . S291
survival comparison with CAPD . . . . . 444
survival data . . . . . S124
T-cell preactivation in (abst) . . . . . 828
TNF alpha in . . . . . 868
tumour necrosis factor alpha (TNF alpha) in . .349, S218
uraemic amyloidosis in (abst) . . . . . 813
vascular access . . . . . 5
vasopressin in . . . . . 631
vitamin E in (abst) . . . . . 830
vs continuous veno-venous haemofiltration (CVVH) (abst) . . . . . 220
Haemodialysis Membranes
biocompatibility of . . . . . S210, S231
monocyte adherence to (abst) . . . . . 799
Haemofiltration
aluminium in . . . . . S33
bicarbonate-based replacement fluid in . . . . . 368
biocompatibility of PMMA membranes in . . . . . S284
fluid balance in . . . . . 257
in lactic acidosis . . . . . 368
phosphataemia in . . . . . S2108
phosphate removal in . . . . . S2108
Haemoglobin
and erythropoietin concentration (abst) . . . . . 222
oxidation in CRF (abst) . . . . . 829
response to rHuEpo (abst) . . . . . 824
Haemolysis, cyclosporin in . . . . . 57
Haemolytic Uraemic Syndrome . . . . . 232
(abst) . . . . . 220
glomerulocystic disease in . . . . . 131
Haemopurification Systems
biocompatibility and functional capability . . . . . S286
Haemorrhagic Fever with Renal Syndrome (HFRS)
GFR in (abst) . . . . . 781
renal function in (abst) . . . . . 908
Haemostasis in chronic renal failure . . . . . 21
Hand Examination in Haemodialysis (abst) . . . . . 813
Hanta Virus Infection (abst) . . . . . 774
HBV Vaccination in uraemia (abst) . . . . . 787
HDL Cholesterol in renal transplantation (abst) . . . 372
Heart Transplantation
atrial natriuretic peptide in (abst) . . . . . 797
*Heliobacter pylori*
in end-stage renal failure and renal transplantation (abst) . . . . . 226
in uraemia (abst) . . . . . 902
Hemlock poisoning
acute tubular necrosis in . . . . . 939
coniine in . . . . . 939
rhabdomyolysis in . . . . . 939
Hemophan Haemodialysis Membrane . . . . . 868
Henoch-Schönlein Nephropathy
IgA-ANCA in (abst) . . . . . 771
Heparin in haemodialysis . . . . . 62
Heparin-Bound Catheter . . . . . S249
Hepatic Cirrhosis
IgA-containing complexes in (abst) . . . . . 767
Hepatitis
and AIDS . . . . . S427
non-A, non-B . . . . . 476, 480
Hepatitis B . . . . . S120, S428
in renal transplantation (abst) . . . . . 836, 838
Hepatitis B Serological Markers . . . . . 476
Hepatitis C . . . . . S427
antibodies against (abst) . . . . . 800
in CAPD . . . . . 944
in dialysis . . . . . 944
in dialysis (abst) . . . . . 298
in haemodialysis . . . . . 476, 480, 944
in haemodialysis (abst) . . . . . 371
in renal transplantation (abst) . . . . . 838, 839
renal transplantation in (abst) . . . . . 832
Hereditary Nephritis . . . . . 893
$HgCl_2$-induced autoimmunity (abst) . . . . . 768
$HgCl_2$ Nephropathy
epsiaminocaproic acid (EACA) in (abst) . . . . . 764
High-Density Lipoprotein (HDL), effect on growth of cultured human renal cortical epithelial cells (abst) 903
High-Flux Dialysis
endotoxins in . . . . . S383
urea kinetic modelling (UKM) in . . . . . S386
Highly Sensitised Recipients
renal transplantation in (abst) . . . . . 831
Histamine Release in Dialysis (abst) . . . . . 800
Histidine-Buffered Peritoneal Dialysis Fluids (abst) . . 812
Histones in systemic lupus erythematosus (SLE) (abst) 901
HIV Infection . . . . . S121, S428
in atypical membranous glomerulonephritis (abst) . 772
HIV-1 Infection, renal disease in (abst) . . . . . 775
HLA Antigen Density . . . . . S25
HLA Antigen Surface Density . . . . . S26
HLA Class II Genes
in small-vessel vasculitis (SVV) (abst) . . . . . 900
Hodgkin's Lymphoma and nephrotic syndrome . . . 155
HRE and aluminium overload (abst) . . . . . 821
Human Mesangial Cells (HMC)
and cytokine-induced expression of IL-8 and IL-6 (abst) . . . . . 303
cytokine secretion (abst) . . . . . 303
Human Neutrophil Elastase . . . . . 232
Humoral Immune Responses . . . . . 125
Hyaluronic Acid
in end-stage renal failure . . . . . 566
in renal graft rejection oedema (abst) . . . . . 838
Hydrocarbons
and renal disease (abst) . . . . . 780
chronic occupational exposure (abst) . . . . . 908
in end-stage renal disease (abst) . . . . . 780
in glomerulonephritis (abst) . . . . . 792
25-Hydroxyvitamin D [25(OH)D] . . . . . 162
Hypercholesterolaemia, lovastatin in (abst) . . . . . 769
Hyperfiltration in hypertension (abst) . . . . . 794
Hyperglycaemia
effects on glomerular haemodynamics (abst) . . . . 754
Hyperkalaemia, salbutamol in (abst) . . . . . 298
Hyperlipidaemia
and urinary albumin excretion . . . . . 398

as risk factor (abst) . . . 789
in nephrotic syndrome . . . 141
Hyperosmolal State
rhabdomyolysis in . . . 203
Hyperparathyroidism
1,25(OH)$_2$ Vit D$_3$ (abst) . . . 819
1 alpha OH vitamin D3 in (abst) . . . 818
calcitriol in (abst) . . . 817, 818
fine-needle ethanol injection in (abst) . . . 816
in chronic renal failure . . . 162, 176
in chronic renal failure (abst) . . . 372
in end-stage renal disease (abst) . . . 817
in haemodialysis (abst) . . . 70
reoperation for . . . 176
spontaneous inflammation-induced remission . . . 134
Hypersensitivity Reactions
to ethylene oxide . . . S350
to haemodialysis . . . S347
Hypertension
atrial natriuretic peptide in (abst) . . . 795, 796, 798
calcium metabolism in (abst) . . . 794
cyclosporin in (abst) . . . 838
hyperfiltration in (abst) . . . 794
in chronic renal failure . . . 252
in glomerulonephritis (abst) . . . 219
in idiopathic glomerulonephritis (abst) . . . 773
in renal failure (abst) . . . 791
in renal transplantation (abst) . . . 838
NAG-values (abst) . . . 781
nalaxone in (abst) . . . 798
opioid receptors in (abst) . . . 798
urinary albumin excretion in (abst) . . . 793
verapamil in . . . 420
Hypertensive Nephrosclerosis in renal failure (abst) . . . 219
Hypertensive Renal Disease . . . 933
Hyperthyroidism in CAPD . . . 843
Hypertonicity, hyperglycaemic-induced (abst) . . . 752
Hypotension
and fluid balance . . . 257
hypovolaemia in (abst) . . . 804
in haemodialysis . . . 562
in haemodialysis (abst) . . . 802
L-threo-3,4-dihydroxyphenylserine (DOPS) in (abst) 802
per-dialytic (abst) . . . 801
Hypothyroidism . . . 79
Hypovolaemia in hypotension (abst) . . . 804
ICAM-1
in lupus nephritis (abst) . . . 763
in renal graft rejection (abst) . . . 834
Idiopathic Membranous Nephropathy
steroids in (abst) . . . 758
IgA$_1$ Anti-GBM-Mediated Nephritis (abst) . . . 777
IgA
binding to mesangial matrix components and cationic polypeptides (abst) . . . 761
glomerulonephritis . . . 11
in Alport's syndrome (abst) . . . 760
IgA-ANCA
Henoch-Schönlein nephropathy (abst) . . . 771
in IgA nephropathy (abst) . . . 771
IgA Antineutrophil Cytoplasmic Antibodies (abst) . . . 900
IgA-Containing Complexes in Hepatic Cirrhosis (abst) 767
IgA Disease
anti-endothelial cell antibodies (AECA) in (abst) . . . 766
IgA Glomerulonephritis, ankylosing spondylitis in (abst) . . . 772
IgA Nephropathy
acute renal failure in (abst) . . . 220
alcohol liver cirrhosis and (abst) . . . 759
anti-endomysium antibodies in (abst) . . . 762
anti-endothelial cell antibodies in (abst) . . . 900
binding of IgA in (abst) . . . 761
clinical presentation and cumulative survival rates (abst) . . . 909
IgA1 in . . . 846
IgA-ANCA in (abst) . . . 771
in end-stage renal failure . . . S134
in interleukin-2 (abst) . . . 768
in interleukin-4 (abst) . . . 768
J-chain mRNA in duodenal lamina propria in (abst) 901
mucosal tolerance failure in (abst) . . . 758
renal biopsy (abst) . . . 774
T-cell activation in (abst) . . . 778
transforming growth factor (TGF beta) in (abst) . . . 754
IgE in Glomerulonephritis (abst) . . . 768
IgG excretion rate . . . 238
Immunoglobulin in cytomegalovirus disease (letter) . . . 525
Immunoglobulins in renal transplantation (abst) . . . 837
Immunoglobulins (Ig), influence of dialysis membranes . . . S341
Immunosuppression
during first six weeks after grafting . . . S411
Immunosuppressive Regimens . . . S113
Immunosuppressive Therapy in primary glomerulonephritis with nephrotic syndrome . . . 381
Indomethacin
in angiotensin-II-induced antinatriuresis (abst) . . . 740
in angiotensin-II-induced antinatriuresis and renal vasoconstriction (abst) . . . 910
Indoxyl Sulphate, albumin-bound . . . 105
Infections in renal transplantation (abst) . . . 836
Inflammatory Processes
phospholipase A$_2$ (PLA$_2$) in (abst) . . . 760
Inflammatory Response, lipocortins in (abst) . . . 760
Innominate-Vein Thrombosis, streptokinase in . . . 206
Insulin-Like Growth Factor 1 Receptor (abst) . . . 218
Insulin-Like Growth Factor-1 (IGF-1)
haemodynamic effects (abst) . . . 303
in diabetic nephropathy (abst) . . . 304
Interleukin-1
in haemodialysis . . . 349
in renal failure (abst) . . . 764
Interleukin-1 alpha
in haemodialysis (abst) . . . 807
Interleukin-1 beta
and peritoneal mesothelial cells (abst) . . . 812
effect on cytokine secretion (abst) . . . 303
effect on fibronectin synthesis (abst) . . . 299
in haemodialysis . . . 868
Interleukin-2
in allograft rejection (abst) . . . 300
in glomerulonephritis (abst) . . . 768
in IgA nephropathy (abst) . . . 768
in renal failure (abst) . . . 764
in renal vasculitis (abst) . . . 762
serum concentration . . . S27
serum determination . . . S26
Interleukin-2 R in dialysis . . . S261
Interleukin-4 in IgA nephropathy (abst) . . . 768
Interleukin-6
in CAPD (abst) . . . 811
in glomerulonephritis (abst) . . . 766

in haemodialysis . . . . . 868, S218, S296
in renal failure (abst) . . . . . 764
in uraemia . . . . . S296
in vasculitis (abst) . . . . . 764
influence of dialysis membranes . . . . . S341
MC derived (abst) . . . . . 303
Interleukin-8, MC derived (abst) . . . . . 303
Intermittent High-Volume Haemofiltration (HVHF)
in multiple organ failure (abst) . . . . . 221
Interstitial Infiltration, T-lymphocyte infiltration (abst) 764
Interstitial Mucinosis and diclofenac . . . . . 595
Interstitial Nephritis, calcium in . . . . . 984
Interstitial Nephritis (book review) . . . . . 74
Intestinal Cells, aluminium uptake by . . . . . 672
Intestinal Infarction in haemodialysis . . . . . 521
Intracellular Fluid Volume (IFV) (abst) . . . . . 776
Intracellular pH Changes and Angiotensin II (abst) . . 755
Intracranial Aneurysm Rupture in autosomal dominant
polycystic kidney disease (abst) . . . . . 770
Iron
and aluminium absorption (abst) . . . . . 817
and aluminium relationship . . . . . 605
status and aluminium uptake . . . . . 672
uptake in aluminium overload . . . . . 637
with rHuEpo (abst) . . . . . 824
Iron Deficiency
in Epo therapy (abst) . . . . . 222
zinc protoporphyrin in (abst) . . . . . 825
Iron Overload
and aluminium (abst) . . . . . 819
and calcium (abst) . . . . . 819
Ischaemic Hepatic Necrosis in haemodialysis . . . . . 521
Isradipine
in cyclosporin-treated renal transplanted patients . . 725
J-Chain mRNA in duodenal lamina propria in IgA
nephropathy (abst) . . . . . 901
Kallikrein mRNA in normal human kidney (abst) . . 906
Kallikrein-Kinin System (abst) . . . . . 756
Kartagener's Syndrome
end-stage renal failure in (letter) . . . . . 747
Ketoanalogues in uraemia (abst) . . . . . 785
Kidney proteins and drugs (book review) . . . . . 601
Kidney Biopsy
erythrocytes in (abst) . . . . . 772
in systemic lupus erythematosus (SLE) (abst) . . . 901
Kidney Donation and Preservation . . . . . S410
Kidney Growth Factor (KGF) from Proximal Tubule
Cells (abst) . . . . . 756
Kidney Transplantation . . . . . 1
circadian rhythm in . . . . . 512
cortisol in . . . . . 512
cyclosporin in . . . . . 512
T-lymphocytes in . . . . . 512
Kinetic Modelling
in dialysis . . . . . 180
in recombinant erythropoietin therapy (abst) . . . . 223
Kt/V
and left ventricular function (abst) . . . . . 806
and protein catabolic rate (abst) . . . . . 809
in Haemodiafiltration (abst) . . . . . 804
L-Threo-3,4-Dihydroxyphenylserine (DOPS) in
Hypotension (abst) . . . . . 802
Lactic Acidosis, haemofiltration in . . . . . 368
Laurence-Moon-Biedl Syndrome . . . . . 982
Lead
in chronic renal failure . . . . . 307
in gout (abst) . . . . . 371
in renal failure (abst) . . . . . 371
Left Ventricular Function and Kt/V (abst) . . . . . 806
Left Ventricular Hypertrophy . . . . . 31
Left Ventricular Hypertropy
regression after renal transplantation (abst) . . . . 226
Leukocyte-Derived Mediators and Biocompatibility . S224
Leukocyte Na/H Antiporter in end-stage renal failure . 615
Leukocyte Sodium Content and Transport . . . . . 91
Leukocytes eluted from haemodialysers . . . . . S231
Leukotriene Release in CAPD . . . . . 495
Levamisole in glomerulonephritis . . . . . 548
Liddle Syndrome
in chronic renal failure (abst) . . . . . 776
in nephrocalcinosis (abst) . . . . . 776
Limulus Amoebocyte-Lysate-Positive Substance in
Haemodialysis . . . . . S362
Lipid Peroxidation in uraemia (abst) . . . . . 787
Lipocortins in inflammatory response (abst) . . . . . 760
Lipoprotein Catabolism . . . . . 141
Lipoprotein Lipase . . . . . 141
Lipoproteins in renal transplantation (abst) . . . . . 840
Lipoxygenase in Glomerular Immune Injury . . . . . 662
Lithium
effect on responses to ANG II (abst) . . . . . 752
in angiotensin II infusion (abst) . . . . . 739
in type II diabetes (abst) . . . . . 904
Lithium-Induced Hyperosmolal State
rhabdomyolysis in . . . . . 203
Lithostathine and $CaCO_3$ crystal growth (abst) . . . . 779
Liver-Kidney Transplantation
in primary hyperoxaluria type 1 (PH1) . . . . . 502
Liver Transplantation
in primary hyperoxaluria type 1 (PH1) . . . . . 502
Long-Term Graft Survival Rates . . . . . S413
Lovastatin in hypercholesterolaemia (abst) . . . . . 769
Low-Density Lipoproteins (LDL)
binding to cultured rat mesangial cells . . . . . 701
effects on human mesangial cell growth and viability
*in vitro* (abst) . . . . . 903
renal biopsies (abst) . . . . . 776
Low-Density Lipoproteins (LDL) Cholesterol
in renal transplantation (abst) . . . . . 372
Low-Turnover Aluminium-Associated Bone Disease
(LTAABD) . . . . . 244
Lung $^{99m}$TcDTPA Transfer
in pulmonary infection . . . . . 582
in renal disease . . . . . 582
Lung Epithelial Permeability
$^{99m}$TcDTPA transfer assessment of . . . . . 582
Lupus Anticoagulant
in end-stage renal disease (ESRD) . . . . . 543
Lupus Nephritis
15-deoxyspergualin (DSP) in (abst) . . . . . 765
ICAM-1 in (abst) . . . . . 763
methylprednisolone in (abst) . . . . . 765
renal disease in (abst) . . . . . 742
Luteinising Hormone, cyclosporin A effect on (abst) . 797
Lymphatic Absorption in CAPD . . . . . 571
Lymphatic Absorption in CAPD (abst) . . . . . 811
Lymphocyte Activation
in kidney transplant cytology (abst) . . . . . 837
Lymphocytes, separation of . . . . . S25
Lymphoglobulin Therapy, cyclosporin in (abst) . . . 835
Lymphokines in Hodgkin's lymphoma . . . . . 155
Magnesium

erythrocyte (abst) . . . 67
in CAPD (abst) . . . 221
in cyclosporin-treated kidney transplant patients (letter) . . . 374
plasma (abst) . . . 67
Magnesium Carbonate in CAPD (abst) . . . 745
Magnesium Hydroxide in dialysis (abst) . . . 818
Maintenance Immunosuppression . . . S115
Melphalan in AL amyloidosis . . . 592
Membrane Characteristics . . . S319
Membrane Development and biocompatibility . . . S317
Membrane Evaluation . . . S320
Membrane Technology . . . S318
Menarche, growth after . . . S437
Mesangial Cell Lipid Accumulation . . . 701
Mesangial Deposits . . . 11
Mesangial Proliferative Glomerulonephritis BCG in . 554
Methylprednisolone in lupus nephritis (abst) . . . 765
6-Methylprednisolone
in renal failure (abst) . . . 373
in systemic vasculitis (abst) . . . 373
MHC Class II Antigens . . . 917
Microalbuminuria
in aminoacid infusion (abst) . . . 770
in insulin-dependent diabetes mellitus (abst) . . . 778
Microscopic Polyarteritis in rapidly progressive glomerulonephritis and acute renal failure . . . 536
Microscopic Polyarteritis (PA)
tubulointerstitial lesions (TIL) (abst) . . . 772
Microscopic Vasculitis (MPA)
anti-endothelial cell antibodies (AECA) in (abst) . . 766
Mitochondrial Myopathies
renal transplantation in (abst) . . . 71
Mitogenic Capacity . . . 44
Monoclonal Anti-DNA Autoantibodies
binding to endothelial cells (abst) . . . 761
binding to nuclei of mesangial cells and fibroblasts *in vitro* (abst) . . . 761
Monoclonal Antibodies
and cytokine release (abst) . . . 836
in restricted tissue distribution (abst) . . . 741
VCAM-1 . . . 917
Monoclonal Antibody OKT3
in CMV infection (abst) . . . 301
in renal transplantation . . . 275
Monocyte Adherence to Haemodialysis Membranes (abst) . . . 799
Monocytes
in haemodialysis . . . S214, S218
in uraemia (abst) . . . 826
Mononuclear Phagocytic System
aluminium uptake by (abst) . . . 218
MPO-ANCA in extracapillary glomerulonephritis . . 389
Mucormycosis, desferrioxamine in . . . 656
Mucosal Tolerance Failure in IgA Nephropathy (abst) 758
Multiple Arterial Thromboses in nephrotic syndrome . 55
Multiple Transplants . . . S120, S417
Musculoskeletal Symptoms in Dialysis (abst) . . . 744
*Mycoplasma pneumoniae* Pneumonia . . . 518
Myeloma, erythropoietin in (abst) . . . 70
Myeloperoxidase
antibodies to (abst) . . . 899
in systemic vasculitis (abst) . . . 762
Myocardial Infarction in end-stage renal disease (abst) 902
Na/H Antiporter in end-stage renal failure . . . 615
NAG-Values in Pregnancy-Induced Hypertension (abst) . . . 781
Nalaxone, hypertension in (abst) . . . 798
Natriuresis
frusemide-induced (abst) . . . 739, 910
in extracellular volume control (abst) . . . 795
Natriuretic Hormones
in extracellular volume control (abst) . . . 795
Necrotising and Crescentic Glomerulonephritis
silica exposure in (abst) . . . 773
Neoplasms and glomerulonephritis (abst) . . . 774
Nephritis, $IgA_1$ anti-GBM-mediated (abst) . . . 777
Nephrocalcinosis, Liddle syndrome in (abst) . . . 776
Nephrology
international yearbook (book review) . . . 378
principles and practice of (book review) . . . 527
Nephrotic Hyperlipidaemia
simvastatin in (abst) . . . 297
Nephrotic Syndrome
albumin synthesis in . . . 141
albumin synthesis rates in (abst) . . . 300
alkylating agents in . . . 381
and Hodgkin's lymphoma . . . 155
congenital (abst) . . . 220
cyclosporin in (letter) . . . 150
diabetic nephropathy with (abst) . . . 769
frusemide in . . . 402
hyperlipidaemia in . . . 141
immunosupprissive therapy in . . . 381
in *Mycoplasma pneumoniae* pneumonia . . . 518
in the elderly (abst) . . . 742
in ulcerative colitis (letter) . . . 227
minimal change (abst) . . . 771
multiple arterial thromboses in . . . 55
prednisone in (abst) . . . 771
pregnancy in (abst) . . . 789
proteinuria in . . . 141
purine analogues in . . . 381
renal transplantation in . . . S440
ticlopidine in (letter) . . . 150
tubular dysfunction in . . . 683
urinary lipoproteins in (abst) . . . 69
Nephrotoxic Nephritis
reactive oxygen species in (abst) . . . 765
Nephrotoxicity
cyclosporin A in (abst) . . . 777
gentamicin-induced . . . 608
Neutral Endopeptidase (NEP) (abst) . . . 740
Neutrophil Adhesiveness in Vasculitis (abst) . . . 906
Neutrophil Count . . . 232
Neutrophil Cytoplasm Components (NCC) autoantibodies (AA) correlation against (abst) . . . 762
Neutrophil Cytoplasmic Antigens in Systemic Vasculitis (abst) . . . 761
Neutrophils, phagocytic function . . . S331
Nifedipine
in renal transplantation (abst) . . . 904
renal haemodynamic response (abst) . . . 69
*Nocardia farcinica* . . . 209
Non-Hodgkin Lymphoma
glomerulonephritis in . . . 51
vasculitis in . . . 51
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
renal involvement . . . 595
Nutrition in chronic renal failure (abst) . . . 789
Nutritional Status in haemodialysis . . . 948
Obstructive Nephropathy in *pseudomyxoma peritonei* . 60

Ocular Complications in Renal Transplantation . . . 649
1,25(OH)$_2$ Vitamin D3 (1,25D3)
effect on $^{45}Ca^{2+}$ influx (abst) . . . 759
effect on glucose intolerance in uraemia (abst) . . . 808
effect on $HgCl_2$-induced autoimmunity (abst) . . . 768
effects on monocytes/macrophages (abst) . . . 818
effect on OK cells (abst) . . . 757
in CAPD (abst) . . . 810
in hyperparathyroidism (abst) . . . 819
in peripheral blood mononuclear cells (PBMC) (abst) 760
in renal transplantation (abst) . . . 831
receptor acquisition in modulator of suppressor cell induction (abst) . . . 760
OK Cells
1,25 (OH)$_2$ Vitamin D3 (1,25D3) effect on (abst) . . 757
Omega-3 Fatty Acids in haemodialysis (letter) . . . 526
Opioid Receptors in hypertension (abst) . . . 798
Opioids
in glucose homeostasis (abst) . . . 798
in insulin response (abst) . . . 798
Oral Adsorbent (AST-120) . . . 105
Organ System Failure (OSF)
in acute renal failure (abst) . . . 784
Osteitis Fibrosa, calcitriol in (abst) . . . 244, 818
Osteocalcin, effect of aluminium on . . . 98, 851
Osteomalacia, aluminium in . . . 851
Oxygen Dissociation Curve
effect of rHuEpo and blood transfusion (abst) . . . 825
Paediatric Registry Database . . . S137
Paired Filtration Dialysis . . . 715
vs. haemodiafiltration . . . S282
Panacreas Transplantation . . . 1
Parathyroid Carcinoma in renal failure (letter) . . . 150
Parathyroid Echography . . . 134
Parathyroid Gland Function in haemodialysis . . . 244
Parathyroid Hormone . . . 98
in uraemia (abst) . . . 759
Parathyroid Hormone (PTH)
and extracellular volume expansion (abst) . . . 794
and skeletal surveys (abst) . . . 224
in dialysis (abst) . . . 817
in erythropoietin resistance in haemodialysis . . . 342
in haemodiafiltration . . . S2104
in renal transplantation (abst) . . . 372, 831
serum values in renal failure . . . 162
Parathyroid Hormone-(PTH)-Calcium Curve . . . 244
Parathyroid Tumour . . . 134
Parathyroidectomy, patient questionnaire . . . S128
Parietal Podocyte and Bowman's capsule (abst) . . . 907
Patient Education . . . 27
Percutaneous Balloon Dilatation . . . 977
Percutaneous Transluminal Renal Angioplasty for Renal Artery Occlusive Disease (abst) . . . 790
Peripheral Blood Mononuclear Cells (PBMC) . S296, S341
(abst) . . . 760
Peritoneal Dialysis . . . 44
*Pseudomonas putrefaciens* bacteraemia (letter) . . . 73
ultrafiltration by . . . 120
with prosthetic graft . . . 215
Peritoneal Dialysis Fluids
and tumour cell line growth (abst) . . . 812
histidine-buffered (abst) . . . 812
Peritoneal Drainage in CAPD (abst) . . . 810
Peritoneal Effluent . . . 44
Peritoneal Function in CAPD (abst) . . . 810
Peritoneal Solute Transport in CAPD . . . 198
Peritonitis in CAPD . . . 495, 643, 659
Phagocytosis in haemodialysis (abst) . . . 829
Phagocytosis Activity of polymorphonuclear cells . . . S335
Phagocytosis Inhibition in uraemia (abst) . . . 788
Phorbol Myristate Acetate (PMA)
effect on fibronectin synthesis (abst) . . . 299
Phosphataemia in haemofiltration . . . S2108
Phosphate . . . 98
Phosphate Kinetics in high-flux haemofiltration . . . S2108
Phosphate Removal
in haemodialysis . . . S2114
in haemofiltration . . . S2108
Phosphocysteamine in cystinosis (abst) . . . 299
Phospholipase $A_2$ in Inflammatory Processes (abst) . . 760
Phospholipids
effect on gentamicin-induced nephrotoxicity . . . 608
Photosensitivity Disorders
in chronic renal failure (abst) . . . 225
Pituitary-Gonadal Axis in chronic renal failure (abst) . 807
Plasma Acute-Phase Proteins
in erythropoietin therapy (abst) . . . 222
Plasma Atrial Natriuretic Peptide
and renin-angiotensin-aldosterone system . . . 557
Plasma Cholesterol in renal transplantation (abst) . . 372
Plasma Oxalate in haemodialysis . . . 440
Plasminogen Activator in haemodialysis . . . S326
Plasminogen Activator Inhibitor-1
tumour necrosis factor (TNF) effect on (abst) . . . 756
Platelet Activating Factor (PAF) in glomerular synthesis of inflammatory markers (abst) . . . 765
Platelet Activation in haemodialysis . . . S240
Platelet Adhesion to Dialysis Membranes . . . S236
Platelet Aggregation
in recombinant human erythropoietin (abst) . . . 223
Platelet derived Growth Factor (PDGF) . . . 11
Plumbism in chronic renal failure (abst) . . . 788
PMMA BK Membrane . . . S269
PMMA BK Membranes . . . S286
PMMA-Containing Dialysers, blood compatibility of . S243
PMMA Membranes . . . S296
biocompatibility of . . . S284
Poisons, elimination (book review) . . . 74
Polyacrylonitrile Membranes . . . 428
free oxygen species metabolism . . . S366
Polyacrylonitrile-Polyethyleneoxide (PAN-PEO) Membrane . . . S249
Polycystic Kidney Disease . . . 27
(abst) . . . 908
in haemodialysis (abst) . . . 809
renal tubular basement membrane in (abst) . . . 906
Poly-L-Lysine . . . 923
Polymorphonuclear Cells, phagocytotis activity of . . S335
Polymorphonuclear Functions in dialysis (letter) . . . 912
Polymorphonuclear Leukocytes (PMN)
and antioxidative homeostasis . . . S371
Polysulphone Dialysers . . . S322
Polysulphone Membranes
(abst) . . . 806
free oxygen species metabolism . . . S366
Polyunsaturated Fatty Acid (PUFA)
and albuminuria (abst) . . . 903
Polyvalent Immunoglobulins
in renal transplantation (letter) . . . 675
Porphyria Cutanea Tarda (PCT) (abst) . . . 225
Porphyrin Metabolism in rHuEpo treatment (abst) . . 823
Potassium, effect of ACE inhibitors (abst) . . . 754

Potassium Adaptation and Prostanoids (abst) . . . . 753
Prednisolone
in AL amyloidosis . . . . . 592
in post-transplant erythrocytosis . . . . . 588
in rapidly progressive glomerulonephritis . . . . . 536
in renal transplantation (abst) . . . . . 832, 835, 836
Prednisone
in nephrotic syndrome (abst) . . . . . 771
in renal transplantation . . . . . 286
Pre-eclampsia, rHuEpo levels in (abst) . . . . . 829
Pregnancy
adriamycin in (abst) . . . . . 789
bacteriuria in (abst) . . . . . 297
in nephrotic syndrome (abst) . . . . . 789
in renal replacement therapy . . . . . S146
in renal transplantation . . . . . 139
in RRT . . . . . S417
in Wegener's granulomatosis . . . . . 139
NAG-values (abst) . . . . . 781
recombinant human erythropoietin in . . . . . 292
rHuEpo levels in (abst) . . . . . 829
Prekallikrein in chronic renal failure (CRF) . . . . . S36
Primary Hyperoxaluria Type 1 (PH1)
alanine in . . . . . 502
glyoxylate aminotransferase in . . . . . 502
liver transplantation in . . . . . 502
liver-kidney transplantation in . . . . . 502
Proliferation Markers
in kidney transplant cytology (abst) . . . . . 837
Prostaglandin $E_2$ ($PGE_2$)
effect of frusemide in nephrotic syndrome . . . . . 402
in uraemia . . . . . 966
Prostaglandins
and growth hormone (abst) . . . . . 791
and peritoneal mesothelial cells (abst) . . . . . 812
Prostanoids and Potassium Adaptation (abst) . . . . 753
Prosthetic Graft, peritoneal dialysis with . . . . . 215
Protein Catabolic Rate and Kt/V (abst) . . . . . 809
Protein Intake . . . . . 17
Proteinase 3 (P3), autoantibodies to (abst) . . . . . 899
Proteinuria
and ammoniagenesis (abst) . . . . . 792
and tubular degradation (abst) . . . . . 792
as risk factor (abst) . . . . . 789
enalapril in . . . . . 936
in benign hypertensive nephrosclerosis (abst) . . . 773
in chronic renal failure . . . . . 21
in nephrotic syndrome . . . . . 141
papers on (book review) . . . . . 601
Proximal Tubular Dysfunction
in non-insulin-dependent diabetes mellitus (abst) . . 774
Proximal Tubule Cells
kidney growth factor (KGF) from (abst) . . . . . 756
Pruritus in haemodialysis . . . . . 105
Pseudo Bartter's Syndrome (abst) . . . . . 770
*Pseudomonas Putrefaciens* Bacteraemia
in peritoneal dialysis (letter) . . . . . 73
*Pseudomyxoma Peritonei*, obstructive nephropathy in . 60
Pulmonary Infection, lung $^{99m}$TcDTPA transfer in . . 582
Purine Analogues in primary glomerulonephritis with nephrotic syndrome . . . . . 381
Pyrogen-Free Sterile Dialysate by Ultrafiltration (abst) 802
Quinton Permcath . . . . . 269
Radiocontrast-Induced Nephropathy (RCIN) (abst) . . 795
Rapamycin
in MHC class 1 response to blood transfusion (abst) 225
Rapidly Progressive Glomerulonephritis
cyclophosphamide in . . . . . 536
extracorporeal immunoadsorption in . . . . . 536
prednisolone in . . . . . 536
Reactive oxygen species (ROS)
(abst) . . . . . 756, 905, 908
in Glomerular Lesions (abst) . . . . . 765
in haemodialysis . . . . . S371
Recombinant Human Erythropoietin . . . . . 31, 110
aluminium content of water for injection used with . 857
aluminium in (abst) . . . . . 743
and blood pressure (abst) . . . . . 829
and glomerular thromboxane (abst) . . . . . 820
and iron (abst) . . . . . 824
and metabolic changes during exercise (abst) . . . . 827
and phagocytosis correction (abst) . . . . . 829
and serum ferritin (letter) . . . . . 912
and T-cell preactivation in haemodialysis (abst) . . 828
and thrombin-antithrombin III complex (abst) . . . 744
C-127 mouse cells (abst) . . . . . 821
coagulation studies . . . . . 862
cognitive function in (abst) . . . . . 223
comparison of intravenous and subcutaneous administration (abst) . . . . . 826
congestive heart failure (abst) . . . . . 825
effect of calcium antagonists (abst) . . . . . 822
effect on bone marrow (abst) . . . . . 823
effect on cardiac structures (abst) . . . . . 827
effect on cytotoxic antibodies (abst) . . . . . 820
effect on oxygen dissociation curve (abst) . . . . . 825
fistula blood flow . . . . . 862
fixed low-dose regime (abst) . . . . . 743
haemodynamic changes in uraemic haemodialysis (abst) . . . . . 830
haemodynamic parameters in HD vs CAPD (abst) . 822
haemoglobin response (abst) . . . . . 824
haemostasia in haemodialysis with (abst) . . . . . 827
in anaemia . . . . . 452, 487
in anaemia (book review) . . . . . 602
in C-127 mouse cells . . . . . S2116
in CAPD (abst) . . . . . 821
in chronic renal failure . . . . . 955
in dialysis (abst) . . . . . 824
in end-stage renal disease (ESRD) . . . . . 342
in haemodialysis . . . . . 562, 862
in haemodialysis (abst) . . . . . 821, 902
in pre-eclampsia (abst) . . . . . 829
in predialysis (abst) . . . . . 824, 826
in pregnancy . . . . . 292
in pregnancy (abst) . . . . . 829
in renal failure (abst) . . . . . 828
in renal transplantation (abst) . . . . . 831
in sickle cell anaemia (abst) . . . . . 302
in thrombophilia (abst) . . . . . 827
in uraemia (abst) . . . . . 826
in uraemic gonadal dysfunction (abst) . . . . . 820
in uraemic haemodialysis patients (abst) . . . . . 830
increase in haematocrit induced by (abst) . . . . . 822
kinetic modelling in (abst) . . . . . 223
measurement in CRF (abst) . . . . . 828
optimal route of administration (abst) . . . . . 826
pain assessment after (abst) . . . . . 823
platelet aggregation in (abst) . . . . . 223
renal failure in . . . . . 709
role of autonomic nervous system (abst) . . . . . 822
Red Blood Cell Fragmentation

creatinine phosphokinase by (abst) . . . . . 802
Red Blood Cells
and antioxidative homeostasis . . . . . S371
mechanical membrane properties . . . . . 110
membrane-bound IgG (abst) . . . . . 744
$Na^+$ transport . . . . . 286
Reflux Nephropathy
and uraemia (abst) . . . . . 775
glomerular morphometry in (abst) . . . . . 907
glomerular permselectivity in (abst) . . . . . 770
Renal Allograft, renin-containing cells in . . . . . 363
Renal Allograft Failure, calcium in . . . . . 984
Renal Allograft Rejection
thymic factor X'Polfa' (abst) . . . . . 837
Renal Allograft Survival and Azathioprine (abst) . . . 71
Renal Allografts
focal segmental glomerulosclerosis in (letter) . . . . 375
ultrasonography of . . . . . 358
Renal Artery Occlusive Disease, percutaneous transluminal renal angioplasty for (abst) . . . . . 790
Renal biopsy
cationic colloidal gold in (abst) . . . . . 905
cytoplasmic lipid inclusions (abst) . . . . . 776
glomerular charge aberrations in (abst) . . . . . 905
glomerular polyanion status . . . . . 923
IgA nephropathy (abst) . . . . . 774
in diabetic patients (abst) . . . . . 769
low-density-lipoproteins (abst) . . . . . 776
percutaneous . . . . . 731
percutaneous (abst) . . . . . 741
ultrasound-guided (abst) . . . . . 741
ultrasound scanning in . . . . . 731
Renal Cell Surface Antigens (abst) . . . . . 758
Renal Damage from Streptokinase (abst) . . . . . 753
Renal Disease
and hydrocarbons (abst) . . . . . 780
early progressive . . . . . 17
end-stage . . . . . 110, 215
glutathione S-transferase (GST) isoenzyme expression in . . . . . 695
IgA-related (abst) . . . . . 900
in HIV-1 infection (abst) . . . . . 775
lung $^{99m}$TcDTPA transfer in . . . . . 582
Renal Failure
6-methylprednisolone in (abst) . . . . . 373
ACE inhibitors in (abst) . . . . . 793
aluminium in (book review) . . . . . 377
blood pressure in (abst) . . . . . 67
calcium channel blockers in . . . . . 420
cardiac death in (abst) . . . . . 771
hypertension in (abst) . . . . . 791
hypertensive nephrosclerosis in (abst) . . . . . 219
induced by rHuEpo (abst) . . . . . 828
lead in (abst) . . . . . 371
parathyroid carcinoma in (letter) . . . . . 150
progression of (abst) . . . . . 773
terminal (book review) . . . . . 74
Renal Function in haemorrhagic fever with renal syndrome (HFRS) (abst) . . . . . 908
Renal Graft Rejection, ICAM-1 in (abst) . . . . . 834
Renal Graft Rejection Oedema
hyaluronic acid in (abst) . . . . . 838
Renal Haemodynamics
in non-insulin-dependent diabetes mellitus (abst) . . 780
Renal Osteodystrophy . . . . . 244
(abst) . . . . . 745
in haemodialysis . . . . . S299
Renal Perfusion in urinary obstruction (abst) . . . . 907
Renal Plasma Flow (RPF)
effect of amino acid infusion . . . . . 410
Renal Preservation Testing (abst) . . . . . 833
Renal Rejection vs Cyclosporin Nephrotoxicity (abst) . 833
Renal Replacement Therapy
demography in Europe . . . . . S15
demography of . . . . . S45
incidence rate (abst) . . . . . 69
pregnancy in . . . . . S146
survival data . . . . . S122, S127
Renal Sympathetic Nervous System (abst) . . . . . 66
Renal Tract Stone (book review) . . . . . 749
Renal Transplantation
$1,25(OH)_2D3$ in (abst) . . . . . 831
acute renal failure in . . . . . 881
age-matching (letter) . . . . . 599
analgesic nephropathy (abst) . . . . . 833
antiepithelial cell antibody (AEC) in (abst) . . . . 294
apolipoprotein in (abst) . . . . . 838
atrial natriuretic peptide (ANP) in (abst) . . . . . 904
atrial natriuretic peptide in (abst) . . . . . 796
azathioprine in (abst) . . . . . 832, 835, 836
bone biopsy in (abst) . . . . . 372
(book review) . . . . . 601
cadaveric . . . . . 887
calcium antagonists in (abst) . . . . . 832
calcium channel blockers in (abst) . . . . . 839, 904
calcium in (abst) . . . . . 831
cross-matches . . . . . 280
cyclosporin in . . . . . 725, 881, 896
(abst) . . . . . 72, 372, 796, 832, 835, 836, 839, 904
(letter) . . . . . 374
cytomegalovirus disease in (letter) . . . . . 525
cytomegalovirus infection in (abst) . . . . . 372, 834
erythrocytosis in . . . . . 588
erythrocytosis in (letter) . . . . . 675
felodipine in (abst) . . . . . 833
HDL cholesterol in (abst) . . . . . 372
*Heliobacter pylori* in (abst) . . . . . 226
hepatitis B in (abst) . . . . . 836, 838
hepatitis C in (abst) . . . . . 838, 839
hypertension in (abst) . . . . . 838
in Alport's syndrome . . . . . 893
in Bardet-Biedl syndrome . . . . . 982
in elderly recipients . . . . . 887
in hepatitis C virus infection (abst) . . . . . 832
in highly sensitised recipients (abst) . . . . . 831
in mitochondrial myopathies (abst) . . . . . 71
in nephrotic syndrome . . . . . S440
infections in (abst) . . . . . 836
LDL cholesterol in (abst) . . . . . 372
lipoproteins in (abst) . . . . . 840
monoclonal antibody OKT3 in . . . . . 275
nifedipine in (abst) . . . . . 904
ocular complications in . . . . . 649
parathyroid hormone in (abst) . . . . . 372, 831
patient and graft survival . . . . . S122
plasma cholesterol in (abst) . . . . . 372
polyvalent immunoglobulins in (letter) . . . . . 675
prednisolone in (abst) . . . . . 832, 835, 836
prednisone in . . . . . 286
pregnancy in . . . . . 139
regression of left ventricular hypertrophy following (abst) . . . . . 226

removal of (abst) . . . 373
rHuEpo in (abst) . . . 831
spermaturia in (abst) . . . 840
steroids in (abst) . . . 836
triglycerides in (abst) . . . 372
ultrasound in . . . 358
ureteric obstruction in . . . 977
visceral leishmaniasis in . . . 736
with previous malignancy . . . S119
Renal Tubular Acidosis in Sjögren's syndrome (abst) . 781
Renal Tubular Basement Membrane
in polycystic kidney disease (PKD) (abst) . . . 906
Renal Tubular Cells . . . 917
Renal Tubular Epithelium
cell basement membrane adhesion in (abst) . . . 741
Renal Tubular Function in chronic glomerulonephritis 466
Renin-Angiotensin System . . . 363
Renin-Angiotensin-Aldosterone System
and plasma atrial natriuretic peptide . . . 557
in chronic renal failure . . . 557
Renin-Angiotensin-Aldosterone System (abst) . . . 66
Renovascular Disease in chronic renal failure (abst) . 786
Renovascular Hypertension, ACE inhibitors in (abst) . 793
Rhabdomyolysis
causes, renal failure and mortality (abst) . . . 784
in hemlock poisoning . . . 939
in lithium-induced hyperosmolal state . . . 203
Rhinocerebral Mucormycosis in Haemodialysis . . . 656
Salbutamol in hyperkalaemia (abst) . . . 298
Salt Excretion by Atrial Natriuretic Peptide (abst) . . 795
Schönlein-Henoch Purpura Nephritis (abst) . . . 765
Sephadex
and alternative complement pathway activation . . 193
Sepsis in acute renal failure (abst) . . . 784
Serum Ferritin
and recombinant human erythropoietin (letter) . . . 912
Serum Little Gastrin in Chronic Renal Failure (abst) . 796
Serum procollagen type I C-term
in chronic renal failure (abst) . . . 786
Sezary Cell Lymphoma . . . 896
*Shigella dysenteriae* Type 1 . . . 232
Shoulder Pain in Haemodialysis . . . 117
Sickle Cell Anaemia
recombinant erythropoietin (Epo) in (abst) . . . 302
Silastic Twin Catheters in Haemodialysis (abst) . . . 799
Silica Exposure in necrotising and crescentic
glomerulonephritis (abst) . . . 773
Simvastatin
in nephrotic hyperlipidaemia (abst) . . . 297
in uraemia (abst) . . . 787
Skeletal Surveys
and parathyroid hormone (PTH) (abst) . . . 224
Small-Vessel Vasculitis (SVV)
HLA class II genes in (abst) . . . 900
Sodium Homeostasis (abst) . . . 66
Sodium Pump Inhibitors in uraemia (abst) . . . 785
Sodium Transport . . . 91
Somatic Growth . . . S435
Spermaturia in renal transplantation (abst) . . . 840
Spinal-Cord Compression in haemodialysis . . . S291
Steroids
in idiopathic membranous nephropathy (abst) . . . 758
in renal transplantation (abst) . . . 836
Streptokinase
in innominate-vein thrombosis . . . 206
renal damage from (abst) . . . 753
Superoxide Dismutase (SOD) (abst) . . . 756, 905
Systemic Lupus Erythematosus (SLE)
antiendothelial cell antibodies, (abst) . . . 766, 900
cyclophosphamide in (abst) . . . 70
histones in (abst) . . . 901
in rapidly progressive glomerulonephritis and acute
renal failure . . . 536
isoelectric spectrotypes of serum antibodies (abst) . 900
kidney biopsy in (abst) . . . 901
ubiquitin in (abst) . . . 901
Systemic Vasculitis. *See* Vasculitis
T-Cell Activation in IgA nephropathy (abst) . . . 778
T-Cell Immunity in uraemia (abst) . . . 759
T-Cell Preactivation in haemodialysis (abst) . . . 828
T-Cell Receptor Expression . . . S25, S27
T-Lymphocyte dysfunction in Hodgkin's lymphoma . . 155
T-Lymphocyte Infiltration
in glomerular and interstitial diseases (abst) . . . 764
T-Lymphocytes in kidney transplantation . . . 512
$^{99m}$Tc-Labelled Erythropoietin (abst) . . . 67
$^{99m}$Tc(V)DMSA Uptake in Dialysis Amyloidosis (abst) 298
Tertatolol, effect on renal function in hypertensive
patients with mild chronic renal failure . . . 252
Thallium Myocardial Perfusion Imaging
for cardiovascular disease (abst) . . . 789
Theophylline Protein Binding in uraemia (abst) . . . 786
Thombogenicity
haemodialysers containing PMMA membranes . . . S243
Thrombin-Antithrombin III Complex and RHE (abst) 744
Thrombin-Antithrombin III Complex Levels (TAT III)
(abst) . . . 902
Thrombogenicity and ACUS . . . S249
Thrombophilia, rHuEpo-induced (abst) . . . 827
Thymic Factor X'Polfa' in Renal Allograft Rejection
(abst) . . . 837
Thymidine Kinase in uraemia (abst) . . . 824
Thyrocervical Trunk, false aneurysm of (letter) . . . 747
Thyroiditis . . . 79
Ticlopidine
in nephrotic syndrome (letter) . . . 150
interaction with cyclosporin (letter) . . . 150
Tissue-Type Plasminogen Activator (t-PA) . . . S326
Total Iron Binding Capacity (TIBC) . . . 637
Transcapillary Ultrafiltration in CAPD . . . 571
Transferrin Receptor . . . 917
Transferrin Saturation Index . . . 452
Transforming Growth Factor (TGF Beta) in IgA
Nephropathy (abst) . . . 754
Transitional-Cell Carcinoma, urine cytology in . . . 346
Transplant Activity, demography of . . . S49
Transplantation
(book review) . . . 601
combined report . . . S15, S137
combined reports (abst) . . . 751, 752
patient's guide to (book review) . . . 152
Transplantectomy, symptoms and results (abst) . . . 373
Trasylol, renal tubular degradation (abst) . . . 740
Triglycerides in renal transplantation (abst) . . . 372
Tubular Basement Membranes (TBM) . . . 457
Tubular Degradation and proteinuria (abst) . . . 792
Tubular Dysfunction in Nephrotic Syndrome . . . 683
Tubulointerstitial lesions (TIL)
in microscopic polyarteritis (PA) (abst) . . . 772
Tubulointerstitial Nephritis (NIT)
and Uveitis Syndrome (abst) . . . 782
Tumour Cell Line Growth and Peritoneal Dialysis

Fluids (abst) . . . 812
Tumour necrosis factor (TNF)
and peritoneal mesothelial cells (abst) . . . 812
effect on cytokine secretion (abst) . . . 303
effect on plasminogen activator inhibitor-1 (abst) . . 756
endotoxin effect on (abst) . . . 805
in CAPD (abst) . . . 811
in cuprophane haemodialysis . . . 435
in dialysis . . . S261
in glomerular synthesis of inflammatory markers (abst) . . . 765
in haemodialysis . . . 349, 868, S218
in haemodialysis (abst) . . . 806
in renal failure (abst) . . . 764
Ubiquitin
in systemic lupus erythematosus (SLE) (abst) . . . 901
Ulcerative Colitis, nephrotic syndrome in (letter) . . . 227
Ultrafiltration
antithrombogenic continuous system . . . S249
by peritoneal dialysis . . . 120
pyrogen-free sterile dialysate by (abst) . . . 802
Ultrafiltration Rate, effect on fluid balance . . . 257
Ultrasound
in renal biopsy . . . 731
of renal allografts . . . 358
renal biopsy (abst) . . . 741
Uraemia . . . 98
acidosis in (abst) . . . 757
aminoacids in (abst) . . . 785
and reflux nephropathy (abst) . . . 775
arterial pressure (abst) . . . 794
atrial natriuretic peptide (abst) . . . 794
chronic . . . 31
$Cl^-/HCO_3^-$ anion exchanger in (abst) . . . 787
creatinine in (abst) . . . 904
endothelin in (abst) . . . 794
Epo in (abst) . . . 826
glucose intolerance in (abst) . . . 808
HBV vaccination in (abst) . . . 787
*Helicobacter pylori* infection in (abst) . . . 902
interleukin-6 (Il-6) in . . . S296
ketoanalogues in (abst) . . . 785
leukocyte intracellular pH and Na/H antiporter activity in . . . 615
lipid peroxidation in (abst) . . . 787
monocytes in (abst) . . . 826
parathyroid hormone in (abst) . . . 759
phagocytosis inhibition in (abst) . . . 788
prostaglandin $E_2$ in . . . 966
rHuEpo in (abst) . . . 830
simvastatin in (abst) . . . 787
sodium pump inhibitors in (abst) . . . 785
T-cell immunity in (abst) . . . 759
theophylline protein binding in (abst) . . . 786
thymidine kinase in (abst) . . . 824
Uraemia-associated Basal Production of IL-1 and TNF alpha . . . 349
Uraemic Acidosis (abst) . . . 806
Uraemic Amyloidosis in HD and CAPD (abst) . . . 813
Uraemic Gonadal Dysfunction (UGD)
effect of erythropoietin (abst) . . . 820
Uraemic Hyperphosphataemia
1,25-dihydroxyvitamin D3 [1,25$(OH)_2$D3] in . . . 171
calcitriol in . . . 170
calcium acetate in . . . 170
calcium carbonate in . . . 170
Uraemic Osteodystrophy
bone histomorphometry in (abst) . . . 816
Uraemic Syndrome, haemolytic . . . 232
Urea Excretion . . . 17
Urea Kinetic Modelling (UKM) . . . 38
in high-flux dialysis . . . S386
Urea Kinetics and direct dialysis quantification (abst) . 801
Ureteric Obstruction in renal transplantation . . . 977
Urinary Albumin Excretion
converting enzyme inhibitors (CEIs) in (abst) . . . 793
in hypertension (abst) . . . 793
Urinary Diversion . . . 60
Urinary Lipoproteins in nephrotic syndrome (abst) . . 69
Urinary Obstruction, renal perfusion in (abst) . . . 907
Urinary Protein Excretion
in diabetic nephropathy . . . 238
in diabetic nephropathy (abst) . . . 776
Urinary Tract Abnormalities in Children
constipation in (abst) . . . 299
Urinary Tract Infection, autovaccination in (abst) . . 782
Urine Anion Gap (abst) . . . 833
Urine Cytology in transitional-cell carcinoma . . . 346
Uveitis Syndrome
and tubulo-interstitial nephritis (NIT) (abst) . . . 782
Vascular Access
haemodialysis . . . 5
Quinton Permcath . . . 269
Vascular Cell Adhesion Molecule-1 (VCAM-1) . . . 917
Vasculitis
6-methylprednisolone in (abst) . . . 373
alpha-1-antitrypsin in (abst) . . . 764
alpha-granule fraction in (abst) . . . 762
antiendothelial cell antibodies in (abst) . . . 900
antiendothelial cell antibody (AECA) in (abst) . . . 295
antimyeloperoxidase antibodies in (abst) . . . 295
antineutrophil cytoplasmic antibodies (ANCA) in . 689
antineutrophil cytoplasmic antibodies (ANCA) in (abst) . . . 295, 764
autoantibodies to endothelial cells in (abst) . . . 761
autoantibodies to neutrophil granulocytes cytoplasma (ANCA) in (abst) . . . 767
C-reactive protein (CRP) in (abst) . . . 764
cyclophosphamide in (abst) . . . 70
in extracapillary glomerulonephritis . . . 389
in non-Hodgkin lymphoma . . . 51
interleukin-2 in (abst) . . . 762
interleukin-6 in (abst) . . . 764
management of . . . S426
myeloperoxidase in (abst) . . . 762
neutrophil adhesiveness in (abst) . . . 906
neutrophil cytoplasmic antigens in (abst) . . . 761
Vasopressin
disturbed secretion and its effects (book review) . . 601
in haemodialysis . . . 631
Verapamil in hypertension . . . 420
Verocytotoxin Producing *Escherichia coli* (VTEC) . . 232
Very-Low-Density Lipoprotein (VLDL) . . . 141
Visceral Leishmaniasis in Renal Transplantation . . . 736
Vitamin C, effect on plasma oxalate in haemodialysis . 440
Vitamin E in haemodialysis (abst) . . . 830
von Willebrand Factor Antigen . . . 232
Wegener's Granulomatosis
ANCA in (abst) . . . 763
and granular gingivitis (letter) . . . 228
cyclophosphamide in . . . 531
in rapidly progressive glomerulonephritis and acute

renal failure . . . . . 536
pregnancy in . . . . . 139
World Health Organisation (WHO) Diagnostic Codes (letter) . . . . . 524
Zinc Protoporphyrin in iron deficiency (abst) . . . . . 825